Chromane and chromene derivatives and uses thereof

ABSTRACT

Compounds of formula I or pharmaceutically acceptable salts thereof are provided: 
     
       
         
         
             
             
         
       
     
     wherein each of R 1 , R 2 , R 3 , R 4 , y, m, n, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Patent ApplicationSer. No. 60/673,820, filed Apr. 22, 2005, the entirety of which ishereby incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to 5-HT_(2C) receptor agonists or partialagonists, processes for their preparation, and uses thereof.

BACKGROUND OF THE INVENTION

Schizophrenia affects approximately 5 million people. The most prevalenttreatments for schizophrenia are currently the ‘atypical’antipsychotics, which combine dopamine (D₂) and serotonin (5-HT_(2A))receptor antagonism. Despite the reported improvements in efficacy andside-effect liability of atypical antipsychotics relative to typicalantipsychotics, these compounds do not appear to adequately treat allthe symptoms of schizophrenia and are accompanied by problematic sideeffects, such as weight gain (Allison, D. B., et. al., Am. J.Psychiatry, 156: 1686-1696, 1999; Masand, P. S., Exp. Opin.Pharmacother. I: 377-389, 2000; Whitaker, R., Spectrum Life Sciences.Decision Resources. 2:1-9, 2000).

Atypical antipsychotics also bind with high affinity to 5-HT_(2C)receptors and function as 5-HT_(2C) receptor antagonists or inverseagonists. Weight gain is a problematic side effect associated withatypical antipsychotics such as clozapine and olanzapine, and it hasbeen suggested that 5-HT_(2C) antagonism is responsible for theincreased weight gain. Conversely, stimulation of the 5-HT_(2C) receptoris known to result in decreased food intake and body weight (Walsh et.al., Psychopharmacology 124: 57-73, 1996; Cowen, P. J., et. al., HumanPsychopharmacology 10: 385-391, 1995; Rosenzweig-Lipson, S., et. al.,ASPET abstract, 2000).

Several lines of evidence support a role for 5-HT_(2C) receptor agonismor partial agonism as a treatment for schizophrenia. Studies suggestthat 5-HT_(2C) antagonists increase synaptic levels of dopamine and maybe effective in animal models of Parkinson's disease (Di Matteo, V., et.al., Neuropharmacology 37: 265-272, 1998; Fox, S. H., et. al.,Experimental Neurology 151: 35-49, 1998). Since the positive symptoms ofschizophrenia are associated with increased levels of dopamine,compounds with actions opposite to those of 5-HT_(2C) antagonists, suchas 5-HT_(2C) agonists and partial agonists, should reduce levels ofsynaptic dopamine. Recent studies have demonstrated that 5-HT_(2C)agonists decrease levels of dopamine in the prefrontal cortex andnucleus accumbens (Millan, M. J., et. al., Neuropharmacology 37:953-955, 1998; Di Matteo, V., et. al., Neuropharmacology 38: 1195-1205,1999; Di Giovanni, G., et. al., Synapse 35: 53-61, 2000), brain regionsthat are thought to mediate critical antipsychotic effects of drugs likeclozapine. However, 5-HT_(2C) agonists do not decrease dopamine levelsin the striatum, the brain region most closely associated withextrapyramidal side effects. In addition, a recent study demonstratesthat 5-HT_(2C) agonists decrease firing in the ventral tegmental area(VTA), but not in the substantia nigra. The differential effects of5-HT_(2C) agonists in the mesolimbic pathway relative to thenigrostriatal pathway suggest that 5-HT_(2C) agonists have limbicselectivity, and will be less likely to produce extrapyramidal sideeffects associated with typical antipsychotics.

SUMMARY OF THE INVENTION

The present invention relates to 5-HT_(2C) receptor agonists or partialagonists and uses thereof. In one aspect, the invention relates tochromane and chromene derivatives that act as agonists or partialagonists of the 5-HT_(2C) receptor. The compounds can be used, forexample, to treat schizophrenia and the concomitant mood disorders andcognitive impairments of schizophrenia and depression. In certainembodiments, compounds of the present invention are less likely toproduce the body weight increases associated with current atypicalantipsychotics. The compounds of the present invention can also be usedfor the treatment of obesity and its comorbidities. Compounds of thepresent invention are also useful for treating a variety of psychotic,depression and related disorders, and cognitive disorders as describedin detail herein.

In certain embodiments, the invention provides a compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein:

-   m is 1 or 2;-   n is 0 or 1;-   designates a single or double bond;-   Ar is thienyl, furyl, pyridyl, or phenyl, wherein Ar is optionally    substituted with one or more R^(x) groups;-   each R^(x) is independently -Ph, halogen, —CN, —R or —OR;-   each R is independently hydrogen, C₁₋₆ aliphatic or halo-substituted    C₁₋₆ aliphatic;-   y is 0-3;-   each R¹ is independently —R, —CN, halogen or —OR;-   R² is hydrogen, C₁₋₃ alkyl, or —O(C₁₋₃ alkyl); and-   each of R³ and R⁴ is independently hydrogen, C₁₋₆ aliphatic or    fluoro-substituted C₁₋₆ aliphatic;

In certain other embodiments, the invention relates to methods fortreating a patient suffering from schizophrenia, schizophreniformdisorder, schizoaffective disorder, delusional disorder,substance-induced psychotic disorder, L-DOPA-induced psychosis,psychosis associated with Alzheimer's dementia, psychosis associatedwith Parkinson's disease, psychosis associated with Lewy body disease,dementia, memory deficit, intellectual deficit associated withAlzheimer's disease, bipolar disorders, depressive disorders, moodepisodes, anxiety disorders, adjustment disorders, eating disorders,epilepsy, sleep disorders, migraines, sexual dysfunction, substanceabuse, addiction to alcohol and various other drugs, including cocaineand nicotine, gastrointestinal disorders, obesity, or a central nervoussystem deficiency associated with trauma, stroke, or spinal cord injury,or other conditions or disorders as described herein, that includesadministering to the patient a therapeutically effective amount of acompound of formula I, or a pharmaceutically acceptable salt thereof.

In still other embodiments, the invention relates to compositionscomprising a compound of formula I or a pharmaceutically acceptable saltthereof, and one or more pharmaceutically acceptable carriers,excipients, or diluents.

DETAILED DESCRIPTION OF THE INVENTION 1. Compounds and Definitions

The compounds of the present invention are agonists or partial agonistsof the 2C subtype of brain serotonin receptors.

In certain embodiments, the invention provides a compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein:

-   m is 1 or 2;-   n is 0 or 1;-   designates a single or double bond;-   Ar is thienyl, furyl, pyridyl, or phenyl wherein Ar is optionally    substituted with one or more R^(x) groups;-   each R^(x) is independently -Ph, halogen, —CN, —R or —OR;-   each R is independently hydrogen, C₁₋₆ aliphatic or halo-substituted    C₁₋₆ aliphatic;-   y is 0-3;-   each R¹ is independently —R, —CN, halogen or —OR;

R² is hydrogen, C₁₋₃ alkyl, or —O(C₁₋₃ alkyl); and

-   each of R³ and R⁴ is independently hydrogen, C₁₋₆ aliphatic or    fluoro-substituted C₁₋₆ aliphatic;    provided that:

when

designates a single bond and n is 0, then R¹ is not —OH in the6-position; and

when

designates a single bond and n is 0, then R¹ is not —OR in the7-position.

The term “aliphatic” or “aliphatic group”, as used herein, means astraight-chain (i.e., unbranched) or branched, substituted orunsubstituted hydrocarbon chain that is completely saturated or thatcontains one or more units of unsaturation, or a monocyclic hydrocarbonthat is completely saturated or that contains one or more units ofunsaturation, but which is not aromatic (also referred to herein as“carbocycle” “cycloaliphatic” or “cycloalkyl”), that has a single pointof attachment to the rest of the molecule. In certain embodiments,aliphatic groups contain 1-4 aliphatic carbon atoms, and in yet otherembodiments, aliphatic groups contain 1-3 aliphatic carbon atoms. Insome embodiments, “cycloaliphatic” (or “carbocycle”) refers to amonocyclic C₃-C₆ hydrocarbon that is completely saturated or thatcontains one or more units of unsaturation, but which is not aromatic,that has a single point of attachment to the rest of the molecule. Suchcycloaliphatic groups include cycloalkyl, cycloalkenyl, and cycloalkynylgroups. Suitable aliphatic groups include, but are not limited to,linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynylgroups and hybrids thereof such as (cycloalkyl)alkyl,(cycloalkenyl)alkyl or (cycloalkyl)alkenyl.

The term “unsaturated,” as used herein, means that a moiety has one ormore units of unsaturation.

The term “lower alkyl,” as used herein, refers to a hydrocarbon chainhaving up to 4 carbon atoms, preferably 1 to 3 carbon atoms, and morepreferably 1 to 2 carbon atoms. The term “alkyl” includes, but is notlimited to, straight and branched chains such as methyl, ethyl,n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or t-butyl.

The term “alkoxy,” as used herein, refers to the group —OR*, wherein R*is a lower alkyl group.

The terms “halogen” or “halo,” as used herein, refer to chlorine,bromine, fluorine or iodine.

The term “halo-substituted,” as used herein, or as part of a moiety suchas “haloalkoxy” refers to an aliphatic group, as defined herein, thathas one or more halogen substituents. In certain embodiment, everyhydrogen atom on said alkyl group is replaced by a halogen atom. Suchhalo-substituted aliphatic groups include —CF₃. Such haloalkoxy groupsinclude —OCF₃.

The term “fluoro-substituted aliphatic,” as used herein, an aliphaticgroup, as defined herein, that has one or more fluorine substituents. Incertain embodiment, a fluoro-substituted aliphatic group is afluoroalkyl group.

The term “fluoroalkyl,” as used herein, or as part of a moiety such as“fluoroalkoxy” refers to an alkyl group, as defined herein, that has oneor more fluorine substituents. In certain embodiment, every hydrogenatom on said alkyl group is replaced by a fluorine atom.

The term “Ph,” as used herein, refers to a phenyl group.

The term “alkenyl,” as used herein refers to an aliphatic straight orbranched hydrocarbon chain having 2 to 8 carbon atoms that may contain 1to 3 double bonds. Examples of alkenyl groups include vinyl,prop-1-enyl, allyl, methallyl, but-1-enyl, but-2-enyl, but-3-enyl, or3,3-dimethylbut-1-enyl. In some embodiments, the alkenyl is preferably abranched alkenyl of 3 to 8 carbon atoms. The term “lower alkenyl” refersto an alkenyl group having 1 to 3 carbon atoms.

The terms “effective amount” and “therapeutically effective amount,” asused herein, refer to the amount of a compound of formula I that, whenadministered to a patient, is effective to at least partially treat acondition from which the patient is suffering. Such conditions include,but are not limited to, schizophrenia, schizoaffective disorder,schizophreniform disorder, L-DOPA-induced psychosis, bipolar disorder,obesity, obsessive compulsive disorder, depression, panic disorder,sleep disorders, eating disorders, epilepsy, pain, or any other disorderas described herein.

The term “pharmaceutically acceptable salts” or “pharmaceuticallyacceptable salt” includes acid addition salts, that is salts derivedfrom treating a compound of formula I with an organic or inorganic acidsuch as, for example, acetic, lactic, citric, cinnamic, tartaric,succinic, fumaric, maleic, malonic, mandelic, malic, oxalic, propionic,hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, glycolic,pyruvic, methanesulfonic, ethanesulfonic, toluenesulfonic, salicylic,benzoic, or similarly known acceptable acids. Where a compound offormula I contains a substituent with acidic properties, for instance,phenolic hydroxyl as R¹ or R^(x), the term also includes salts derivedfrom bases, for example, sodium salts. In certain embodiments, thepresent invention provides the hydrochloride salt of a compound offormula I.

The term “patient,” as used herein, refers to a mammal. In certainembodiments, the term “patient”, as used herein, refers to a human.

The terms “administer,” “administering,” or “administration,” as usedherein, refer to either directly administering a compound or compositionto a patient, or administering a prodrug derivative or analog of thecompound to the patient, which will form an equivalent amount of theactive compound or substance within the patient's body.

The terms “treat” or “treating,” as used herein, refers to partially orcompletely alleviating, inhibiting, preventing, ameliorating and/orrelieving the condition.

The terms “suffer” or “suffering” as used herein refers to one or moreconditions that a patient has been diagnosed with, or is suspected tohave.

2. Description of Exemplary Compounds

In certain embodiments, the invention relates to a compound of formulaI:

or a pharmaceutically acceptable salt thereof, wherein:

-   m is 1 or 2;-   n is 0 or 1;-   designates a single or double bond;-   Ar is thienyl, furyl, pyridyl, or phenyl wherein Ar is optionally    substituted with one or more R^(x) groups;-   each R^(x) is independently -Ph, halogen, —CN, —R or —OR;-   each R is independently hydrogen, C₁₋₆ aliphatic or halo-substituted    C₁₋₆ aliphatic;-   y is 0-3;-   each R¹ is independently —R, —CN, halogen or —OR;-   R² is hydrogen, C₁₋₃ alkyl, or —O(C₁₋₃ alkyl); and-   each of R³ and R⁴ is independently hydrogen, C₁₋₆ aliphatic or    fluoro-substituted C₁₋₆ aliphatic.

As defined generally above, the n group of formula I is 0 or 1. Incertain embodiments, n is 0 thus forming a compound of formula Ia:

or a pharmaceutically acceptable salt thereof, wherein R¹, R², R³, R⁴,Ar, y, and m are as defined above for compounds of formula I and inclasses and subclasses as described above and herein.

According to another embodiment, the n group of formula I is 1, thusforming a compound of formula Ib:

or a pharmaceutically acceptable salt thereof, wherein R¹, R², R³, R⁴,Ar, y, and m are as defined above for compounds of formula I and inclasses and subclasses as described above and herein.

As defined generally above, y is 0-3 and each R¹ group of formula I isindependently —R, —CN, halogen or —OR. In certain embodiments, each R¹group of formula I is independently hydrogen, C₁₋₃ aliphatic, halogen,—OMe or —CF₃. In still other embodiments, y is 1, and R¹ is halogen.

According to one embodiment, y is 1, n is 1, and R¹ is at the 7-positionof the bicyclic ring of formula I, thus forming a compound of formulaIIa or IIb:

or a pharmaceutically acceptable salt thereof, wherein each R¹, R², R³,R⁴, Ar, and m are as defined above for compounds of formula I and inclasses and subclasses as described above and herein.

According to another embodiment, y is 1, n is 0, and R¹ is at the 6- or7-position of the bicyclic ring of formula I, thus forming a compound offormula IIc, IId, IIe or IIf:

or a pharmaceutically acceptable salt thereof, wherein each R¹, R², R³,R⁴, Ar, and m are as defined above for compounds of formula I and inclasses and subclasses as described above and herein.

As defined generally above, each of the R³ and R⁴ groups of formula I isindependently hydrogen, C₁₋₆ aliphatic or fluoro-substituted C₁₋₆aliphatic. In certain embodiments, each of the R³ and R⁴ groups offormula I is independently hydrogen, methyl, ethyl, 2-fluoroethyl,2,2-difluoroethyl or cyclopropyl. In other embodiments, one of the R³and R⁴ groups of formula I is hydrogen and the other R³ or R⁴ ishydrogen, methyl, ethyl, 2-fluoroethyl, 2,2-difluoroethyl orcyclopropyl. In other embodiments, neither of the R³ and R⁴ groups offormula I is hydrogen. In still other embodiments, both of the R³ and R⁴groups of formula I are hydrogen.

As defined generally above, each R¹ group of formula I is independently—R, —CN, halogen or —OR. In certain embodiments, each R¹ group offormula I is hydrogen. In other embodiments, at least one each R¹ groupof formula I is halogen. According to another aspect of the presentinvention, one R¹ group of formula I is hydrogen and the other R¹ groupsof formula I are independently halogen, —OH, lower alkyl, lower alkoxy,trifluoromethyl, trifluoromethoxy, or —CN. Yet another aspect of thepresent invention provides a compound of formula I wherein y is 1 and R¹is halogen. In certain embodiments, y is 1 and R¹ is fluoro or chloro.

As defined generally above, the Ar group of formula I is thienyl, furyl,pyridyl, or phenyl, wherein said phenyl is optionally substituted withone or more R^(x) substituents independently selected from -Ph, —R, —CN,halogen or —OR. In certain embodiments, the Ar group of formula I isunsubstituted phenyl. In other embodiments, the Ar group of formula I isphenyl with at least one R^(x) substituent in the ortho position. Inother embodiments, the Ar group of formula I is phenyl with at least oneR^(x) substituent in the ortho position selected from -Ph, halogen,lower alkyl, lower alkoxy, or trifluoromethyl. According to one aspectthe present invention provides a compound of formula I wherein Ar isphenyl di-substituted in the ortho and meta positions with halogen,lower alkyl or lower alkoxy. Yet another aspect of the present inventionprovides a compound of formula I wherein Ar is phenyl di-substituted inthe ortho and para positions with halogen, lower alkyl or lower alkoxy.In certain embodiments, Ar is phenyl substituted at both ortho-positionswith independently selected halogen or methyl. Exemplary substituents onthe phenyl moiety of the Ar group of formula I include —OMe, fluoro,chloro, methyl, and trifluoromethyl.

According to one embodiment, Ar is phenyl substituted with R^(x) in theortho-position thus forming a compound of formula IIIa or IIIb:

or a pharmaceutically acceptable salt thereof, wherein each R¹, R², R³,R⁴, R^(x), y and m are as defined above for compounds of formula I andin classes and subclasses as described above and herein.

According to another embodiment, the present invention provides acompound of formula IIIc or IIId:

or a pharmaceutically acceptable salt thereof, wherein each R¹, R², R³,R⁴, R^(x), y and m are as defined above for compounds of formula I andin classes and subclasses as described above and herein.

In certain embodiments, the Ar group of formula I is selected from thefollowing:

According to another embodiment, the Ar group of formula I is pyridyl.

As defined generally above, the R² of formula I is hydrogen, C₁₋₃ alkyl,or —O(C₁₋₃ alkyl). In certain embodiments, the R² of formula I ishydrogen, methyl, or methoxy. In other embodiments, the R² of formula Iis hydrogen or methyl. In still other embodiments, the R² of formula Iis hydrogen.

Compounds of the present invention contain asymmetric carbon atoms andthus give rise to stereoisomers, including enantiomers anddiastereomers. Accordingly, it is contemplated that the presentinvention relates to all of these stereoisomers, as well as to mixturesof the stereoisomers. Throughout this application, the name of theproduct of this invention, where the absolute configuration of anasymmetric center is not indicated, is intended to embrace theindividual stereoisomers as well as mixtures of stereoisomers. Incertain embodiments of the invention, compounds having an absolute (R)configuration are preferred.

In certain embodiments, the present invention provides a compound offormula IVa, IVb, IVc, or IVd:

or a pharmaceutically acceptable salt thereof, wherein each R¹, R², R³,R⁴, Ar, y and m are as defined above for compounds of formula I and inclasses and subclasses as described above and herein.

According to another embodiment, the present invention provides acompound of any of formula Va, Vb, Vc, Vd, Ve, Vf, Vg, or Vh:

or a pharmaceutically acceptable salt thereof, wherein each R¹, R², R³,R⁴, R^(x), y and m are as defined above for compounds of formula I andin classes and subclasses as described above and herein.

Where an enantiomer is preferred, it may, in some embodiments beprovided substantially free of the corresponding enantiomer. Thus, anenantiomer substantially free of the corresponding enantiomer refers toa compound which is isolated or separated via separation techniques orprepared free of the corresponding enantiomer. “Substantially free,” asused herein, means that the compound is made up of a significantlygreater proportion of one enantiomer. In certain embodiments thecompound is made up of at least about 90% by weight of a preferredenantiomer. In other embodiments of the invention, the compound is madeup of at least about 99% by weight of a preferred enantiomer. Preferredenantiomers may be isolated from racemic mixtures by any method known tothose skilled in the art, including chiral high pressure liquidchromatography (HPLC) and the formation and crystallization of chiralsalts or prepared by methods described herein. See, for example,Jacques, et al., Enantiomers, Racemates and Resolutions (WileyInterscience, New York, 1981); Wilen, S. H., et al., Tetrahedron 33:2725(1977); Eliel, E. L. Stereochemistry of Carbon Compounds (McGraw-Hill,N.Y., 1962); Wilen, S. H. Tables of Resolving Agents and OpticalResolutions p. 268 (E. L. Eliel, Ed., Univ. of Notre Dame Press, NotreDame, Ind. 1972).

It is further recognized that atropisomers of the present compounds mayexit. The present invention thus encompasses atropisomeric forms ofcompounds of formula I as defined above, and in classes and subclassesdescribed above and herein.

Exemplary compounds of formula I are set forth in Table 1, below.

TABLE 1 Exemplary Compounds of Formula I: I-1

I-2

I-3

I-4

I-5

I-6

I-7

I-8

I-9 I-10

I-11

I-12

I-13

I-14

I-15

I-16

I-17

I-18

I-19

I-20

I-21

I-22

I-23

I-24

I-25

I-26

I-27

I-28

I-29

I-30

I-31

I-32

I-33

I-34

I-35

I-36

I-37

I-38

I-39

I-40

I-41

I-42

I-43

I-44

I-45

I-46

I-47

I-48

I-49

I-50

I-51

I-52

I-53

I-54

I-55

I-56

I-57

I-58

I-59

I-60

I-61

I-62

I-63

I-64

I-65

I-66

I-67

I-68

I-69

I-70

I-71

I-72

I-73

I-74

I-75

I-76

I-77

I-78

I-79

I-80

I-81

I-82

I-83

I-84

I-85

I-86

I-87

I-88

I-89

I-90

I-91

I-92

I-93

I-94

I-95

I-96

I-97

I-98

I-99

I-100

I-101

I-102

I-103

I-104

I-105

I-106

I-107

I-108

I-109

I-110

I-111

I-112

I-113

I-114

I-115

I-116

I-117

I-118

I-119

I-120

I-121

I-122

I-123

I-124

I-125

I-126

I-127

I-128

I-129

I-130

I-131

I-132

I-133

I-134

I-135

It will be appreciated that for each racemic compound disclosed in Table1, above, both enantiomers are separately contemplated and includedherein. For example, for compound I-1 depicted above as a racemate, eachof its enantiomers of structures I-1a and I-1b:

are contemplated and included herein.

It will be appreciated that for each enantiomer disclosed in Table 1,above, the opposite enantiomer is contemplated and included herein. Forexample, for compounds I-36 and I-57 depicted above as a singleenantiomer, their opposite enantiomers of structures I-36a and I-57a:

are also contemplated and included herein.

In addition, for each enantiomer disclosed in Table 1, above, theracemate of that compound is also contemplated and included herein. Forexample, for compounds I-36 and I-57 depicted above as a singleenantiomer, their racemates of structures I-36b and I-57b:

are also contemplated and included herein.

3. General Methods of Providing the Present Compounds

Compounds of the present invention are prepared by methods known to oneof ordinary skill in the art and by methods illustrated in Scheme 1-17,below. Unless otherwise noted, all variables are as defined above and inclasses and subclasses described above and herein.

The chroman and 2H-chromene derivatives of formula Ia of the presentinvention are prepared as illustrated in Scheme 1, below. Unlessotherwise noted the variables are as defined above. Specifically, Suzukicoupling of the appropriately substituted bromide or triflate (1) with asuitable coupling partner, such as arylboronic acids, using a palladiumcatalyst under basic conditions affords the biaryl derivative (2). Thesource of palladium is normally tetrakis(triphenylphosphine) palladium(0) or another suitable source such astrans-dichlorobis(tri-o-tolylphosphine)palladium (II). The normalchoices for the reaction base are sodium or potassium carbonate, cesiumor potassium fluoride or potassium phosphate, and the solvent choicesinclude tetrahydrofuran, dioxane, ethylene glycol dimethyl ether, waterand toluene. Displacement of the tosylate leaving group in (2) with amonoalkylamine or dialkylamine affords a compound of formula Ia. Thereaction can be executed in a suitable aprotic solvent including but notlimited to tetrahydrofuran or dimethyl sulfoxide at temperatures rangingfrom room temperature to 100° C.

Alternatively, the tosylate (2) can be converted to the azide (3), ontreatment with sodium azide, and the azide reduced to amine with asuitable reducing agent such as triphenylphosphine in tetrahydrofuranand water to afford compounds of formula Ia, wherein R³ and R⁴ arehydrogen, Scheme 2.

The intermediate tosylates (1), wherein X is OTf, can be prepared asillustrated in Scheme 3. Wittig reaction of an appropriately substituted2-hydroxy-3-methoxybenzaldehyde (4) with a phosphorus ylid gives analkene (5). Mitsunobu etherification of (5) on treatment with asubstituted allylic alcohol (6), diethyl azodicarboxylate andtriphenylphosphine affords diene (7). The diene (7) is then subjected toa ring closing metathesis reaction on treatment withbis(tricyclohexylphosphine)benzylidine ruthenium (IV) dichloride(Schwab, P. et al. Journal of the American Chemical Society 1996, 118,100) to give 2H-chromene derivative (8). Hydrogenation of the doublebond of the 2H-chromene derivative (8) in the presence of a metalcatalyst gives the chroman derivative (9). Suitable metal catalystsinclude palladium on activated carbon, platinum (IV) oxide or sulfidedplatinum on carbon and the choice of catalyst is dependent on thesubstituents on the aromatic ring. The methyl ether present on (9) iscleaved on treatment with iodotrimethylsilane in a halogenated solventsuch as 1,2-dichloroethane to give phenol (10). The phenol (10) isreacted with trifluoromethanesulfonic anhydride in the presence of abase such as pyridine or N,N-diisopropylethylamine to give the triflate(1), wherein R² is hydrogen, X is OTf and

represents a single bond.

Alternatively, the intermediate tosylate (1), wherein X is bromide, canbe prepared as illustrated in Scheme 4 and Scheme 5.

The substituted 2-bromophenol (11) is alkylated with allyl bromide inthe presence of a suitable base such as sodium hydride or potassiumcarbonate to give (12). Claisen rearrangement of (12) in a refluxinghigh-boiling point solvent such as 1-methyl-2-pyrrolidinone or ethyleneglycol gives phenol derivative (13). The double bond in (13) isisomerized to give (14), in which the double bond is in conjugation withthe aromatic ring, on treatment with a suitable palladium catalyst suchas bis(acetonitrile) palladium (II) dichloride. Mitsunobu etherificationof (14) on treatment with a substituted allylic alcohol (6), diethylazodicarboxylate and triphenylphosphine affords diene (15), wherein R²is hydrogen. Alternatively, treatment of phenol (14) with a substitutedvinyloxirane (16) in the presence of a suitable palladium catalyst, suchas tetrakis(triphenylphosphine) palladium (0), will give the diene (17)(Goujon, J-Y. et al. Journal of the Chemical Society Perkin Trans 12002, 496). Treatment of the alcohol (17) with p-toluenesulfonylchloride in the presence of a suitable base such as pyridine orN,N-diisopropylethylamine gives the tosylate (15), wherein R² is C₁₋₃alkyl and m is 1.

As illustrated in Scheme 5, subjecting diene (15) to a ring closingmetathesis reaction on treatment withbis(tricyclohexylphosphine)benzylidine ruthenium (IV) dichloride gives2H-chromene derivative (18). Hydrogenation of the double bond of the2H-chromene derivative (18) without reduction of the aryl bromide can beachieved using a suitable catalyst such as platinum (IV) oxide orsulfided platinum to give a chroman derivative of formula I, wherein

represents a single bond and X is bromide.

Alternatively, the intermediate 8-arylchroman or 8-aryl-2H-chromeneintermediates (2) can be prepared as illustrated in Scheme 6.

Diene (19) is subjected to a ring closing metathesis reaction ontreatment with bis(tricyclohexylphosphine)benzylidine ruthenium (IV)dichloride to give 2H-chromene derivative (20). Hydrogenation of thedouble bond of the 2H-chromene derivative (20) can be achieved using asuitable catalyst such as platinum (IV) oxide or sulfided platinum togive the chroman derivative (2), wherein

represents a single bond, Scheme 6.

Synthesis of an intermediate diene of formula 19 is illustrated inScheme 7.

Suzuki coupling of 2-methoxyphenylboronic acids (21) with different arylhalides using a palladium catalyst under basic conditions affordsanisole derivatives (22). The source of palladium is normallytetrakis(triphenylphosphine) palladium (0) or another suitable sourcesuch as trans-dichlorobis(tri-o-tolylphosphine)palladium (II).Typically, the reaction base is sodium or potassium carbonate, cesium orpotassium fluoride or potassium phosphate, and the solvent includestetrahydrofuran, dioxane, ethylene glycol dimethyl ether, water, tolueneand mixtures thereof. Cleavage of the methyl ether in (22) with borontribromide gives phenol (23) that can be alkylated with allyl bromide inthe presence of a suitable base to give allyl ether derivatives (24).Claisen rearrangement of (24) in a refluxing high-boiling point solventsuch as 1-methyl-2-pyrrolidinone or ethylene glycol gives phenolderivative (25). The double bond in (25) is isomerized to give (26), inwhich the double bond is in conjugation with the aromatic ring, ontreatment with bis(acetonitrile) palladium (II) dichloride in refluxingdichloromethane. Mitsunobu etherification of (26) on treatment with asubstituted allylic alcohol (6), diethyl azodicarboxylate andtriphenylphosphine affords diene (19), wherein R² is hydrogen.Alternatively, treatment of phenol (26) with a substituted vinyloxirane(16) in the presence of a suitable palladium catalyst, such astetrakis(triphenylphosphine) palladium (0), will give the diene (27)(Goujon, J-Y. et al. Journal of the Chemical Society Perkin Trans 12002, 496). Treatment of the alcohol (27) with p-toluenesulfonylchloride in the presence of a suitable base such as pyridine orN,N-diisopropylethylamine gives the tosylate (19), wherein R²=C₁₋₃ alkyland m is 1, Scheme 7.

An alternative synthesis of compounds of formula (Ia) is illustrated inScheme 8 and Scheme 9.

Diene (27) is subjected to a ring closing metathesis reaction ontreatment with bis(tricyclohexylphosphine)benzylidine ruthenium (IV)dichloride to give 2H-chromene derivative (28). Hydrogenation of thedouble bond of the 2H-chromene derivative (28) can be achieved using asuitable catalyst such as platinum (IV) oxide or sulfided platinum togive the chroman derivative (29), Scheme 8.

Mitsunobu homologation of the chroman or 2H-chromene alcohol (30) withacetone cyanohydrin in the presence ofN,N,N′,N′-tetramethylazodicarboxamide and tributylphosphine (Tsunoda, T.et al. Tetrahedron Letters 1999, 40, 7355) gives nitrile (31). Thenitrile (31) may be reduced to give the corresponding aldehyde (32) ontreatment with a suitable metal hydride reducing agent, such asdiisobutylaluminum hydride. Reductive amination then gives the compoundsof formula Ia, wherein m is 2.

The 2,3,4,5-tetrahydro-benzo[b]oxepine derivatives (Ib) of the presentinvention are prepared as illustrated in Scheme 10.

Displacement of the tosylate leaving group in (33) with a monoalkylamineor dialkylamine affords a compound of formula Ib. The reaction can beexecuted in a suitable aprotic solvent including but not limited totetrahydrofuran or dimethyl sulfoxide at temperatures ranging from roomtemperature to 100° C.

Alternatively, a tosylate (33) can be converted to azide (34), ontreatment with sodium azide, and the azide reduced to amine with asuitable reducing agent such as triphenylphosphine in tetrahydrofuranand water to give the compounds of formula Ib, wherein R³ and R⁴ arehydrogen, Scheme 11.

Synthesis of the intermediate tosylate (33) is illustrated in Scheme 12.

Diene (35) is subjected to a ring closing metathesis reaction ontreatment with bis(tricyclohexylphosphine)benzylidine ruthenium (IV)dichloride to give 2H-chromene derivative (36). Hydrogenation of thedouble bond of the 2H-chromene derivative (36) can be achieved using asuitable catalyst such as platinum (IV) oxide or sulfided platinum togive the chroman derivative (33), wherein

represents a single bond, Scheme 12. Isomerization of the double bondcan be achieved by treatment of 36 withdichlorobis(acetonitrile)palladium (II) in refluxing methylene chlorideto give the chroman derivative (33), wherein

represents a double bond, Scheme 12.

Synthesis of the diene (35) is illustrated in Scheme 13.

Mitsunobu etherification of (25) on treatment with a substituted allylicalcohol (6), diethyl azodicarboxylate and triphenylphosphine affordsdiene (35), wherein R² is hydrogen. Alternatively, treatment of phenol(25) with a substituted vinyloxirane (16) in the presence of a suitablepalladium catalyst, such as tetrakis(triphenylphosphine) palladium (0),will give the diene (37) (Goujon, J-Y. et al. Journal of the ChemicalSociety Perkin Trans 1 2002, 496). Treatment of the alcohol (37) withp-toluenesulfonyl chloride in the presence of a suitable base such aspyridine or N,N-diisopropylethylamine gives the tosylate (35), whereinR²=C₁₋₃ alkyl and m is 1, Scheme 13.

Scheme 14, below, depicts an alternative method for preparing compoundsof the present invention.

In step S-1 a compound of formula H is allowed to react via conjugateaddition with a compound of formula J, following which the R^(a) groupsare removed to afford the product of formula G, as depicted in Scheme15, below. One of ordinary skill in the art will appreciate that a widevariety of reaction conditions may be employed to promote thistransformation, therefore a wide variety of reaction conditions areenvisioned; see generally, March's Advanced Organic Chemistry:Reactions, Mechanisms, and Structure, M. B. Smith and J. March, 5^(th)Edition, John Wiley & Sons, 2001 and Comprehensive OrganicTransformations, R. C. Larock, 2^(nd) Edition, John Wiley & Sons, 1999.For example, the conjugate addition step may be run in the presence orabsence of a base, and with or without heating. In certain embodiments,the conjugate addition is run in the presence of potassium carbonate,potassium hydroxide, sodium hydroxide, tetrabutylammonium hydroxide,benzyltrimethylammonium hydroxide, triethylbenzylammonium hydroxide,1,1,3,3-tetramethylguanidine, 1,8-diazabicyclo[5.4.0]undec-7-ene,N-methylmorpholine, diisopropylethylamine, tetramethylethylenediamine,pyridine, or triethylamine. In certain embodiments, the reaction iscarried out in a suitable medium. A suitable medium is a solvent or asolvent mixture that, in combination with the combined reacting partnersand reagents, facilitates the progress of the reaction therebetween. Thesuitable solvent may solubilize one or more of the reaction components,or, alternatively, the suitable solvent may facilitate the suspension ofone or more of the reaction components; see, generally, March (2001). Incertain embodiments the present transformation is run in excess of thephenol reagent (corresponding to formula H), diphenyl ether, dioxane,anisole, acetone, tetrahydrofuran, ethyl acetate, isopropyl acetate,dimethylformamide, ethylene glycol, toluene, water,diisopropylethylamine, triethylamine, pyridine, N-methylmorpholine,acetonitrile, N-methylpyrrolidine, or mixtures thereof. In otherembodiments the reaction is conducted at temperatures between around 25°C. and about 110° C. In yet other embodiments, the reaction is conductedat around 25° C. In other embodiments, the conjugate addition is carriedout according to the procedures outlined in Ruhemann, S. J. Chem. Soc.1900, 77, 1121, Gudi, M. N. et al. Indian J. Chem. 1969, 7, 971, Cairns,H. et al. J. Med. Chem. 1972, 15, 583, Stoermer, M. J. and Fairlie, D.P. Aust. J. Chem. 1995, 48, 677, and Fitzmaurice, C. et al. BritishPatent No. 1262078, (filed 24 May, 1968).

At step S-2, a compound of formula G is cyclized to afford a compound offormula F. One of ordinary skill in the art will recognize that thereare a wide variety of reaction conditions that can be employed tocyclize compounds of formula G, therefore, a wide variety of conditionsare envisioned; see generally, March, (2001) and Larock (1999). Incertain embodiments, the cyclization is promoted by treating a compoundof formula G with a suitable Brønsted acid. Exemplary acids includehydrochloric, sulfuric, phosphoric, polyphosphoric, methanesulfonic,Eaton's reagent (P₂O₅/MeSO₃H), chlorosulfonic, camphorsulfonic, andp-toluenesulfonic. In other embodiments, additional reagents areemployed, including, for example, phosphorus pentoxide, phosphorustrichloride, phosphorus pentachloride, acetyl chloride, or aceticanhydride. One of ordinary skill in the art will recognize that some ofthe conditions described will promote formation of an intermediateacylchloride prior to undergoing cyclization. In yet another embodiment,the reaction is conducted with acetyl chloride or water as solvent. Instill other embodiments, the cyclization is conducted as described inRuhemann (1900), Gudi (1969), Cairns (1972), Stoermer (1995), orFitzmaurice, C. et al. British Patent No. 1262078, (filed 24 May, 1968).

In step S-3, a compound of formula F is reduced to afford a compound offormula E. One of ordinary skill in the art will recognize thatcompounds of formulae E, D, C, A, II, and II•HX contain a stereogeniccarbon. Accordingly, this invention encompasses each individualenantiomer of compounds of formulae E, D, C, A, II, and II•HX as well asmixtures thereof. While a single stereochemical isomer is depicted forformulae E, D, C, A, II, and II•HX in Scheme 14, it will be appreciatedthat mixtures of enantiomers of these formulae are accessible enrichedin either enantiomer via the present invention. As used herein, theterms “enantiomerically enriched” and “enantioenriched” denote that oneenantiomer makes up at least 75% of the preparation. In certainembodiments, the terms denote that one enantiomer makes up at least 80%of the preparation. In other embodiments, the terms denote that at least90% of the preparation is one of the enantiomers. In other embodiments,the terms denote that at least 95% of the preparation is one of theenantiomers. In still other embodiments, the terms denote that at least97.5% of the preparation is one of the enantiomers. In yet anotherembodiment, the terms denote that the preparation consists of a singleenantiomer to the limits of detection (also referred to as“enantiopure”). As used herein, when “enantioenriched” or“enantiomerically enriched” are used to describe a singular noun (e.g.,“an enantioenriched compound of formula II” or “an enantioenrichedchiral amine”), it should be understood that the “compound” or “acid”may be enantiopure, or may in fact be an enantioenriched mixture ofenantiomers. Similarly, when “racemic” is used to describe a singularnoun (e.g., “a racemic compound of formula E”), it should be understoodthat the term is in fact describing a 1:1 mixture of enantiomers.

In one aspect of the present invention, step S-3 is carried out by (a)first subjecting the compound of formula F to hydrogenation conditions,(b) forming diastereomeric salts by combining the racemic mixture of thehydrogenation product with an enantioenriched chiral amine, (c)selectively crystallizing one of the diastereomeric salts to afford adiastereomerically enriched mixture of salts, and (d) recovering theacid in enantioenriched form from the diastereomerically enriched salt,as depicted in Scheme 16, below. In certain embodiments, thehydrogenation in (a) is conducted in the presence of a palladiumcatalyst. In other embodiments, the palladium catalyst is palladium oncarbon. In still other embodiments, the hydrogenation is run inmethanol, ethanol, or acetic acid. According to one aspect of thepresent invention, the hydrogenation is run in methanol. In yet otherembodiments, the hydrogenation is conducted in the presence of sulfuricacid, acetic acid, or both. In some embodiments, the hydrogenation isconducted in the presence of sulfuric acid. In still other embodiments,the hydrogenation is conducted as described in Witiak, D. T. et al. J.Med. Chem. 1975, 18, 934. In another aspect of the present invention,the enantioenriched chiral amine is (R)-1-phenyl-propylamine. In certainembodiments, the crystallization in step (c) is conducted inacetonitrile, methanol, ethanol, isopropanol, ethyl acetate, isopropylacetate, diethyl ether, tert-butyl methyl ether, benzene, toluene,dichloromethane or the like. In certain embodiments, the free acid isliberated in step (d) by treating the salt with hydrochloric acid orsulfuric acid. In other embodiments, step (d) is conducted in toluene,water, or mixtures thereof. In other embodiments, the resolution step isconducted as described in Wigerinck, P. T. B. P. et al., Internationalpatent application number WO 9929687 A1 (1999); Van Lommen, G. R. E. etal., European patent application publication number EP 145067 A2 (1985);or Schaff, T. K. et al. J. Med. Chem. 1983, 26, 328.

In another aspect of the present invention, step S-3 is carried out by(a) first subjecting the compound of formula F to hydrogenationconditions, (b) resolving the racemic reduced product by enzymaticmeans. In certain embodiments, the enzymatic resolution is carried outaccording to Schutt, H., German patent application publication number DE4430089 A1 (1996); Urban, F. J., European patent application publicationnumber EP 0448254 A2 (1991); and Rossi, R. F., Jr., international patentapplication publication number WO 9640975 A1 (1996).

In yet another aspect of the present invention, step S-3 is carried outby (a) hydrogenating a compound of formula F in an asymmetric fashion toafford an intermediate ketone-containing compound in enantiomericallyenriched form, and (b) hydrogenating said intermediate to reduce theketo moiety and afford a compound of formula E in enantiomericallyenriched form, as shown in Scheme 17, below. In certain embodiments, theasymmetric hydrogenation in step (a) is catalyzed by a suitable chiralcatalyst. In certain embodiments, the chiral catalyst is a complexcomprising a transition metal species and a suitable chiral ligand. Incertain embodiments, the transition metal species is a late transitionmetal species (e.g., a Ru, Rh, Pd, Ir, or Pt species). In otherembodiments the transition metal species is a rhodium or rutheniumspecies. In certain embodiments, the chiral ligand contains a phosphorusmoiety that is capable of binding a transition metal species (e.g., aphosphine or phosphite moiety). In other embodiments the chiral ligandcontains an olefinic moiety that is capable of binding a transitionmetal species. In yet other embodiments, the chiral ligand contains acarbene moiety that is capable of binding to a transition metal species.Suitable chiral ligands for asymmetric hydrogenation are well known inthe art; see, e.g., Stereochemistry of Organic Compounds, E. L. Elieland S. H. Silen, 1994, John Wiley and Sons; Asymmetric Catalysis inOrganic Synthesis, R. Noyori, 1994, John Wiley and Sons; X. Cui and K.Burgess, Chem. Rev. 2005, 105, 3272; and W. Tang and X. Zhang, Chem.Rev. 2003, 103, 3029. Additional exemplary chiral ligands include, butare not limited to, JosiPhos-type, MandyPhos™-type, WalPhos-type,TaniaPhos™-type, RoPhos-type, DIPAMP-type, Butiphane-type, BPE-type,QUINAP-type, BINAP-type, NorPhos-type, MonoPhos™-type, TunePhos-type,MalPhos-type, DuPhos-type, PHOX-type, KetalPhos-type, f-KetalPhos-type,TangPhos-type, BIPHEP-type, ferrotane-type, Binaphane-type,f-Binaphane-type, Binapine-type, FAP-type, MOP-type, DIOP-type,ChiraPhos-type, BPPM-type, and BICP-type. The term “asymmetrichydrogenation,” as used herein refers to the hydrogenation of an achiralor chiral substrate which results in an enantiomerically enriched chiralproduct. In certain embodiments the asymmetric hydrogenation iscatalyzed by a chiral transition metal-containing species. In certainembodiments, the hydrogenation in step (b) is is conducted in thepresence of a palladium catalyst. In other embodiments, the palladiumcatalyst is palladium on carbon. In still other embodiments, thehydrogenation is run in methanol. In yet other embodiments, thehydrogenation is conducted in the presence of sulfuric acid and aceticacid.

In step S-4, a compound of formula E is amidated to afford a compound offormula D. One of ordinary skill in the art will recognize that thereare a wide variety of reaction conditions that can be employed toamidate compounds of formula G, therefore, a wide variety of conditionsare envisioned; see generally, March (2001); Larock (1999); Benz, G.“Synthesis of Amides and Related Compounds.” in Comprehensive OrganicSynthesis, Trost, B. M., Editor, Pergamon Press: New York, N.Y., Vol. 6;and Bailey, P. D. et al. “Amides” in Comprehensive Organic FunctionalGroup Transformation, Katritzky, et. al. Editors, Pergamon: New York,N.Y., Vol. 5. In certain embodiments, the amidation is conducted byfirst activating the carboxylic acid to facilitate acylation (e.g., byreaction with SOCl₂ or similar reagents), and subsequently treating theactivated species with a source of ammonia [e.g., ammonia gas orsolution in tetrahydrofuran toluene, heptane, tert-butyl methyl ether,diethyl ether, ethyl acetate, isopropyl acetate, dichloromethane,chloroform, dichloroethan, or water (e.g., NH₄OH)]. In otherembodiments, this reaction is conducted by first activating thecarboxylic acid to facilitate acylation by reaction with SOCl₂ andsubsequently treating the activated species with NH₄OH. In still otherembodiments, the reaction is run in toluene, benzene, ethyl acetate,dichloromethane, chloroform, dichloroethane, combinations thereof. Insome embodiments, the cyclization is run in the absence of solvent. Inother embodiments, the reaction is run at a temperature between about25° C. and 150° C. In still other embodiments, the reaction is run at atemperature between about 50° C. and about 100° C. In yet otherembodiments, the reaction is conducted according to Zhang, M. et al.Tetrahedron Lett. 2004, 45, 5229 or Devant, R. International patentapplication publication number WO05037817 (2005).

In step S-5, the amide moiety in compounds of formula D is reduced to anamine, and the resulting amine is protected to afford compounds offormula C. In compounds of formulae C and A, PG¹ and PG² are aminoprotecting groups. Protected amines are well known in the art andinclude those described in detail in Greene (1999). Suitablemono-protected amines further include, but are not limited to,aralkylamines, carbamates, allyl amines, amides, and the like. Examplesof suitable mono-protected amino moieties includet-butyloxycarbonylamino (—NHBOC), ethyloxycarbonylamino,methyloxycarbonylamino, trichloroethyloxycarbonylamino,allyloxycarbonylamino (—NHAlloc), benzyloxocarbonylamino (—NHCBZ),allylamino, benzylamino (—NHBn), fluorenylmethylcarbonyl (—NHFmoc),formamido, acetamido, chloroacetamido, dichloroacetamido,trichloroacetamido, phenylacetamido, trifluoroacetamido, benzamido,t-butyldiphenylsilyl, and the like. Suitable di-protected amines includeamines that are substituted with two substituents independently selectedfrom those described above as mono-protected amines, and further includecyclic imides, such as phthalimide, maleimide, succinimide, and thelike. Suitable di-protected amines also include pyrroles and the like,and 2,2,5,5-tetramethyl-[1,2,5]azadisilolidine and the like.Notwithstanding the definition above, one of either PG¹ or PG² incompounds of formulae C and A may be hydrogen. According to one aspectof the invention, the —N(PG¹)(PG²) moiety of formulae C and A, ist-butyloxycarbonylamino (—NHBOC).

One of ordinary skill in the art will recognize that there are a widevariety of reaction conditions that can be employed to reduce an amide,therefore, a wide variety of conditions are envisioned; see generally,March, (2001) and Larock (1999). In certain embodiments, the reductionstep is performed by treating a compound of formula D with Red-Al[sodium bis(2-methoxyethoxy)aluminumhydride] or lithium aluminumhydride. In other embodiments, the reduction step is run in toluene,benzene, tetrahydrofuran, diethyl ether, tert-butyl methyl ether, or amixture thereof. In certain embodiments, the reduction step is run at atemperature between about −40° C. and about 100° C. In otherembodiments, the reduction step is run at a temperature between about 0°C. and 40° C. In still other embodiments the reduction is conducted asdescribed in Gross, J. L. Tetrahetron Lett. 2003, 44, 8563; Mayweg, A.et al., U.S. Pat. No. 5,250,769 (2005); Devant, R. et al., Internationalpatent application publication number WO 05037817 (2005); Mitsuda, M. etal., International patent application publication number WO 03040382(2003); Bokel, H. et al., International patent application publicationnumber WO 02020507 (2002); or Bokel, H. et al., German patentapplication publication number DE 10120619 (2002).

Similarly, one of ordinary skill in the art will recognize that thereare a wide variety of methods that can be employed to protect an amine,therefore, a wide variety of conditions are contemplated; see generally,Green (1999).

In step S-6, a CG¹ group is introduced at the open ortho positionrelative to the sp2-hybridized carbon bearing the chromane oxygen informula C. The CG¹ group of formula A is a coupling group thatfacilitates transition metal-mediated C_(sp2)-C_(sp2) coupling betweenthe attached C_(sp2) carbon and the C_(sp2) carbon bearing a CG²coupling group in compounds of formula B, as shown in step S-7. Suitablecoupling reactions are well known to one of ordinary skill in the artand typically involve one of the coupling groups being anelectron-withdrawing group (e.g., Cl, Br, I, OTf, etc.), such that theresulting polar carbon-CG bond is susceptible to oxidative addition byan electron-rich metal (e.g., a low-valent palladium or nickel species),and the complementary coupling group being an electropositive group(e.g., boronic acids, boronic esters, boranes, stannanes, silyl species,zinc species, aluminum species, magnesium species, zirconium species,etc.), such that the carbon which bears the electropositive couplinggroup is susceptible to transfer to other electropositive species (e.g.,a Pd^(II-IV) species or a Ni^(II-IV) species). Exemplary reactions andcoupling groups include those described in Metal-CatalyzedCross-Coupling Reactions, A. de Meijere and F. Diederich, Eds., 2^(nd)Edition, John Wiley & Sons, 2004; and Handbook of OrganopalladiumChemistry for Organic Synthesis, Negishi, E., de Meijere, A. Editors,Wiley: New York, N.Y., 2002. In certain embodiments, CG¹ in compounds offormula A is a boronic acid, a boronic ester, or a borane. In otherembodiments, CG¹ in compounds of formula A is a boronic ester. Accordingto one aspect of the present invention, CG¹ in compounds of formula A isa boronic acid.

Reactions and reaction sequences that are used to promote thetransformation depicted in step S-6 include initial directedorthometallation followed by treatment with suitable reagent to afford acompound of formula A. In certain embodiments, directed orthometallationis succeeded with treatment with a borate ester, which is optionallysubsequently hydrolyzed to afford a boronic acid; see, e.g., Snieckus,V. Chem. Rev. 1990, 90, 879 and Schlosser, M. Angew. Chem. Int. Ed.2005, 44, 376. Another exemplary sequence involves halogenation followedby a metallation/transmetallation sequence to afford a compound offormula A. In certain embodiments, halogenation and transmetallation issucceeded with treatment with a borate ester, which is optionallysubsequently hydrolyzed to afford a boronic acid; see, generally, deMeijere (2004) and Snieckus (1990). According to one aspect of thepresent invention, a compound of formula C is first subjected toorthometallation to afford an intermediate arylmetal compound that isallowed to react with a borate ester to afford, following aqueousworkup, a compound of formula A. In certain embodiments, theorthometallation is accomplished by treating a compound of formula Cwith an alkyl lithium reagent. In other embodiments the alkyllithiumreagent employed is selected from tert-butyllithium, n-butyllithium,s-butyllithium, hexyllithium, and the like. In other embodiments thealkyllithium reagent employed is tert-butyllithium. In yet otherembodiments, the reaction is run in tetrahydrofuran, diethyl ether,dimethoxyethane, tert-butyl methyl ether, or combinations thereof. Inother embodiments, the lithiation reaction is run in tetrahydrofuran. Instill other embodiments the reaction is run at a temperature betweenabout 0° C. and about −90° C. In still other embodiments the reaction isrun at a temperature between about −30° C. and about −50° C. In certainembodiments, the lithiation is run in the presence of one or more ofN,N,N′,N′-tetramethylethylenediamine, or hexamethylphosphoric triamide.In other embodiments, the borate ester is triisopropylborate [B(OiPr)₃].According to another aspect of the present invention, a compound offormula C is first brominated, then is subjected to halogen-metalexchange to afford an intermediate arylmetal compound that is allowed toreact with a borate ester to afford, optionally following hydrolysis(by, e.g., treatment with aqueous hydrochloric acid, aqueous sulfuricacid, or the like) to the boronic acid, a compound of formula A.

In step S-7, a compound of formula A is coupled to a compound of formulaB, via a C_(sp2)-C_(sp2) coupling reaction between the carbon centersbearing complementary coupling groups CG¹ and CG² to provide a compoundof formula II. Suitable coupling reactions and suitable coupling groupsare as described above (see the description of embodiments for CG¹,above). In certain embodiments, CG² in compounds of formula B is Br, I,or OTf. According to one aspect of the present invention, CG incompounds of formula B is Br. In certain embodiments, the transformationis catalyzed by a palladium species. According to one aspect of theinvention, the transformation is catalyzed by palladium tetrakistriphenylphosphine. In certain embodiments, the coupling reaction is runwith dimethylacetamide, tetrahydrofuran, dimethoxyethane, toluene,dimethylformamide, N-methylpyrrolidine, or mixtures thereof, as solvent.In certain embodiments the coupling reaction is run withdimethylacetamide as solvent. According to another aspect of the presentinvention, the reaction is run in the presence of potassium phosphate orpotassium carbonate. In other embodiments, the reaction is heated.According to one aspect of the invention, the reaction is heated to atemperature of about 100° C.

One of ordinary skill in the art will appreciate that a compound offormula II, as prepared by the methods of the present invention, may betreated with a suitable Brønsted acid, HX, as depicted in step S-8, toform a salt thereof (represented by formula II•HX). Exemplary acidsinclude hydrogen halides, carboxylic acids, sulfonic acids, sulfuricacid, and phosphoric acid. According to one aspect of the presentinvention, a compound of formula II is treated with HCl to form acompound of formula II•HX wherein X is Cl. In certain embodiments, wherethe acid is HCl, it is introduced into the medium containing thecompound of formula II in gaseous form. In other embodiments, the acidis introduced into the medium containing the compound of formula II as asolution in methanol, ethanol, isopropanol, or water. In yet otherembodiments, the acid is introduced into the medium containing thecompound of formula II as a solution in isopropanol. In certainembodiments, the medium containing the compound of formula II isisopropanol. According to one aspect of the present invention, thedeprotection step of step S-7 and the salt formation of step S-8 areconducted in a single step by employing the acid HX in the deprotectionstep.

Although certain exemplary embodiments are depicted and described aboveand herein, it will be appreciated that compounds of the invention canbe prepared according to the methods described generally above usingappropriate starting materials by methods generally available to one ofordinary skill in the art. Additional embodiments are exemplified inmore detail herein.

4. Uses, Formulation and Administration

Compounds of the present invention have affinity for and agonist orpartial agonist activity at the 2C subtype of brain serotonin receptorsand are thus of interest for the treatment of a variety of disordersand/or the alleviation of one or more associated symptoms. Suchdisorders associated with modulations of the 2C subtype of brainserotonin receptors are described in detail below. The present inventioncontemplates that compounds of the present invention are associated witha rapid onset of action. In addition, compounds of the present inventionlack the side-effect of sexual dysfunction.

Compounds of the present invention are useful for treating one or morepsychotic disorders, as described herein, without causingdiabetogenesis. Diabetogenesis is a side-effect associated with atypicalantipsychotic agents. Without wishing to be bound by any particulartheory, it is believed that the diabetogenesis associated with atypicalantipsychotic agents results from the fact that those agents are5-HT_(2C) antagonists. As described herein, the present compounds are5-HT_(2C) agonists, or partial agonists, and therefore are notassociated with diabetogenesis.

Compounds of the present invention are useful for treating one or morepsychotic disorders such as schizophrenia including paranoid type,disorganized type, catatonic type, and undifferentiated type,schizophreniform disorder, schizoaffective disorder, delusionaldisorder, substance-induced psychotic disorder, and psychotic disordernot otherwise specified; L-DOPA-induced psychosis; psychosis associatedwith Alzheimer's dementia; psychosis associated with Parkinson'sdisease; and psychosis associated with Lewy body disease.

Compounds of the present invention are also useful for treating symptomsrelated to psychotic disorders of the schizophrenic types, including theso called “positive” and “negative” symptoms of schizophrenia. Thesesymptoms include for example hallucinations, delusions, paranoia,anxiety, agitation, excessive aggression, tension, thought disorder,blunted affect, and social or emotional withdrawal in psychoticpatients. Other symptoms often associated with psychotic disordersinclude cognition disorders or deficits such as poor attention andimpaired function, depression, suicide, metabolic syndrome, andsubstance abuse. Thus, another embodiment of the present inventionprovides a method for treating one or more symptoms associated with apsychotic disorder.

In other embodiments, the present compounds are useful for treatinganxiety disorders such as panic attack, agoraphobia, panic disorder,specific phobia, social phobia, social anxiety disorder, obsessivecompulsive disorder, posttraumatic stress disorder, acute stressdisorder, generalized anxiety disorder, separation anxiety disorder,substance-induced anxiety disorder, and anxiety disorder not otherwisespecified.

According to another embodiment, the present compounds are useful fortreating bipolar disorders. Such bipolar disorders include bipolar Idisorder, bipolar II disorder, and cyclothymic disorder; bipolar mania,dementia, and depression with psychotic features. The present compoundsare also useful for treating (including the preventing) of cycling thatmay occur between bipolar depression and bipolar mania.

A more complete description of the aforementioned mental disorders canbe found in the Diagnostic and Statistical Manual of Mental Disorders,4^(th) edition, Washington, D.C., American Psychiatric Association(1994), incorporated herein by reference in its entirety.

In certain embodiments, compounds of the present invention areadministered in combination with one or more anti-psychotic agents. Suchanti-psychotic agents are well known in the art and include clozapine(e.g., Clozaril®), risperidone (e.g., Risperidal®), olanzapine (e.g.,Zyprexa®), quetiapine (e.g., Seroquel®), ziprasidone (e.g., Geodon®),aripiprazole, amisulpiride, chlorpromazine, fluphenazine, haloperidol(e.g., Haldol®), loxapine, mesoridazine, molindone, perphenazine,pimozide, seroquel, sulpiride, thioridazine, thiothixene,trifluoperazine, and bifeprunox to name a few.

The combination of a compound of the present invention with one or moreanti-psychotic agents is useful for treating schizophrenia includingparanoid type, disorganized type, catatonic type, and undifferentiatedtype, schizophreniform disorder, schizoaffective disorder, delusionaldisorder, substance-induced psychotic disorder, and psychotic disordernot otherwise specified; L-DOPA-induced psychosis; psychosis associatedwith Alzheimer's dementia; psychosis associated with Parkinson'sdisease; psychosis associated with Lewy body disease; bipolar disorderssuch as bipolar I disorder, bipolar II disorder, and cyclothymicdisorder; bipolar mania, dementia, and depression with psychoticfeatures. In some embodiments, these combinations are useful in thetreatment of bipolar disorder, including for example treating thecycling between bipolar depression and bipolar mania.

In other embodiments, administration of a compound of the presentinvention with an anti-psychotic agent provide anti-psychotic benefitswhile eliminating or minimizing certain side affects (e.g., akathisia,dystonia, Parkinsonism dyskinesia and late dyskinesia and the like)typically observed when the anti-psychotic agent(s) is/are taken alone.

In other embodiments, compounds of the present invention are useful fortreating one or more depressive disorders such as major depressivedisorder, seasonal affective disorder, dysthymic disorder,substance-induced mood disorder, depressive disorder not otherwisespecified, and treatment resistant depression.

Another aspect of the present invention provides a method for treatingone or more mood episodes such as major depressive episode, manicepisode, mixed episode, and hypomanic episode; and adjustment disorderssuch as adjustment disorders with anxiety and/or depressed mood.

Compounds of the present invention are also useful for treating symptomsrelated to depressive disorders including somatic symptoms such asneuropathic pain and sexual dysfunction. Other somatic symptoms includehopelessness, helplessness, anxiety and worries, memory complaints withor without objective signs of cognitive impairment, loss of feeling ofpleasure (anhedonia), slowed movement, irritability, and lack ofinterest in personal care, such as poor adherence to medical or dietaryregimens.

In certain embodiments, the present invention provides a method oftreating sexual dysfunction related to depression. In other embodiments,the present invention provides a method of treating sexual dysfunctionassociated with administering a serotonin reuptake inhibitor (SRI) fortreating a depressive or other disorder. Such methods of treating sexualdysfunction are described in detail below.

In certain embodiments, compounds of the present invention areadministered in combination with one or more antidepressive agents.Suitable antidepressant agents include, for example, serotonin reuptakeinhibitors (SRIs), norepinephrine reuptake inhibitors (NRIs), combinedserotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidaseinhibitors (MAOIs), reversible inhibitors of monoamine oxidase (RIMAs),phosphodiesterase-4 (PDE4) inhibitors, corticotropin releasing factor(CRF) antagonists, alpha.-adrenoreceptor antagonists or other compoundsincluding atypical antidepressants. Additional antidepressants foradministering in combination with compounds of the present inventioninclude triple uptake inhibitors such as DOV 216303 and DOV 21947 . . .; melatonin agonists such as agomelotine, super neurotransmitter uptakeblockers (SNUBs; e.g., NS-2389 from GlaxoSmithKline and Neurosearch;(R)-DDMA from Sepracor), and/or substance P/neurokinin receptorantagonists (e.g., aprepitant/MK-869 from Merck; NKP-608 from Novartis;CPI-122721 from Pfizer; R673 from Roche; TAK637 from Takeda; andGW-97599 from GlaxoSmithKline).

Another class of antidepressant agents for administering in combinationwith compounds of the present invention are noradrenergic and specificserotonergic antidepressants (NaSSAs). A suitable example of a NaSSA ismirtazepine.

Suitable NRIs for administering in combination with compounds of thepresent invention include tertiary amine tricyclics and secondary aminetricyclics. Suitable examples of tertiary amine tricyclics include:amitriptyline, clomipramine, doxepin, imipramine (See U.S. Pat. No.2,554,736, incorporated herein by reference in its entirety) andtrimipramine, and pharmaceutically acceptable salts thereof. Suitableexamples of secondary amine tricyclics include: amoxapine, desipramine,maprotiline, nortriptyline and protriptyline, and pharmaceuticallyacceptable salts thereof.

Another NRI for administering in combination with compounds of thepresent invention is reboxetine (Edronax™;2-[.alpha.-(2-ethoxy)phenoxy-benzyl]morpholine, usually administered asthe racemate; See U.S. Pat. No. 4,229,449, incorporated herein byreference in its entirety).

Suitable SSRIs for administering in combination with compounds of thepresent invention include: citalopram(1-[3-(dimethylamino)propyl]-(4-fluorophenyl)-1,3-dihydr-o-5-isobenzofurancarbonitrile;See U.S. Pat. No. 4,136,193; Christensen et al., Eur. J. Pharmacol.41:153, 1977; Dufour et al., Int. Clin. Psychopharmacol. 2:225, 1987;Timmerman et al., ibid., 239, each of which is incorporated herein byreference in its entirety); fluoxetine(N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine, marketed inthe hydrochloride salt form and as the racemic mixture of its twoisoforms; see, for example, U.S. Pat. No. 4,314,081; Robertson et al.,J. Med. Chem. 31:1412, 1988, each of which is incorporated herein byreference); fluoxetine/olanzapine in combination; fluvoxamine(5-methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanoneO-(2-aminoethyl)oxime; See U.S. Pat. No. 4,085,225; Claassen et al.,Brit. J. Pharmacol. 60:505, 1977; De Wilde et al., J. Affective Disord.4:249, 1982; Benfield et al., Drugs 32:313, 1986, each of which isincorporated herein by reference in its entirety); paroxetine(trans-(−)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine;See U.S. Pat. No. 3,912,743; U.S. Pat. No. 4,007,196; Lassen, Eur. J.Pharmacol. 47:351, 1978; Hassan et al., Brit. J. Clin. Pharmacol.19:705, 1985; Laursen et al., Acta Psychiat. Scand. 71:249, 1985;Battegay et al., Neuropsychobiology 13:31, 1985, each of which isincorporated herein by reference in its entirety); sertraline,(1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthylaminehydrochloride; See U.S. Pat. No. 4,536,518, incorporated herein byreference in its entirety); escitalopram (see U.S. Pat. RE34,712); andpharmaceutically acceptable salts thereof.

Suitable MAOIs for administering in combination with compounds of thepresent invention include: isocarboxazid, phenelzine, selegiline andtranylcypromine, and pharmaceutically acceptable salts thereof.

Suitable reversible MAOIs for administering in combination withcompounds of the present invention include: moclobemide(4-chloro-N-[2-(4-morpholinyl)-ethyl]benzamide; See U.S. Pat. No.4,210,754, incorporated herein by reference in its entirety),selegiline, and pharmaceutically acceptable salts thereof.

Suitable SNRIs for administering in combination with compounds of thepresent invention include venlafaxine (see U.S. Pat. No. 4,535,186,incorporated herein by reference in its entirety; see also U.S. Pat.Nos. 5,916,923, 6,274,171, 6,403,120, 6,419,958, 6,444,708, each ofwhich is incorporated herein by reference in its entirety), andpharmaceutically acceptable salts and analogs, including theO-desmethylvenlafaxine succinate salt; milnacipran(N,N-diethyl-2-aminomethyl-1-phenylcyclopropanecarboxamide; see U.S.Pat. No. 4,478,836; Moret et al., Neuropharmacology 24:1211-19, 1985,each of which is incorporated herein by reference in its entirety);nefazodone (available from Bristol Myers Squibb and Dr. Reddy LabsInc.); duloxetine; and pharmaceutically acceptable salts thereof.

Suitable CRF antagonists for administering in combination with compoundsof the present invention include those compounds described inInternational Patent Specification Nos. WO 94/13643, WO 94/13644, WO94/13661, WO 94/13676 and WO 94/13677.

Suitable atypical antidepressants for administering in combination withcompounds of the present invention include: bupropion (Wellbutrin™;(.+−.)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone),lithium, nefazodone, trazodone and viloxazine, and pharmaceuticallyacceptable salts thereof. Another suitable atypical antidepressant issibutramine.

Particular antidepressants for administering in combination withcompounds of the present invention include, but are not limited to,adinazolam, alaproclate, alnespirone, amineptine, amitriptyline,amitriptyline/chlordiazepoxide combination, amoxapine, aprepitant,atipamezole, azamianserin, bazinaprine, befuraline, bifemelane,binodaline, bipenamol, brofaromine, buproprion, caroxazone, cericlamine,cianopramine, cimoxatone, citalopram, clemeprol, clomipramine,clovoxamine, dazepinil, deanol, demexiptiline, desipramine,O-desmethylvenlafaxine, dibenzepin, dothiepin, doxepin, droxidopa,duloxetine, elzasonan, enefexine, eptapirone, escitalopram, estazolam,etoperidone, femoxetine, fengabine, fezolamine, fluotracen, fluoxetine,fluvoxamine, gepirone, idazoxan, imipramine, indalpine, indeloxazine,iprindole, isocarboxazid, levoprotiline, litoxetine, lofepramine,maprotiline, medifoxamine, metapramine, metralindole, mianserin,milnacipran, minaprine, mirtazapine, moclobemide, montirelin,nebracetam, nefopam, nefozodine, nemititide, nialamide, nomifensine,norfluoxetine, nortriptyline, orotirelin, oxaflozane, paroxetine,pheneizine, pinazepam, pirlindone, pizotyline, protryptiline,reboxetine, ritanserin, robalzotan, rolipram, selegiline, sercloremine,sertraline, setiptiline, sibutramine, sulbutiamine, sulpiride,sunepitron, teniloxazine, thozalinone, thymoliberin, tianeptine,tiflucarbine, tofenacin, tofisopam, toloxatone, tomoxetine,tranylcypromine, trazodone, trimiprimine, venlafaxine, veralipride,vilazodone, viloxazine, viqualine, zimelidine and zometrapine, andpharmaceutically acceptable salts thereof, and St. John's wort herb, orHypencuin perforatum, or extracts thereof.

Suitable classes of anti-anxiety agents for administering in combinationwith compounds of the present invention include 5-HT_(1A) agonists orantagonists, especially 5-HT_(1A) partial agonists, neurokinin receptor(NK) antagonists (e.g., saredutant and osanetant) and corticotropinreleasing factor (CRF) antagonists. Suitable 5-HT_(1A) receptor agonistsor antagonists that may be used in the present invention include, inparticular, the 5-HT_(1A) receptor partial agonists buspirone,flesinoxan, gepirone and ipsapirone, and pharmaceutically acceptablesalts thereof. An example of a compound with 5-HT_(1A) receptorantagonist/partial agonist activity is pindolol. new 5HT_(1A) agonistsvariza, alnespirone, gepirone, sunepitron, MKC242, vilazodone,eptapirone, and ORG12962 from Organon; new 5HT_(1A) antagonists such asrobalzotan; new 5-HT_(1B) agonists such as elzasonan; new 5HT₂antagonists such as YM-992 (from Yamanouchi Pharmaceuticals) andnemifitide.

According to the present invention, the inventive combinations may beadministered in conjunction with one or more other agents that is usefulin treating depression or other mood disorders. Alternatively oradditionally, inventive combinations may be administered with one ormore other pharmaceutical agents active in treating any other symptom ormedical condition present in the mammal that is related or unrelated tothe depression or mood disorder being experienced by the mammal.Examples of such pharmaceutical agents include, for example,anti-angiogenic agents, anti-neoplastic agents, anti-diabetic agents,anti-infective agents, pain-relieving agents, anti-psychotic agents,gastrointestinal agents, etc., or combinations thereof. Otherpharmaceutical agents useful in the practice of the present inventioninclude, for example, adjunctive therapies typically used to enhance theeffects of an antidepressant. Such adjunctive agents may include, forinstance, mood stabilizers (e.g., lithium, valproic acid, carbamazepine,etc.); pindolol, stimulants (e.g., methylphenidate, dextroamphetamine,etc.); or thyroid augmenting agents (e.g., T₃); anti-psychotics,anti-anxiety agents (e.g., benzodiazepines), and/or agents that relievesexual dysfunction (e.g., buspirone, which also has anti-anxietyeffects; dopaminergic agents such as amantadine, pramipexole, bupropion,etc.).

As 5-HT_(2C) modulators, compounds of the present invention are usefulfor treating a variety of disorders. Such disorders include premenstrualsyndrome (PMS), premenstrual dysphoric disorder (PMDD), motion or motordisorders such as Parkinson's disease; chronic fatigue syndrome,anorexia nervosa, disorders of sleep (e.g., sleep apnea), and mutism.

Premenstrual dysphoric disorder, or PMDD, is a severe form of PMS. LikePMS, PMDD typically occurs the week before the onset of menstruation anddisappears a few days after. PMDD is characterized by severe monthlymood swings and physical symptoms that interfere with everyday life,especially a woman's relationships with her family and friends. PMDDsymptoms go far beyond what are considered manageable or normalpremenstrual symptoms.

PMDD is a combination of symptoms that may include irritability,depressed mood, anxiety, sleep disturbance, difficulty concentrating,angry outbursts, breast tenderness and bloating. The diagnostic criteriaemphasize symptoms of depressed mood, anxiety, mood swings orirritability. The condition affects up to one in 20 American women whohave regular menstrual periods. According to another embodiment, thepresent invention provides a method for treating one or more symptomsassociated with PMDD.

Selective serotonin reuptake inhibitors (SSRIs) are the currentpreferred method for treating symptoms associated with PMDD. Accordingto another aspect, the present invention provides a method for treatingPMDD, or one or more symptoms associated with PMDD, by administering acompound of formula I in combination with an SSRI. In certainembodiments, the SSRI is fluoxetine, venlafaxine, paroxetine,duloxetine, or sertraline.

According to another embodiment, compounds of the present invention areuseful for treating a variety of eating disorders. In certainembodiments, the eating disorder is hyperphagia, bulimia or anorexianervosa. In certain embodiments, compounds of the present invention areuseful for treating gastrointestinal disorders, such as malfunction ofgastrointestinal motility or intestinal propulsion. Compounds of thepresent invention are also useful in connection with weight loss orcontrol (e.g., reduction in calorie or food intake, and/or appetitesuppression). Such methods are particularly useful for treating obesitywith its consequent comorbidities including diabetes insipidus, Type IIdiabetes, cardiovascular disease, hypertension, hyperlipidemia, stroke,osteoarthritis, sleep apnea, gall bladder disease, gout, some cancers,some infertility, and early mortality.

In certain embodiments, compounds of the present invention areadministered in combination with one or more anti-obesity agents. Suchanti-obesity agents are known in the art and include apolipoprotein-Bsecretion/microsomal triglyceride transfer protein (apo-B/MTP)inhibitors, 11β-hydroxy steroid dehydrogenase-1 (11(β-HSD type 1)inhibitors, PYY₃₋₃₆ and analogs thereof, MCR-4 agonists,cholecystokinin-A (CCK-A) agonists, monoamine reuptake inhibitors (suchas sibutramine), sympathomimetic agents, R3 adrenergic receptoragonists, dopamine agonists (such as bromocriptine),melanocyte-stimulating hormone receptor analogs, cannabinoid 1 receptorantagonists (e.g., rimonabant), melanin concentrating hormoneantagonists, leptins (the OB protein), leptin analogs, leptin receptoragonists, galanin antagonists, lipase inhibitors (such astetrahydrolipstatin, i.e. orlistat), anorectic agents (such as abombesin agonist), Neuropeptide-Y receptor antagonists, thyromimeticagents, dehydroepiandrosterone or an analog thereof, glucocorticoidreceptor agonists or antagonists, orexin receptor antagonists, urocortinbinding protein antagonists, glucagon-like peptide-1 receptor agonists,ciliary neurotrophic factors (such as Axokine™), human agouti-relatedproteins (AGRP), ghrelin receptor antagonists, histamine 3 receptorantagonists or inverse agonists, and neuromedin U receptor agonists.

In other embodiments, a compound of the present invention isadministered in combination with an anti-obesity agent selected fromorlistat, sibutramine, bromocriptine, ephedrine, leptin, rimonabant,pseudoephedrine, PYY3.36 or an analog thereof, and2-oxo-N-(5-phenylpyrazinyl)spiro-[isobenzofuran-1(3H),4-piperidine]-1-carboxamide. According to another aspect of theinvention, a compound of the present invention is administered incombination with an anti-obesity agent in conjunction with typicaltreatments for obesity such as exercise and a sensible diet.

According to another embodiment, a compound of the present invention isadministered in combination with one or more agents for treatingdiabetes and associated conditions. In certain embodiments, a compoundof the present invention is administered in combination with one or moresuch agents including insulin and insulin analogs (e.g., LysProInsulin); GLP-1 (7-37) (insulinotropin) and GLP-1 (7-36)-NH₂;sulfonylureas and analogs thereof: chlorpropamide, glibenclamide,tolbutamide, tolazamide, acetohexamide, Glypizide®, glimepiride,repaglinide, meglitinide; biguanides: metformin, phenformin, buformin;“2-antagonists and imidazolines: midaglizole, isaglidole, deriglidole,idazoxan, efaroxan, fluparoxan; other insulin secretagogues:linogliride, A-4166; glitazones: ciglitazone, Actos® (pioglitazone),englitazone, troglitazone, darglitazone, Avandia® (BRL49653); fatty acidoxidation inhibitors: clomoxir, etomoxir; glucosidase inhibitors:acarbose, miglitol, emiglitate, voglibose, MDL-25,637, camiglibose,MDL-73,945; 13-agonists: BRL 35135, BRL 37344, RO 16-8714, ICI D7114, CL316,243; or phosphodiesterase inhibitors: L-386,398.

In other embodiments, a compound of the present invention isadministered in combination with one or more lipid-lowering agents:benfluorex: vanadate and vanadium complexes (e.g., Nagiivan®) andperoxovanadium complexes; amylin antagonists; glucagon antagonists;gluconeogenesis inhibitors; somatostatin analogs; antilipolytic agents:nicotinic acid, acipimox, WAG 994, pramlintide (Symlin″), AC 2993,nateglinide, aldose reductase inhibitors (e.g., zopolrestat), glycogenphosphorylase inhibitors, sorbitol dehydrogenase inhibitors,sodium-hydrogen exchanger type 1 (NNE-1) inhibitors and/or cholesterolbiosynthesis inhibitors or cholesterol absorption inhibitors, especiallya HMG-CoA reductase inhibitor, or a HMG-CoA synthase inhibitor, or aHMG-CoA reductase or synthase gene expression inhibitor, a CETPinhibitor, a bile acid sequesterant, a fibrate, an ACAT inhibitor, asqualene synthetase inhibitor, or an anti-oxidant. In other embodiments,a compound of the present invention is administered in combination withone or more naturally occurring compounds that acts to lower plasmacholesterol levels. Such naturally occurring compounds are commonlyreferred to as nutraceuticals and include, for example, garlic extract,Hoodia plant extracts, and niacin.

In certain embodiments, compounds of the present invention are usefulfor inducing, assisting or maintaining desirable bladder control in amammal. The methods are particularly useful for treating a mammal thatis experiencing or susceptible to bladder instability or urinaryincontinence. Inventive methods include prevention, treatment orinhibition of bladder-related urinary conditions and bladderinstability, including idiopathic bladder instability, nocturnalenuresis, nocturia, voiding dysfunction and urinary incontinence(including, for example, stress incontinence, urge incontinence, and/ormixed incontinence). Also treatable or preventable by administration ofa compound of this invention is bladder instability secondary toprostate hypertrophy, as is a method for enhancing urethral tone andreducing undesirable urine leakage even in an otherwise healthy person.For example, the inventive methods are applicable to alleviating urineleakage often occurring in women during the first year after childbirth.

In other embodiments, the present compounds are useful for treatingurine retention or detrusor sphincter dyssynergia. Patients sufferingfrom urine retention include those suffering from spinal cord injuriesor male patients with benign prostatic hyperplasia.

According to the present invention, a compounds of the present inventionis also useful in promoting the temporary delay of urination wheneverdesirable. Such compounds may be utilized in accordance with the presentinvention to stabilize the bladder in any applicable context. Inventivemethods therefore may be utilized to allow a recipient to control theurgency and frequency of urination.

In some embodiments of the invention, compounds of the present inventionare administered to a mammal in need thereof for the treatment,prevention, inhibition and/or amelioration of urge urinary incontinence(also known as bladder instability, neurogenic bladder, voidingdysfunction, hyperactive bladder, detrusor overactivity, detrusorhyper-reflexia or uninhibited bladder) or mixed urinary incontinence.Inventive uses include, but are not limited to, those for bladderactivities and instabilities in which the urinary urgency is associatedwith prostatitis, prostatic hypertrophy, interstitial cystitis, urinarytract infections or vaginitis. The methods of this invention may also beused to assist in inhibition or correction of the conditions ofFrequency-Urgency Syndrome, and lazy bladder, also known as infrequentvoiding syndrome.

Compounds of the present invention may also be used to treat, prevent,inhibit, or limit the urinary incontinence, urinary instability orurinary urgency associated with or resulting from administrations ofother medications, including diuretics, vasopressin antagonists,anticholinergic agents, sedatives or hypnotic agents, narcotics,alpha-adrenergic agonists, alpha-adrenergic antagonists, or calciumchannel blockers.

Compounds of the present invention are useful for inducing or assistingin urinary bladder control or preventing or treating the maladiesdescribed herein in humans in need of such relief, including adult andpediatric uses. They may also be utilized for veterinary applications,particularly including canine and feline bladder control methods. Ifdesired, the methods herein may also be used with farm animals, such asovine, bovine, porcine and equine breeds.

According to the present invention, compounds of the present inventionmay be administered alone to modulate bladder activity, or alternativelymay be administered in combination with (whether simultaneously orsequentially) one or more other pharmaceutical agents useful in themodulation of bladder activity. Alternatively or additionally, thecompounds of the present invention may be administered in combinationwith one or more other pharmaceutical agents useful in the treatment orprevention of one or more other symptoms, disorders, or diseasessuffered by the individual in need of bladder activity modulation.

Other pharmaceutical agents useful in the modulation of bladderactivity, and particularly for treatment, prevention, inhibition, and/oramelioration of urinary incontinence, include, for example, desmopressinacetate (available as DDAVP® Nasal Spray and DDAVP® tablets from AventisPharmaceuticals), as well as a desmopressin acetate rhinal tube(available from Ferring Pharmaceuticals Inc.). Other products include,for example, tolterodine tartrate (available as Detrol™ tablets fromPharmacia & Upjohn), oxybutinin chloride (available in the form ofDitropan® tablets and syrup and Ditropan XL® extended release tabletsfrom ALZA Pharmaceuticals), propanthaline bromide (available in tabletform from Roxane Laboratories, Inc.), hyoscyamine and hyoscyaminesulfate (available, respectively, as Cystopaz® tablets and Cystopaz-M®timed release capsules from PolyMedica Pharmaceuticals (U.S.A.), Inc.),hyoscyamine hydrobromide, flavoxate HCl (available in Urispas® 100 mgtablets from ALZA Pharmaceuticals), imipramine HCl (available in 10 mg,25 mg and 50 mg tablets from Geneva Pharmaceuticals, Inc.),phenylpropanolamine, midodrine HCl (available in 2.5 mg and 5 mgProamatine® tablets from Shire US Inc.), phenoxybenzamine HCl (availableas Dibenzyline® capsules from WellSpring Pharmaceuticals Corporation),and prazosin HCl (available in Minipress® capsules from Pfizer Inc.).Each of these medicaments may be administered in the pharmaceuticallyeffective amounts and regimens known in the art, including those listedin the Physicians' Desk Reference, 55 Edition, 2001, published byMedical Economics Company, Inc. at Monvale, N.J. 07645-1742, therelevant portions of which are incorporated herein by reference.

Yet other pharmaceutical agents that can act to modulate bladderactivity include, for example, other regulators of the 5HT_(2C)receptor. For example, United States Patent Application 2004/0235856(previously incorporated herein by reference in its entirety) describesa variety of 5HT_(2C) receptor modulators that are useful in accordancewith the practice of the present invention. Additional 5HT_(2C) agonistsare exemplified in Bishop et al., Expert Opin. Ther. Patent13:1691-1705, 2003, the entire contents of which are incorporated hereinby reference.

Still other pharmaceutical agents that can act to modulate bladderactivity include, for example, modulators of one or more KCNQ potassiumchannels. In some embodiments of the present invention, compounds of thepresent invention are administered in conjunction with one or moreagonists of KCNQ 2/3 or KCNQ 3/5. Such KCNQ modulators include, forexample, compounds described in U.S. Pat. No. 5,384,330 and thosedescribed in U.S. Pat. No. 5,565,483, as well as those described inUnited States Patent Application Number 2002/0183395; and United StatesPatent Application Number 2004/0029949. The entire contents of each ofthese patents and patent applications is incorporated herein byreference. In some embodiments of the present invention, compounds ofthe present invention are administered with retigabine.

In some embodiments of the present invention, compounds of the presentinvention are administered in conjunction with one or more compoundswhich act as vasopressin agonists including, but not limited to thosedescribed in U.S. Pat. No. 6,194,407 (Failli et al.), U.S. Pat. No.6,090,803 (Failli et al.), U.S. Pat. No. 6,096,736 (Ogawa et al.), andU.S. Pat. No. 6,096,735 (Ogawa et al.).

In general, it will often be desirable in accordance with the presentinvention to administer one or more compounds of the present inventionin conjunction with one or more alpha-adrenergic receptor agonistsand/or one or more other sympathomimetic drugs.

According to the present invention, compounds of formula I may be usedto treat, prevent, or alleviate dependence, withdrawal, or symptomsthereof for any of a variety of substances including, for example,recreational substances (e.g., alcohol, tobacco [for example,nicotine]), pharmacologic agents (e.g., pain relievers [for example,Vicodin®, Lortab®, Lorcet®, Percocet®, Percodan®, Tylox®, Hydrocodone,OxyContin®, methadone, Tramadol, etc], tranquilizers, stimulants, orsedatives), and illicit drugs (e.g., marijuana, heroine, cocaine,ecstasy, LSD, PCP, methamphetamine, etc.).

The term “substance abuse”, as used herein, may be defined withreference to criteria set form in the Diagnostic and Statistical Manualof Mental Disorders, 4^(th) Ed. (1994) (“DSM-IV”), which was prepared bythe Task Force on Nomenclature and Statistics of the AmericanPsychiatric Association. A feature of substance abuse is a maladaptivepattern of substance use manifested by recurrent and significant adverseconsequences related to the repeated use of substances. As recited inthe DSM-IV, substance abuse is defined as maladaptive pattern ofsubstance abuse leading to clinically significant impairment ordistress, as manifested by one (or more) of the following, occurringwithin a 12-month period: (1) recurrent substance use resulting in afailure to fulfill major role obligations at work, school, or home; (2)recurrent substance use in situations in which it is physicallyhazardous; (3) recurrent substance-related legal problems; and (4)continued substance use despite having persistent or recurrent social orinterpersonal problems cause or exacerbated by the effects of thesubstance. In addition, the DMS-IV requires that the symptoms ofsubstance abuse do not meet the criteria for substance dependence.

The term “substance dependence”, as used herein, may be defined withreference to criteria set form in the Diagnostic and Statistical Manualof Mental Disorders, 4^(th) Ed. (1994) (“DSM-IV”), which was prepared bythe Task Force on Nomenclature and Statistics of the AmericanPsychiatric Association. The criteria for substance dependence set forthin DSM-IV is a pattern of substance use, leading to clinicallysignificant impairment or distress as manifested by at least threeselected from the following group, occurring at any time within the sametwelve month period: (1) tolerance as defined by either (a) a need forsubstantially increased amounts of the substance to achieve the desiredeffect; or (b) substantially diminished effect with continued use of thesame amount of the substance; (2) withdrawal, as demonstrated by either(a) the characteristic withdrawal syndrome for the specific substance;or (b) the same, or a closely related substance is taken to relieve oravoid withdrawal symptoms; (3) the substance is often taken in largeramounts or over a longer period then was intended; (4) there is apersistent desire or unsuccessful efforts to cut down or controlsubstance use; (5) a great deal of time is spent in activities to obtainthe substance, use the substance, or recover from its effects; (6)important social, occupational or recreational activities are given upor reduced because of substance use; and (7) the substance use iscontinued despite knowledge of having a persistent or recurrent physicalor psychological problem that is likely to have been caused orexacerbated by the substance. Substance dependence can be withphysiological dependence; that is evidence of tolerance or withdrawal ispresent, or without physiological dependence, where no evidence oftolerance or withdrawal is present. Four of the conditions set forth inDSM-IV include remission. These types of remission are based on theinterval of time that has elapsed since the cessation of dependenciesand whether there is continued presence of one or more of the symptomsincluded in the criteria for dependencies.

In certain embodiments, compounds of the present invention are usefulfor treating alcoholism (e.g., alcohol abuse, addiction and/ordependence including treatment for abstinence, craving reduction andrelapse prevention of alcohol intake) and/or tobacco abuse (e.g.,smoking addiction, cessation and/or dependence including treatment forcraving reduction and relapse prevention of tobacco smoking).

In evaluating substance abuse in accordance with the present invention,reference may be made, for example, to the National Survey on Drug Useand Health (NSDUH), which obtains information on nine differentcategories of illicit drug use: marijuana, cocaine, heroin,hallucinogens, inhalants, and nonmedical use of prescription-type painrelievers, tranquilizers, stimulants, and sedatives. In thesecategories, hashish is included with marijuana, and crack is considereda form of cocaine. Several drugs are grouped under the hallucinogenscategory, including LSD, PCP, peyote, mescaline, mushrooms, and“Ecstasy” (MDMA). Inhalants include a variety of substances, such asamyl nitrite, cleaning fluids, gasoline, paint, and glue. The fourcategories of prescription-type drugs (pain relievers, tranquilizers,stimulants, and sedatives) cover numerous drugs available throughprescriptions and sometimes illegally “on the street.” Methamphetamineis considered a type of stimulant. Respondents are asked to report onlyuses of drugs that were not prescribed for them or drugs they took onlyfor the experience or feeling they caused. Over-the-counter drugs andlegitimate uses of prescription drugs are not included. NSDUH reportscombine the four prescription-type drug groups into a category referredto as “any psychotherapeutics.”

The NSDUH categorizes alcohol abuse through use of questions about thefrequency of the consumption of alcoholic beverages, such as beer, wine,whiskey, brandy, and mixed drinks. An extensive list of examples of thekinds of beverages covered is given to respondents prior to the questionadministration. A “drink” is defined as a can or bottle of beer, a glassof wine or a wine cooler, a shot of liquor, or a mixed drink with liquorin it. Times when the respondent only had a sip or two from a drink arenot considered as consumption. For this report, estimates for theprevalence of alcohol use are reported primarily at three levels definedfor both males and females and for all ages as follows:

Current use—At least one drink in the past 30 days (includes binge andheavy use).Binge use—Five or more drinks on the same occasion at least once in thepast 30 days (includes heavy use).Heavy use—Five or more drinks on the same occasion on at least 5different days in the past 30 days

The NSDUH also characterizes the use of tobacco products, includingcigarettes, chewing tobacco, snuff, cigars, and pipe tobacco. Foranalytic purposes, data for chewing tobacco and snuff are combined as“smokeless tobacco.” Cigarette use is defined as smoking “part or all ofa cigarette.” Questions to determine nicotine dependence among currentcigarette smokers also are included in NSDUH. Nicotine dependence isbased on criteria from the Nicotine Dependence Syndrome Scale (NDSS) orthe Fagerstrom Test of Nicotine Dependence (FTND).

In other embodiments, compounds of the present invention are useful fortreating withdrawal from drug addiction including addiction to nicotine,alcohol, and other substances of abuse. Individuals often suffer thesymptoms of nicotine withdrawal as a consequence of the discontinued useof tobacco in any form, including, but not limited to smoking ofcigarette, cigar, or pipe tobacco, or the oral or intranasal ingestionof tobacco or chewing tobacco. Such oral or intranasal tobacco includes,but is not limited to snuff and chewing tobacco. The cessation ofnicotine use or reduction in the amount of nicotine use, is oftenfollowed within 24 hours by symptoms including dysphoric, depressedmood; light-headedness; insomnia; irritability, frustration or anger;anxiety; nervous tremor; difficulty concentrating; restlessness;decreased heart rate; increased appetite or weight gain; and the cravingfor tobacco or nicotine. These symptoms often cause clinicallysignificant distress or impairment in social, occupational, or otherimportant areas of functioning.

The discontinued or reduction in administration of an opioid, typicallyself-administration, through injection or orally, through smoking orintranasal ingestion, often results in the presence of a characteristicopioid withdrawal condition. This withdrawal condition can also beprecipitated by administration of an opioid antagonist such as naloxoneor naltrexone after opioid use. Opioid withdrawal is characterized bysymptoms that are generally opposite to the opioid agonist effects.These withdrawal symptoms may include anxiety; restlessness; muscleaches, often in the back and legs; craving for opioids; irritability andincreased sensitivity to pain; dysphoric mood; nausea or vomiting;lacrimation; rhinorrhoea; papillary dilation; piloerection; sweating;diarrhea; yawning; fever; and insomnia. When dependence is onshort-acting opioids, such as heroin, withdrawal symptoms usually occurwithin 6-24 hours after the last dose, while with longer-acting opioids,such as methadone, symptoms may take 2-4 days to emerge. These symptomsoften cause clinically significant distress or impairment in social,occupational or other important areas of functioning. The presentinvention is most preferably used to alleviate one or more symptomsattributed to opioid withdrawal when such symptoms are not due to ageneral medical condition and are not better accounted for by anothermedical disorder.

The discontinued or reduction in use of ethanol (ethanol containingbeverages) results in the onset of ethanol withdrawal conditions.Ethanol withdrawal conditions are characterized by symptoms that beginwhen blood concentrations of ethanol decline sharply, within 4 to 12hours after ethanol use has been stopped or reduced. These ethanolwithdrawal symptoms include craving for ethanol; autonomic hyperactivity(such as sweating or pulse rate greater than 100); hand tremor;insomnia; nausea; vomiting; transient visual, tactile, or auditoryhallucinations or illusions; psychomotor agitation; anxiety; and grandmal seizures. These symptoms often cause clinically significant distressor impairment in social, occupational, or other important areas offunctioning. The present invention is most preferably used to alleviateone or more symptoms attributed to ethanol withdrawal when such symptomsare not due to a general medical condition and are not better accountedfor by another medical disorder.

According to another embodiment, a compound of the present invention isadministered in combination with one or more agents useful for treatingsubstance abuse. In certain embodiments, a compound of the presentinvention is administered in combination with one or more agents totreat tobacco abuse. Such agents include nicotine receptor partialagonists bupropion hypochloride (Zyban™) and nicotine replacementtherapies.

According to yet another embodiment, a compound of the present inventionis administered in combination with one or more agents to treatalcoholism, such as opioid antagonists (e.g., naltrexone, ReVia™),nalmefene, disulfuram (Antabuse™), and acamprosate (Campral™).

In certain embodiments, a compound is administered in combination withone or more agents for reducing alcohol withdrawal symptoms such asbenzodiazepines, beta-blockers, clonidine, carbamazepine, pregabalin,and gabapentin (Neurontin™). In other embodiments of the invention,therapy utilizing compounds of the present invention is administeredconcomitantly with, in connection with, and/or subsequent to aneducational and/or behavioral modification program to enhance continuedabstinence from substance dependence or abuse. The method of the presentinvention may be particularly useful in treating symptoms of withdrawaloften observed in rehabilitation or other treatment programs. Therefore,the programs can be more effective by focusing on educational andbehavioral modification goals, further reducing the incidence of programnon-completion.

In certain embodiments, compounds of the present invention are usefulfor treating one or more intellectual deficit disorders comprisingadministering a compound of the present invention. In other embodiments,such intellectual deficit disorders include dementia, such as dementiaof aging, vascular dementia, mild cognitive impairment, age-relatedcognitive decline, and mild neurocognitive disorder; Alzheimer'sdisease, and memory deficit, attention deficit disorders (ADD, alsoknown as Attention Deficit Hyperactivity Disorder or ADHD) in bothchildren and adults. In certain embodiments, the present inventionprovides a method of treating ADD and/or ADHD in a pediatric patientcomprising administering to said patient a compound of formula I orpharmaceutical composition thereof.

In other embodiments, the present invention provides a method oftreating one or more cognition disorders. According to another aspect,the cognition disorder is a learning disorder. Such learning disordersare known in the art and include autism, dyslexia, Asperger's syndrome,a neurobiological disorder similar to autism and characterized byserious deficits in social and communication skills; specific learningdisability, a disorder in one or more of the basic psychologicalprocesses involved in understanding or in using spoken or writtenlanguage, which may manifest itself in an imperfect ability to listen,think, speak, read, write, spell or to do mathematical calculations;dysgraphia, a disorder that causes difficulty with forming letters orwriting within a defined space; dyscalculia, a disorder that causespeople to have problems doing arithmetic and grasping mathematicalconcepts; dyspraxia, a problem with the body's system of motion thatinterferes with a person's ability to make a controlled or coordinatedphysical response in a given situation; visual perceptual deficit,difficulty receiving and/or processing accurate information from thesense of sight, although there is nothing wrong with vision; andauditory perceptual deficit, difficulty receiving accurate informationthrough auditory means, even though there is no problem with hearing.

In certain embodiments, the present invention provides a method fortreating one or more impulsivity disorders (e.g. borderline personalitydisorder), disruptive behavior disorders, or impulse control disorders.In certain embodiments, the present invention provides a method fortreating Tourette's syndrome (TS), an inherited, neurological disordercharacterized by repeated and involuntary body movements (tics) and/oruncontrollable vocal sounds.

According to another aspect, the present invention provides a method fortreating one or more behavioral addictions and addictive disorders.Behavioral addictions and addictive disorders result from theintoxication one senses from the release of brain chemicals (e.g.,serotonin, adrenaline, epinephrine, etc.) during certain activities.Such disorders are known in the art and include gambling, sex addiction,eating disorders, spending addiction, rage/anger, workaholism, exerciseaddiction, risk taking addictions, and perfectionism to name a few.

In certain embodiments, a compound of the present invention isadministered in combination with one or more cognitive improvementagents. Such agents are well known in the art and include donepezilhydrochloride (Aircept™) and other acetylcholinesterase inhibitors;galantamine, neuroprotective agents (e.g., memantine); ADD/ADHD agents(e.g., methylphenidate (Ritalin™), atomoxetine (Strattera™),methylphenidate, sustained release (Concerta™) andamphetamine/dextroamphetamine (Adderall™).

According to another aspect, the present invention provides a method fortreating sexual dysfunction comprising administering a compound of thepresent invention. In certain embodiments, the sexual dysfunction isassociated with a depressive disorder. In other embodiments, the sexualdysfunction is associated with treatment of a disorder by administrationof a serotonin reuptake inhibitor. Compounds of the present inventionare useful for treating sexual dysfunction in the male and in thefemale. Such disorders include male erectile dysfunction (MED) andfemale sexual dysfunction (FSD), e.g. female sexual arousal disorder(FSAD).

In other embodiments, the present invention provides a method fortreating one or more disorders associated with sexual dysfunctionincluding: HSDD, characterized by a deficiency, or absence of, sexualfantasies and desire for sexual activity; FSAD, characterized by apersistent or recurrent inability to attain, or to maintain untilcompletion of the sexual activity, an adequate lubrication-swellingresponse of sexual excitement; FOD characterized by persistent orrecurrent delay in, or absence of, orgasm following a normal sexualexcitement phase; Sexual Pain Disorders such as dyspareunia andvaginismus; and/or HSDD characterized by a woman who has no or littledesire to be sexual, and has no or few sexual thoughts or fantasies.

According to another embodiment, a compound of the present invention isadministered in combination with one or more agents for treating malesexual dysfunction (e.g., male erectile dysfunction). Such agents areknown in the art and include a dopaminergic agent (e.g. D2, D3 or D4agonists and apomorphine); an NPY (neuropeptide Y) (preferably an NPY-1and/or NPY-5 inhibitor); a melanocortin receptor agonist or modulator ormelanocortin enhancer; an NEP inhibitor; a PDE inhibitor (preferably, acGMP PDE-5 inhibitor); a bombesin receptor antagonist or modulator, anda soluble secreted endopeptidase inhibitor (SEPi). In certainembodiments, a compound of the present invention is administered incombination with one or more agents for treating male sexual dysfunctionsuch as alprostadil or sildenafil.

According to yet another embodiment, a compound of the present inventionis administered in combination with one or more agents for treatingfemale sexual dysfunction. Such agents are known in the art and includeestrogen receptor modulators (e.g., estrogen agonists and/or estrogenantagonists); testosterone replacement agents, testosterone (Tostrelle),dihydrotestosterone, dehydroepiandrosterone (DHEA), a testosteroneimplant; e.g. dehydroandrostendione, estrogen, estrogen,medroxyprogesterone, medroxyprogesterone acetate (MPA), a combination ofestrogen and a methyl testosterone hormone replacement therapy agent;Premarin, Cenestin, Oestrofeminal, Equin, Estrace, Estrofem, EllesteSolo, Estring, Eastraderm TTS, Eastraderm Matrix, Dermestril, Premphase,Preempro, Prempak, Premique, Estratest, Estratest HS, Tibolone, adopaminergic agent; e.g. apomorphine or a selective D2, D3 or D2/D₃agonist such as, pramipexole and ropirinol, a NPY (neuropeptide Y)inhibito; e.g. a NPY (neuropeptide Y) inhibitor such as a NPY1 or NPY5inhibitor, preferably NPY1 inhibitor, a melanocortin receptor modulatoror a melanocortin enhancer; e.g. melanotan II, PT-14, PT-141, a NEP(neutral endopeptidase) inhibitor; a PDE (phosphodiesterase) inhibitor;e.g. sildenafil, and/or a bombesin receptor modulator.

According to the present invention, compounds of the present inventionare useful for treating any of a variety of different types of painexperienced by mammals, such as humans. For example, the compounds ofthe present invention may be used to treat treating acute pain (shortduration) or chronic pain (regularly reoccurring or persistent), whethercentralized or peripheral.

Examples of pain that can be acute or chronic and that can be treated inaccordance with the methods of the present invention includeinflammatory pain, musculoskeletal pain, bony pain, lumbosacral pain,neck or upper back pain, visceral pain, somatic pain, neuropathic pain,cancer pain, pain caused by injury or surgery such as burn pain, orheadaches such as migraines or tension headaches, or combinations ofthese pains. One skilled in the art will recognize that these pains mayoverlap one another. For example, a pain caused by inflammation may alsobe visceral or musculoskeletal in nature.

In one embodiment of the present invention, one or more compounds of thepresent invention is/are administered in mammals to treat chronic painsuch as neuropathic pain associated for example with damage to orpathological changes in the peripheral or central nervous systems;cancer pain; visceral pain associated with for example the abdominal,pelvic, and/or perineal regions or pancreatitis; musculoskeletal painassociated with for example the lower or upper back, spine,fibromyalgia, temporomandibular joint, or myofascial pain syndrome; bonypain associated with for example bone or joint degenerating disorderssuch as osteoarthritis, rheumatoid arthritis, or spinal stenosis;headaches such migraine or tension headaches; or pain associated withinfections such as HIV, sickle cell anemia, autoimmune disorders,multiple sclerosis, or inflammation such as osteoarthritis or rheumatoidarthritis.

In some embodiments, the compounds of the present invention are used totreat chronic pain that is neuropathic pain, visceral pain,musculoskeletal pain, bony pain, headache, cancer pain or inflammatorypain or combinations thereof, in accordance with the methods describedherein. Inflammatory pain can be associated with a variety of medicalconditions such as osteoarthritis, rheumatoid arthritis, surgery, orinjury. Neuropathic pain may be associated with for example diabeticneuropathy, peripheral neuropathy, post-herpetic neuralgia, trigeminalneuralgia, lumbar or cervical radiculopathies, fibromyalgia,glossopharyngeal neuralgia, reflex sympathetic dystrophy, casualgia,thalamic syndrome, nerve root avulsion, or nerve damage cause by injuryresulting in peripheral and/or central sensitization such as phantomlimb pain, reflex sympathetic dystrophy or postthoracotomy pain, cancer,chemical injury, toxins, nutritional deficiencies, or viral or bacterialinfections such as shingles or HIV, or combinations thereof. Inventivetreatment methods further include treatments in which the neuropathicpain is a condition secondary to metastatic infiltration, adiposisdolorosa, burns or central pain conditions related to thalamicconditions.

Neuropathic pains described above may also be, in some circumstances,classified as “painful small fiber neuropathies” such as idiopathicsmall-fiber painful sensory neuropathy, or “painful large fiberneuropathies” such as demylinating neuropathy or axonal neuropathy, orcombinations thereof. Such neuropathies are described in more detail,for example, in the J. Mendell et al., N. Engl. J. Med. 2003,348:1243-1255, which is hereby incorporated by reference in itsentirety.

In another embodiment, the compounds useful in the present invention maybe administered to totally or partially inhibit a neuropathic paincondition from developing. For example, compounds of the presentinvention may be administered to a mammal who is at risk for developinga neuropathic pain condition such as a mammal who has contractedshingles or a mammal who is being treated for cancer.

In one embodiment, the compounds useful in the present invention may beadministered prior to or during a surgical procedure to partially ortotally inhibit development of pain associated with the surgicalprocedure.

As mentioned previously, the methods of the present invention may beused to treat pain that is somatic and/or visceral in nature. Forexample, somatic pain that can be treated in accordance with the methodsof the present invention includes pain associated with structural orsoft tissue injury experienced during surgery, dental procedures, burns,or traumatic body injuries. Examples of visceral pain that can betreated in accordance with the methods of the present invention includethose types of pain associated with or resulting from maladies of theinternal organs such as ulcerative colitis, irritable bowel syndrome,irritable bladder, Crohn's disease, rheumatologic (arthralgias), tumors,gastritis, pancreatitis, infections of the organs, or biliary tractdisorders, or combinations thereof. One skilled in the art will alsorecognize that the pain treated according to the methods of the presentinvention may also be related to conditions of hyperalgesia, allodynia,or both. Additionally, chronic pain to be treated in accordance with thepresent invention may be with or without peripheral or centralsensitization.

The present invention also provides use of the compounds of the presentinvention to treat acute and/or chronic pains associated with femaleconditions, which may also be referred to as female-specific pain. Suchtypes of pain include those that are encountered solely or predominatelyby females, including pain associated with menstruation, ovulation,pregnancy or childbirth, miscarriage, ectopic pregnancy, retrogrademenstruation, rupture of a follicular or corpus luteum cyst, irritationof the pelvic viscera, uterine fibroids, adenomyosis, endometriosis,infection and inflammation, pelvic organ ischemia, obstruction,intra-abdominal adhesions, anatomic distortion of the pelvic viscera,ovarian abscess, loss of pelvic support, tumors, pelvic congestion orreferred pain from non-gynecological causes.

In certain embodiments, a compound of the present invention isadministered in combination with a pain relieving agent. Examples ofpain relieving agents that may be administered with compounds of thepresent invention include, but are not limited to, analgesics such asnon-narcotic analgesics or narcotic analgesics; anti-inflammatory agentssuch as non-steroidal anti-inflammatory agents (NSAIDs), steroids oranti-rheumatic agents; migraine preparations such as beta adrenergicblocking agents, ergot derivatives, or isometheptene; tricyclicantidepressants such as amitryptyline, desipramine, or imipramine;anti-epileptics such as gabapentin, carbamazepine, topiramate, sodiumvalproate or phenyloin; α₂ agonists; or selective serotonin reuptakeinhibitors/selective norepinephrine uptake inhibitors, or combinationsthereof.

One skilled in the art will recognize that some agents described hereinact to relieve multiple conditions such as pain and inflammation, whileother agents may just relieve one symptom such as pain. A specificexample of an agent having multiple properties is aspirin, where aspirinis anti-inflammatory when given in high doses, but at lower doses isjust an analgesic. The pain relieving agent may include any combinationof the aforementioned agents, for example, the pain relieving agent maybe a non-narcotic analgesic in combination with a narcotic analgesic.

Non-narcotic analgesics useful in the practice of the present inventioninclude, for example, salicylates such as aspirin, ibuprofen (Motrin®,Advil®), ketoprofen (Orudis®), naproxen (Naprosyn®), acetaminophen,indomethacin or combinations thereof. Examples of narcotic analgesicagents that may be used in combination with compounds of the presentinvention include opioid analgesics such as fentenyl, sufentanil,morphine, hydromorphone, codeine, oxycodone, buprenorphine orpharmaceutically acceptable salts thereof or combinations thereof.Examples of anti-inflammatory agents that may be used in combinationwith compounds of the present invention include but are not limited toaspirin; ibuprofen; ketoprofen; naproxen; etodolac (Lodine®); COX-2inhibitors such as celecoxib (Celebrex®), rofecoxib (Vioxx®), valdecoxib(Bextra®), parecoxib, etoricoxib (MK663), deracoxib,2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine,4-(2-oxo-3-phenyl-2,3-dihydrooxazol-4-yl)benzenesulfonamide,darbufelone, flosulide,4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluorobenzenesulfonamide),meloxicam, nimesulide,1-Methylsulfonyl-4-(1,1-dimethyl-4-(4-fluorophenyl)cyclopenta-2,4-dien-3-yl)benzene,4-(1,5-Dihydro-6-fluoro-7-methoxy-3-(trifluoromethyl)-(2)-benzothiopyrano(4,3-c)pyrazol-1-yl)benzenesulfonamide,4,4-dimethyl-2-phenyl-3-(4-methylsulfonyl)phenyl)cyclo-butenone,4-Amino-N-(4-(2-fluoro-5-trifluoromethyl)-thiazol-2-yl)-benzenesulfonamide,1-(7-tert-butyl-2,3-dihydro-3,3-dimethyl-5-benzo-furanyl)-4-cyclopropylbutan-1-one, or their physiologically acceptable salts, esters orsolvates; sulindac (Clinoril®); diclofenac (Voltaren®); piroxicam(Feldene®); diflunisal (Dolobid®), nabumetone (Relefen®), oxaprozin(Daypro®), indomethacin (Indocin®); or steroids such as Pediapedprednisolone sodium phosphate oral solution, Solu-Medrol®methylprednisolone sodium succinate for injection, Prelone® brandprednisolone syrup.

Further examples of anti-inflammatory agents that may be used fortreating pain, for example associated with rheumatoid arthritis, inaccordance with the present invention include naproxen, which iscommercially available in the form of EC-Naprosyn® delayed releasetablets, Naprosyn®, Anaprox® and Anaprox® DS tablets and Naprosyn®suspension from Roche Labs, Celebrex® brand of celecoxib tablets, Vioxx®brand of rofecoxib, Celestone® brand of betamethasone, Cupramine® brandpenicillamine capsules, Depen® brand titratable penicillamine tablets,Depo-Medrol® brand of methylprednisolone acetate injectable suspension,Arava™ leflunomide tablets, Azulfidine EN-tabs® brand of sulfasalazinedelayed release tablets, Feldene® brand piroxicam capsules, Cataflam®diclofenac potassium tablets, Voltaren® diclofenac sodium delayedrelease tablets, Voltaren®-XR diclofenac sodium extended releasetablets, or Enbrel® etanerecept products.

Examples of yet other agents used to treat inflammations, especiallyrheumatoid arthritis, include immunosuppressants such as Gengraf™ brandcyclosporine capsules, Neoral® brand cyclosporine capsules or oralsolution, or Imuran® brand azathioprine tablets or IV injection;Indocin® brand indomethacin capsules, oral suspension or suppositories;Plaquenil® brand hydroxychloroquine sulfate; or Remicade® infliximabrecombinant for IV injection; or gold compounds such as auranofin orMyochrisyine® gold sodium thiomalate injection.

As 5-HT_(2C) modulators, compounds of the present invention are usefulfor treating a variety of disorders. Such disorders include premenstrualsyndrome, motion or motor disorders such as Parkinson's disease andepilepsy; migraines, chronic fatigue syndrome, anorexia nervosa,disorders of sleep (e.g., sleep apnea), and mutism.

In other embodiments, compounds of the present invention are useful fortreating one or more central nervous system deficiencies associated, forexample, with trauma, stroke, and spinal cord injuries,neurodegenerative diseases or toxic or infective CNS diseases (e.g.,encephalitis or meningitis), or Parkinson's disease. The compounds ofthe present invention can therefore be used to improve or inhibitfurther degradation of central nervous system activity during orfollowing the malady or trauma in question. Included in theseimprovements are maintenance or improvement in motor and motilityskills, control, coordination and strength.

5. Pharmaceutically Acceptable Compositions

In other embodiments, the invention relates to compositions comprisingat least one compound of formula I, or a pharmaceutically acceptablesalt thereof, and one or more pharmaceutically acceptable carriers,excipients, or diluents. Such compositions include pharmaceuticalcompositions for treating or controlling disease states or conditions ofthe central nervous system. In certain embodiments, the compositionscomprise mixtures of one or more compounds of formula I.

In certain embodiments, the invention relates to compositions comprisingat least one compound of formula I, or a pharmaceutically acceptablesalt thereof, and one or more pharmaceutically acceptable carriers,excipients, or diluents. Such compositions are prepared in accordancewith acceptable pharmaceutical procedures, such as, for example, thosedescribed in Remingtons Pharmaceutical Sciences, 17th edition, ed.Alfonoso R. Gennaro, Mack Publishing Company, Easton, Pa. (1985), whichis incorporated herein by reference in its entirety. Pharmaceuticallyacceptable carriers are those carriers that are compatible with theother ingredients in the formulation and are biologically acceptable.

The compounds of formula I can be administered orally or parenterally,neat, or in combination with conventional pharmaceutical carriers.Applicable solid carriers can include one or more substances that canalso act as flavoring agents, lubricants, solubilizers, suspendingagents, fillers, glidants, compression aids, binders,tablet-disintegrating agents, or encapsulating materials. In powders,the carrier is a finely divided solid that is in admixture with thefinely divided active ingredient. In tablets, the active ingredient ismixed with a carrier having the necessary compression properties insuitable proportions and compacted in the shape and size desired. Thepowders and tablets preferably contain up to 99% of the activeingredient. Suitable solid carriers include, for example, calciumphosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch,gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose,polyvinylpyrrolidine, low melting waxes and ion exchange resins.

Liquid carriers can be used in preparing solutions, suspensions,emulsions, syrups and elixirs. The active ingredient can be dissolved orsuspended in a pharmaceutically acceptable liquid carrier such as water,an organic solvent, a mixture of both, or a pharmaceutically acceptableoil or fat. The liquid carrier can contain other suitable pharmaceuticaladditives such as, for example, solubilizers, emulsifiers, buffers,preservatives, sweeteners, flavoring agents, suspending agents,thickening agents, colors, viscosity regulators, stabilizers orosmo-regulators. Suitable examples of liquid carriers for oral andparenteral administration include water (particularly containingadditives as above, e.g. cellulose derivatives, preferably sodiumcarboxymethyl cellulose solution), alcohols (including monohydricalcohols and polyhydric alcohols e.g. glycols) and their derivatives,and oils (e.g. fractionated coconut oil and arachis oil). For parenteraladministration, the carrier can also be an oily ester such as ethyloleate and isopropyl myristate. Sterile liquid carriers are used insterile liquid form compositions for parenteral administration. Theliquid carrier for pressurized compositions can be halogenatedhydrocarbon or other pharmaceutically acceptable propellant.

Liquid pharmaceutical compositions that are sterile solutions orsuspensions can be administered by, for example, intramuscular,intraperitoneal or subcutaneous injection. Sterile solutions can also beadministered intravenously. Compositions for oral administration can bein either liquid or solid form.

The compounds of formula I can be administered rectally or vaginally inthe form of a conventional suppository. For administration by intranasalor intrabronchial inhalation or insufflation, the compounds of formula Ican be formulated into an aqueous or partially aqueous solution, whichcan then be utilized in the form of an aerosol. The compounds of FormulaI can also be administered transdermally through the use of atransdermal patch containing the active compound and a carrier that isinert to the active compound, is non-toxic to the skin, and allowsdelivery of the agent for systemic absorption into the blood stream viathe skin. The carrier can take any number of forms such as creams andointments, pastes, gels, and occlusive devices. The creams and ointmentscan be viscous liquid or semisolid emulsions of either the oil-in-wateror water-in-oil type. Pastes comprised of absorptive powders dispersedin petroleum or hydrophilic petroleum containing the active ingredientcan also be suitable. A variety of occlusive devices can be used torelease the active ingredient into the blood stream such as asemipermeable membrane covering a reservoir containing the activeingredient with or without a carrier, or a matrix containing the activeingredient. Other occlusive devices are known in the literature.

Preferably the pharmaceutical composition is in unit dosage form, e.g.as tablets, capsules, powders, solutions, suspensions, emulsions,granules, or suppositories. In such form, the composition is sub-dividedin unit dose containing appropriate quantities of the active ingredient;the unit dosage forms can be packaged compositions, for example,packeted powders, vials, ampoules, prefilled syringes or sachetscontaining liquids. The unit dosage form can be, for example, a capsuleor tablet itself, or it can be the appropriate number of any suchcompositions in package form.

The amount of compound of formula I provided to a patient will varydepending upon what is being administered, the purpose of theadministration, such as prophylaxis or therapy, the state of thepatient, the manner of administration, and the like. In therapeuticapplications, compounds of formula I are provided to a patient sufferingfrom a condition in an amount sufficient to treat or at least partiallytreat the symptoms of the condition and its complications. An amountadequate to accomplish this is a “therapeutically effective amount” asdescribed previously herein. The dosage to be used in the treatment of aspecific case must be subjectively determined by the attendingphysician. The variables involved include the specific condition and thesize, age, and response pattern of the patient. The treatment ofsubstance abuse follows the same method of subjective drugadministration under the guidance of the attending physician. Generally,a starting dose is about 5 mg per day with gradual increase in the dailydose to about 1000 mg per day, to provide the desired dosage level inthe patient.

6. Combination with Other Agents

Compounds of formula I may be administered alone in order to treatvarious disorders in accordance with the present invention, or may becombined with one or more other pharmaceutical agents as describedherein. Where the present invention involves administration of two ormore pharmaceutical agents, the two or more agents may be administeredsimultaneously (such as individually at the same time, or together in apharmaceutical composition), and/or successively with one another. Ingeneral, a compound of formula I and the other pharmaceutical agent(s)are administered in a manner so that both are present in the mammal bodyfor a certain period of time to treat the disorder.

Also, the two or more pharmaceutical agents may be delivered via thesame route of administration or by different routes. Desirable routes ofadministration may well depend upon the particular agent(s) chosen, manyof which have recommended administration route(s) known to those skilledin the art. For example, opioids are generally administered by oral,intravenous, or intramuscular administration routes. Similarly, as isknown in the art, doses of pharmaceutical agents in a composition may beaffected by administration route. In general, pharmaceutical agents maybe dosed and administered according to practices known to those skilledin the art such as those disclosed in references such as the Physicians'Desk Reference, 55 Edition, 2001, published by Medical Economics Co.,Inc., Montvale, N.J.

A more complete list of pharmaceutically active agents, including painrelieving agents, can be found in the Physicians' Desk Reference, 55Edition, 2001, published by Medical Economics Co., Inc., Montvale, N.J.Each of these agents may be administered in conjunction with one or morecompounds of formula I according to the present invention. For most orall of these agents, recommended effective dosages and regimes are knownin the art; many can be found in the above-referenced Physicians' DeskReference, 55 Edition, 2001, published by Medical Economics Co., Inc.,Montvale, N.J.

In certain embodiments, the present invention is directed to prodrugs ofcompounds of formula I. The term “prodrug,” as used herein, means acompound that is convertible in vivo by metabolic means (e.g. byhydrolysis) to a compound of formula I. Various forms of prodrugs areknown in the art such as those discussed in, for example, Bundgaard,(ed.), Design of Prodrugs, Elsevier (1985); Widder, et al. (ed.),Methods in Enzymology, vol. 4, Academic Press (1985); Krogsgaard-Larsen,et al., (ed). “Design and Application of Prodrugs, Textbook of DrugDesign and Development, Chapter 5, 113-191 (1991), Bundgaard, et al.,Journal of Drug Delivery Reviews, 8:1-38 (1992), Bundgaard, J. ofPharmaceutical Sciences, 77:285 et seq. (1988); and Higuchi and Stella(eds.) Prodrugs as Novel Drug Delivery Systems, American ChemicalSociety (1975), each of which is hereby incorporated by reference in itsentirety.

EXAMPLES

As depicted in the Examples below, in certain exemplary embodiments,compounds are prepared according to the following general procedures. Itwill be appreciated that although the general methods depict thesynthesis of certain compounds of the present invention, the followinggeneral methods, in addition to the Schemes set forth above and othermethods known to one of ordinary skill in the art, can be applied to allcompounds and subclasses and species of each of these compounds, asdescribed herein.

Example 1N-{[8-(2-chlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}-N-methylaminehydrochloride

Step 1: A suspension of methyltriphenylphosphonium bromide (19.7 g, 55.0mmol) in anhydrous tetrahydrofuran (200 mL) was cooled to 0° C. andn-butyllithium (2.5 M in hexanes, 24.0 mL, 60.0 mmol) was added during5-10 minutes with stirring. The resulting clear, orange solution wasstirred at 0° C. for an additional 30 minutes and then was added viacannula to a solution of o-vanillin (3.80 g, 25.0 mmol) intetrahydrofuran (100 mL) at 23° C. After 3 hours, the reaction wasquenched with saturated aqueous ammonium chloride solution (100 mL),diluted with water (300 mL), and the aqueous phase was extracted withether (3×200 mL). The organic phase was washed with water (300 mL) andbrine (300 mL), dried over magnesium sulfate and filtered through a plugof silica gel (10 cm diam×5-6 cm H). Concentration under reducedpressure provided crude 2-methoxy-6-vinyl-phenol as a clear, colorlessoil (4.20 g) that was used without further purification. ¹H NMR (DMSO):δ3.79 (s, 3H, OCH ₃), 5.19 (dd, 1H, CH═CHH), 5.74 (dd, 1H, CH═CHH), 6.74(t, 1H, ArH), δ6.86 (dd, 1H, ArH), 6.96 (dd, 1H, CH═CHH), 7.04 (dd, 1H,ArH), and 8.74 (s, 1H, ArOH).

Step 2: A solution of crude 2-methoxy-6-vinyl-phenol (4.20 g, 25.0mmol), 2-hydroxy-3-buten-1-yl p-tosylate (7.27 g, 30.0 mmol) andtriphenylphosphine (7.87 g, 30.0 mmol) in tetrahydrofuran (ca. 200 mL)was treated with diethylazodicarboxylate (5.22 g, 30.0 mmol) via syringeat 23° C. with stirring. After 18 hours, the reaction was quenched withwater (200 mL) and the organic phase was separated. The aqueous phasewas extracted with ethyl acetate (2×250 mL) and the combined organicphases were washed with water (200 mL) and brine (300 mL), dried overmagnesium sulfate and concentrated under reduced pressure to yield anoily yellow residue (21.3 g) which was pre-adsorbed on silica gel (50 gin dichloromethane). Purification by flash chromatography using asolvent gradient of 5 to 20% ethyl acetate in hexane provided2-(2-methoxy-6-vinylphenoxy)but-3-enyl 4-methylbenzenesulfonate (4.4 g,47% overall) as a clear, colorless oil. HRMS: calcd for C₂₀H₂₂O₅S+H⁺,375.12607; found (ESI, [M+H]⁺), 375.1273.

Step 3: A solution of 2-(2-methoxy-6-vinylphenoxy)but-3-enyl4-methylbenzenesulfonate (4.4 g, 12 mmol) in dichloromethane (100 mL)was treated withbenzylidene-bis(tricyclohexylphosphine)dichlororuthenium (0.9 g) at 23°C. with stirring. After 4 hours, the solvent volume was reduced underreduced pressure (to ca. 10 mL) and the solution was pre-adsorbed onsilica gel (5 g). Purification by flash chromatography using a solventgradient of 10 to 20% ethyl acetate in hexane provided8-methoxy-2H-1-benzopyran-2-methanol 4-methylbenzenesulfonate (4.0 g,98%) as a dark oil. MS (ESI) m/z 345.0 ([M−H]⁻).

Step 4: A solution of 8-methoxy-2H-1-benzopyran-2-methanol4-methylbenzenesulfonate (13.8 g, 39.8 mmol) in ethyl acetate (280 mL)was hydrogenated over 10% palladium-on-carbon (2.8 g) at 55 psi in a 2 LParr flask. After 6 hours, the catalyst was filtered (Celite) and washedwith ethyl acetate (3×100 mL). Concentration of the filtrate providedtoluene-4-sulfonic acid 8-methoxy-chroman-2-yl methyl ester (13.9 g,100%) as a tan solid. MS (ESI) m/z 349.0 ([M+H]⁺).

Step 5: A solution of toluene-4-sulfonic acid 8-methoxy-chroman-2-ylmethyl ester (10.5 g, 30.1 mmol) in 1,2-dichloroethane (ca. 300 mL) wastreated with iodotrimethylsilane (9.4 mL, d 1.406, 66 mmol) at 23° C.with stirring and the solution was heated at 80° C. (oil bath). After 5hours, the cooled solution was quenched with 1 N aqueous hydrochloricacid (250 mL) and stirred for 5-10 minutes. The organic phase wasseparated and the aqueous phase was extracted with dichloromethane(2×250 mL). The combined organic phases were washed with saturatedaqueous sodium bicarbonate solution (400 mL) and brine (400 mL), driedover magnesium sulfate and concentrated under reduced pressure to yielda dark oil (10.6 g) which was pre-adsorbed on silica gel (20 g indichloromethane). Purification by flash chromatography using a solventgradient of 10 to 20% ethyl acetate in hexane providedtoluene-4-sulfonic acid 8-hydroxy-chroman-2-yl methyl ester (7.6 g, 75%)as an off-white solid.

HRMS: calcd for C₁₇H₁₈O₅S+H, 335.09532; found (ESI, [M+H]⁺), 335.0942.

Step 6: A solution of toluene-4-sulfonic acid 8-hydroxy-chroman-2-ylmethyl ester (14.0 g, 41.9 mmol) and pyridine (10.2 mL, 126 mmol) indichloromethane (ca. 300 mL) was treated with trifluoromethanesulfonicanhydride (14.1 mL, 83.8 mmol) at 0° C. with stirring. After ca. 5minutes, the cooling bath was removed and the solution was warmed to 23°C. After 1 additional hour, the reaction solution was diluted withdichloromethane (300 mL) and washed with 1 N aqueous hydrochloric acid(500 mL), water (3×500 mL) and saturated brine (500 mL). The organicphase was dried over magnesium sulfate and concentrated under reducedpressure to provide(8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate (19.0 g, 97%) as a light tan solid. HRMS: calcdfor C₁₈H₁₇F₃O₇S₂+H, 467.04460; found (ESI, [M+H]⁺), 467.0438.

Step 7: A mixture of(8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate (0.49 g, 1.05 mmol), 2-chlorophenylboronic acid(0.33 g, 2.1 mmol), potassium carbonate (0.44 g, 3.2 mmol) and lithiumchloride (0.13 g, 3.1 mmol) in dioxane (3.75 ml) and water (1.25 mL) waspurged with nitrogen for 20 minutes.Tetrakis(triphenylphosphine)palladium(0) (60 mg, 0.052 mmol) was addedand the reaction mixture heated at 100° C. for 1 hour. The cooledreaction mixture was then partitioned between ethyl acetate (50 mL) and1 M aqueous sodium hydroxide (50 mL). The organic layer was separated,washed with water (50 mL) dried over magnesium sulfate, filtered andconcentrated under reduced pressure to afford an orange oil.Purification by flash chromatography using a solvent gradient of 5 to10% ethyl acetate in hexane gave 400 mg (89%) of[8-(2-chlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate as a white solid. HRMS: calcd forC₂₃H₂₁ClO₄S+NH₄ ⁺, 446.11873; found (ESI, [M+NH₄]⁺), 446.1179.

Step 8: To a suspension of[8-(2-chlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate (0.13 g, 0.30 mmol) in dimethylsulfoxide (0.5mL) was added a solution of methylamine (2.0 M in tetrahydrofuran, 1.5mL, 3.0 mmol) and the mixture heated to 60° C. in a sealed vial for 24hours. The cooled reaction mixture was then diluted with diethyl ether(10 mL), washed with water (5×5 mL) and saturated brine (5 mL), driedover magnesium sulfate, filtered and concentrated under reduced pressureto afford a yellow oil. Purification by flash chromatography using asolvent gradient of 0.5 to 5% ammonia saturated methanol solution indichloromethane gave 69 mg (79%) ofN-{[8-(2-chlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}-N-methylamine.The product was dissolved in diethyl ether (1 mL) and a solution ofhydrogen chloride (1.0 M in diethyl ether, 0.25 mL, 0.25 mmol) was addedfollowed by 2-propanol (3 drops). The resulting white precipitate wasfiltered to afford 74 mg (76%) ofN-{[8-(2-chlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}-N-methylaminehydrochloride as a white solid. HRMS: calcd for C₁₇H₁₈ClNO+H⁺,288.11497; found (ESI, [M+H]⁺), 288.1143.

Example 2 {[8-(2-chlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}aminetrifluoroacetate

Step 1: A solution of[8-(2-chlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate, prepared in Example 1, step 7 (0.25 g, 0.58mmol) and sodium azide (0.15 g, 2.3 mmol) in anhydrous dimethylsulfoxide (9.5 mL) was heated to 70° C. under nitrogen for 16 hours. Thecooled reaction mixture was then diluted with diethyl ether (50 mL),washed with water (5×25 mL) and saturated brine (25 mL), dried overmagnesium sulfate, filtered and concentrated under reduced pressure toafford 0.14 g (82%) of 2-azidomethyl-8-(2-chloro-phenyl)-chroman as acolorless oil that was used without further purification. MS (ESI) m/z272.0 ([M+H-N₂]⁺).

Step 2: To a solution of 2-azidomethyl-8-(2-chloro-phenyl)-chroman (0.14g, 0.47 mmol) in tetrahydrofuran (7.8 mL) was added polymer-boundtriphenylphosphine (3 mmol/g, 0.31 g, 0.93 mmol) followed by water (0.8mL) and the mixture gently shaken for 22 hours. The brown suspension wasthen filtered through celite, the filter cake washed with diethyl ether(50 mL) and the combined filtrates dried over magnesium sulfate,filtered and concentrated under reduced pressure to afford a yellow oil.Purification by reverse phase HPLC using a solvent gradient of 5 to 95%acetonitrile in water containing 0.1% trifluoroacetic acid followed bytrituration of the product with diethyl ether (3×2 mL) gave 77 mg (45%)of {[8-(2-chlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}aminetrifluoroacetate as a tan solid. HRMS: calcd for C₁₆H₁₆ClNO+H⁺,274.09932; found (ESI, [M+H]⁺), 274.0992.

Example 3{[(2R)-8-(2,5-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}methylaminehydrochloride

Step 1: Racemic(8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate, was dissolved in acetonitrile and theresulting solution injected onto a Supercritical Fluid Chromatographyinstrument. The baseline resolved enantiomers were collected using theconditions described below.

Column: Whelk-O-1 (4.6×250 mm)

Mobile Phase: 8% 2-propanol/92% CO₂

Column Temperature: 35° C.

Flow Rate: 2 mL/minute

Wavelength: 222 nm

((2S)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate (98.2% enantiomeric excess) was isolated aspeak 1.

HRMS: calcd for C₁₈H₁₇F₃O₇S₂+H⁺, 467.04406; found (ESI, [M+H]⁺),467.0468.

((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate (>99.8% enantiomeric excess) was isolated as peak 2.

[α]_(D) ²⁵=−30° (c=0.0114 g/mL, DMSO);

HRMS: calcd for C₁₈H₁₇F₃O₇S₂+H⁺, 467.04406; found (ESI, [M+H]⁺),467.0453.

Step 2: A mixture of((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate (0.50 g, 1.1 mmol), 2,5-dichlorophenylboronicacid (0.42 g, 2.2 mmol), potassium carbonate (0.46 g, 3.3 mmol) andlithium chloride (0.14 g, 3.3 mmol) in dioxane (3.75 ml) and water (1.25mL) was purged with nitrogen for 30 minutes.Tetrakis(triphenylphosphine)palladium (0) (60 mg, 0.052 mmol) was addedand the reaction mixture heated at 100° C. for 4 hours. The cooledreaction mixture was then partitioned between ethyl acetate (15 mL) and1 M aqueous sodium hydroxide (15 mL). The organic layer was separated,washed with saturated brine (15 mL) dried over magnesium sulfate,filtered and concentrated under reduced pressure to afford an orangeoil. Purification by flash chromatography using a solvent gradient of 5to 20% ethyl acetate in hexane gave 0.46 g (90%) of[(2R)-8-(2,5-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate as an off-white solid. HRMS: calcd forC₂₃H₂₀Cl₂O₄S+H⁺, 463.05321; found (ESI, [M+H]⁺), 463.0553.

Step 3: To a suspension of[(2R)-8-(2,5-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate (0.15 g, 0.324 mmol) in dimethylsulfoxide (0.5mL) was added a solution of methylamine (2.0 M in tetrahydrofuran, 1.62mL, 3.24 mmol) and the mixture heated to 60° C. in a sealed vial for 24hours. The cooled reaction mixture was then diluted with diethyl ether(10 mL), washed with 1.0 M aqueous sodium hydroxide solution (5 mL) andwater (5×5 mL), dried over magnesium sulfate, filtered and concentratedunder reduced pressure to afford a yellow oil. Purification by flashchromatography using a solvent gradient of 0.5 to 5% ammonia saturatedmethanol solution in dichloromethane gave{[(2R)-8-(2,5-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}methylamineas a colorless syrup. The product was dissolved in diethyl ether (1 mL)and a solution of hydrogen chloride (1.0 M in diethyl ether, 0.25 mL,0.25 mmol) was added followed by 2-propanol (3 drops). The resultingwhite precipitate was filtered and the solid product triturated withdiethyl ether (3×3 mL) to afford 56 mg (48%) of{[(2R)-8-(2,5-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}methylaminehydrochloride as a white solid. MS (ESI) m/z 322.0 ([M+H]⁺).

Example 4{[(2R)-8-(2,4-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}methylaminehydrochloride

Prepared according to Example 3, replacing 2,5-dichlorophenylboronicacid with 2,4-dichlorophenylboronic acid in step 2. MS (ESI) m/z 322.0([M+H]⁺).

Example 5N-methyl-N-{[(2R)-8-phenyl-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 3, replacing 2,5-dichlorophenylboronicacid with phenylboronic acid in step 2. HRMS: calcd for C₁₇H₁₉NO+H⁺,254.15394; found (ESI, [M+H]⁺), 254.1546.

Example 6N-{[(2R)-8-(2-methoxyphenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}-N-methylaminehydrochloride

Prepared according to Example 3, replacing 2,5-dichlorophenylboronicacid with 2-methoxyphenylboronic acid in step 2. HRMS: calcd forC₁₈H₂₁NO₂+H⁺, 284.16450; found (ESI, [M+H]⁺), 284.1661.

Example 7N-{[(2R)-8-(2,4-dimethoxyphenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}-N-methylaminehydrochloride

Prepared according to Example 3, replacing 2,5-dichlorophenylboronicacid with 2,4-dimethoxyphenylboronic acid in step 2. HRMS: calcd forC₁₉H₂₃NO₃+H⁺, 314.17507; found (ESI, [M+H]⁺), 314.1743.

Example 8N-methyl-N-{[(2R)-8-(2-methylphenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 3, replacing 2,5-dichlorophenylboronicacid with 2-methylphenylboronic acid in step 2. HRMS: calcd forC₁₈H₂₁NO+H⁺, 268.16959; found (ESI, [M+H]⁺), 268.1699.

Example 9N-methyl-N-{[(2R)-8-pyridin-3-yl-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 3, replacing 2,5-dichlorophenylboronicacid with 3-pyridineboronic acid in step 2. HRMS: calcd forC₁₆H₁₈N₂O+H⁺, 255.14919; found (ESI, [M+H]⁺), 255.1508.

Example 10N-{[(2R)-8-(2-chlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}-N-methylaminehydrochloride

Prepared according to Example 3, replacing 2,5-dichlorophenylboronicacid with 2-chlorophenylboronic acid in step 2. HRMS: calcd forC₁₇H₁₈ClNO+H⁺, 288.11497; found (ESI, [M+H]⁺), 288.1146.

Example 11{[(2R)-8-(2-chlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Step 1: A mixture of((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate, prepared in Example 3, step 1 (0.50 g, 1.1mmol), 2-chlorophenylboronic acid (0.34 g, 2.2 mmol), potassiumcarbonate (0.46 g, 3.3 mmol) and lithium chloride (0.14 g, 3.3 mmol) indioxane (3.75 mL) and water (1.25 mL) was purged with nitrogen for 30minutes. Tetrakis(triphenylphosphine)palladium (0) (60 mg, 0.052 mmol)was added and the reaction mixture heated to 100° C. for 4 hours. Thecooled reaction mixture was then partitioned between ethyl acetate (15mL) and 1 M aqueous sodium hydroxide (15 mL). The organic layer wasseparated, washed with saturated brine (15 mL) dried over magnesiumsulfate, filtered and concentrated under reduced pressure to afford anorange oil. Purification by flash chromatography using a solventgradient of 5 to 20% ethyl acetate in hexane gave 0.38 g (81%) of[(2R)-8-(2-chlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzene sulfonate as a white solid. HRMS: calcd forC₂₃H₂₁ClO₄S+H⁺, 429.09218; found (ESI, [M+H]⁺), 429.0924.

Step 2: A solution of[(2R)-8-(2-chlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate (0.24 g, 0.56 mmol) and sodium azide (0.15 g,2.24 mmol) in anhydrous dimethyl sulfoxide (10 mL) was heated to 70° C.under nitrogen for 15 hours. The cooled reaction mixture was thendiluted with diethyl ether (50 mL), washed with water (5×25 mL) andsaturated brine (25 mL), dried over magnesium sulfate, filtered andconcentrated under reduced pressure to afford 0.14 g (82%) of{[(2R)-8-(2-chlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}azide as acolorless oil that was used without further purification.

Step 3: To a solution of{[(2R)-8-(2-chlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}azide (0.14g, 0.47 mmol) in tetrahydrofuran (7.8 mL) and water (0.8 mL) was addedpolymer-bound triphenylphosphine (˜3 mmol/g, 0.36 g, 1.08 mmol) and themixture gently shaken for 3 days. The brown suspension was then filteredthrough celite, the filter cake washed with diethyl ether (10 mL) andthe combined filtrates dried over magnesium sulfate, filtered andconcentrated under reduced pressure to afford a yellow oil. The crudeproduct was purified by reverse phase HPLC using a solvent gradient of 5to 95% acetonitrile in water containing 0.1% trifluoroacetic acid. Thefractions containing product were concentrated under reduced pressure toremove acetonitrile and the aqueous phase basified by the addition ofsodium carbonate and then extracted with ethyl acetate (100 mL). Theseparated organic phase was dried over magnesium sulfate andconcentrated under reduced pressure to afford{[(2R)-8-(2-chlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}amine as ayellow syrup. The product was dissolved in diethyl ether (1 mL) and asolution of hydrogen chloride (1.0 M in diethyl ether, 0.25 mL, 0.25mmol) was added followed by 2-propanol (2 drops). The resulting whiteprecipitate was filtered and the solid product triturated with diethylether (3×3 mL) to afford 36 mg (25%) of{[(2R)-8-(2-chlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride as a white solid.

HRMS: calcd for C₁₆H₁₆ClNO+H⁺, 274.09932; found (ESI, [M+H]⁺), 274.1016.

Example 12{[(2R)-8-(2,5-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing 2-chlorophenylboronic acidwith 2,5-dichlorophenylboronic acid in step 1. HRMS: calcd forC₁₆H₁₅Cl₂NO+H⁺, 308.06034; found (ESI, [M+H]⁺), 308.0602.

Example 13{[(2R)-8-(2,4-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing 2-chlorophenylboronic acidwith 2,4-dichlorophenylboronic acid in step 1. HRMS: calcd forC₁₆H₁₅Cl₂NO+H⁺, 308.06034; found (ESI, [M+H]⁺), 308.0616.

Example 14 {[(2R)-8-phenyl-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing 2-chlorophenylboronic acidwith phenylboronic acid in step 1. HRMS: calcd for C₁₆H₁₇NO+H⁺,240.13829; found (ESI, [M+H]⁺), 240.1398.

Example 15{[(2R)-8-(2-methoxyphenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing 2-chlorophenylboronic acidwith 2-methoxyphenylboronic acid in step 1. HRMS: calcd forC₁₇H₁₉NO₂+H⁺, 270.14885; found (ESI, [M+H]⁺), 270.1502.

Example 16{[(2R)-8-(2,4-dimethoxyphenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing 2-chlorophenylboronic acidwith 2,4-dimethoxyphenylboronic acid in step 1. HRMS: calcd forC₁₈H₂₁NO₃+H⁺, 300.15942; found (ESI, [M+H]⁺), 300.1589.

Example 17{[(2R)-8-(2-methylphenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing 2-chlorophenylboronic acidwith 2-methylphenylboronic acid in step 1. HRMS: calcd for C₁₇H₁₉NO+H⁺,254.15394; found (ESI, [M+H]⁺), 254.1538.

Example 18{[(2R)-8-pyridin-3-yl-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing 2-chlorophenylboronic acidwith 3-pyridineboronic acid in step 1. HRMS: calcd for C₁₅H₁₆N₂O+H⁺,241.13354; found (ESI, [M+H]⁺), 241.1329.

Example 19{[(2S)-8-(2-chlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}methylaminehydrochloride

Prepared according to Example 3, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl-4-methylbenzenesulfonate with((2S)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate and 2,5-dichlorophenylboronic acid with2-chlorophenylboronic acid in step 2. HRMS: calcd for C₁₇H₁₈ClNO+H⁺,288.11497; found (ESI, [M+H]⁺), 288.1161.

Example 20{[(2S)-8-(2,5-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}methylaminehydrochloride

Prepared according to Example 3, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate with((2S)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate in step 2. HRMS: calcd for C₁₇H₁₇Cl₂NO+H⁺,322.07599; found (ESI, [M+H]⁺), 322.0782.

Example 21{[(2S)-8-(2,4-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}methylaminehydrochloride

Prepared according to Example 3, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate with((2S)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate and 2,5-dichlorophenylboronic acid with2,4-dichlorophenylboronic acid in step 2. HRMS: calcd forC₁₇H₁₇Cl₂NO+H⁺, 322.07599; found (ESI, [M+H]⁺), 322.0775.

Example 22N-methyl-1-[(2S)-8-phenyl-3,4-dihydro-2H-chromen-2-yl]methanaminehydrochloride

Prepared according to Example 3, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate with((2S)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate and 2,5-dichlorophenylboronic acid withphenylboronic acid in step 2. HRMS: calcd for C₁₇H₁₉NO+H⁺, 254.15394;found (ESI, [M+H]⁺), 254.1565.

Example 23{[(2S)-8-(2-methoxyphenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}methylaminehydrochloride

Prepared according to Example 3, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate with((2S)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate and 2,5-dichlorophenylboronic acid with2-methoxyphenylboronic acid in step 2. HRMS: calcd for C₁₈H₂₁NO₂+H⁺,284.16450; found (ESI, [M+H]⁺), 284.1635.

Example 24{[(2S)-8-(2,4-dimethoxyphenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}methylaminehydrochloride

Prepared according to Example 3, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate with((2S)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate and 2,5-dichlorophenylboronic acid with2,4-dimethoxyphenylboronic acid in step 2. HRMS: calcd for C₁₉H₂₃NO₃+H⁺,314.17507; found (ESI, [M+H]⁺), 314.1766.

Example 25N-methyl-1-[(2S)-8-(2-methylphenyl)-3,4-dihydro-2H-chromen-2-yl]methanaminehydrochloride

Prepared according to Example 3, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate with((2S)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate and 2,5-dichlorophenylboronic acid with2-methylphenylboronic acid in step 2. HRMS: calcd for C₁₈H₂₁NO+H⁺,268.16959; found (ESI, [M+H]⁺), 268.1712.

Example 26N-methyl-1-[(2S)-8-pyridin-3-yl-3,4-dihydro-2H-chromen-2-yl]methanaminehydrochloride

Prepared according to Example 3, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate with((2S)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate and 2,5-dichlorophenylboronic acid with3-pyridineboronic acid in step 2. HRMS: calcd for C₁₆H₁₈N₂O+H⁺,255.14919; found (ESI, [M+H]⁺), 255.1495.

Example 27{[(2S)-8-(2-chlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate with((2S)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate in step 1. HRMS: calcd for C₁₆H₁₆ClNO+H⁺,274.09932; found (ESI, [M+H]⁺), 274.0986.

Example 28{[(2S)-8-(2,5-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate with((2S)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate and 2-chlorophenylboronic acid with2,5-dichlorophenylboronic acid in step 1. HRMS: calcd forC₁₆H₁₅Cl₂NO+H⁺, 308.06034; found (ESI, [M+H]⁺), 308.0623.

Example 29{[(2S)-8-(2,4-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate with((2S)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate and 2-chlorophenylboronic acid with2,4-dichlorophenylboronic acid in step 1. HRMS: calcd forC₁₆H₁₅Cl₂NO+H⁺, 308.06034; found (ESI, [M+H]⁺), 308.06.

Example 30 {[(2S)-8-phenyl-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate with((2S)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate and 2-chlorophenylboronic acid withphenylboronic acid in step 1. HRMS: calcd for C₁₆H₁₇NO+H⁺, 240.13829;found (ESI, [M+H]⁺), 240.1381.

Example 31{[(2S)-8-(2-methoxyphenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate with((2S)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate and 2-chlorophenylboronic acid with2-methoxyphenylboronic acid in step 1. HRMS: calcd for C₁₇H₁₉NO₂+H⁺,270.14885; found (ESI, [M+H]⁺), 270.1485.

Example 32{[(2S)-8-(2,4-dimethoxyphenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate with((2S)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate and 2-chlorophenylboronic acid with2,4-dimethoxyphenylboronic acid in step 1. HRMS: calcd for C₁₈H₂₁NO₃+H⁺,300.15942; found (ESI, [M+H]⁺), 300.1585.

Example 33{[(2S)-8-(2-methylphenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate with((2S)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate and 2-chlorophenylboronic acid with2-methylphenylboronic acid in step 1. HRMS: calcd for C₁₇H₁₉NO+H⁺,254.15394; found (ESI, [M+H]⁺), 254.155.

Example 34{[(2S)-8-pyridin-3-yl-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate with((2S)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate and 2-chlorophenylboronic acid with3-pyridineboronic acid in step 1. HRMS: calcd for C₁₅H₁₆N₂O+H⁺,241.13354; found (ESI, [M+H]⁺), 241.1346.

Example 35{[(2R)-8-(2,6-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}methylaminehydrochloride

Step 1: A mixture of 1-bromo-2,6-dichlorobenzene (5.0 g, 0.022 mol),2-methoxyphenylboronic acid (5.045 g, 0.033 mol) and potassium carbonate(7.65 g, 0.055 mol) in dioxane (130 mL) and water (13 mL) was purgedwith nitrogen for 20 minutes.Trans-dichlorobis(tri-o-tolylphosphine)palladium (II) (0.87 g, 0.0011mol) was added and the reaction mixture heated to 100° C. for 36 hours.The cooled reaction mixture was then filtered through celite washing thefilter cake with ethyl acetate. The combined organic filtrates werediluted to 500 mL by the addition of ethyl acetate, then washed with 2.0M aqueous sodium hydroxide (2×350 mL), water (350 mL) and saturatedbrine (350 mL), dried over magnesium sulfate, filtered and concentratedunder reduced pressure to afford a yellow oil. Purification by flashchromatography using a solvent gradient of 0.5 to 2% ethyl acetate inhexane gave 2.74 g (49%) of 2′,6′-dichloro-1,1′-biphenyl-2-yl methylether as a white solid. MS (EI) m/z 252 (M^(+.)).

Step 2: To a solution of 2′,6′-dichloro-1,1′-biphenyl-2-yl methyl ether(5.83 g, 0.023 mol) in anhydrous dichloromethane (100 mL) at 0° C. undernitrogen was added a solution of boron tribromide (1.0 M indichloromethane, 27.6 mL, 0.0276 mol) dropwise over 40 minutes via asyringe pump. The reaction mixture was then stirred at room temperaturefor 17 hours, then quenched by the addition of absolute ethanol (50 mL).The mixture was stirred at room temperature for 1.5 hours thenconcentrated under reduced pressure to afford a dark oil. The oil wasdissolved in 2.0 M aqueous sodium hydroxide solution (200 mL) and theresulting milky suspension extracted with diethyl ether (200 mL). Theseparated aqueous phase was then cooled to 0° C. and acidified to pH 1by the addition of concentrated hydrochloric acid. The resulting milkysuspension was extracted with ethyl acetate (300 mL), the separatedorganic phase washed with water (200 mL) and saturated brine (200 mL),dried over magnesium sulfate and concentrated under reduced pressure toafford a yellow oil. Purification by flash chromatography using asolvent gradient of 3 to 15% ethyl acetate in hexane gave 4.99 g (91%)of 2′,6′-dichloro-1,1′-biphenyl-2-ol as a white solid. MS (EI) m/z 238(M^(+.)).

Step 3: To a solution of 2′,6′-dichloro-1,1′-biphenyl-2-ol (5.4 g,0.0226 mol) in acetone (100 mL) was added potassium carbonate (3.75 g,0.0271 mol) followed by allyl bromide (2.58 mL, 0.0298 mol) and thereaction mixture heated to reflux for 24 hours. The cooled reactionmixture was poured into water (300 mL), the mixture stirred vigorouslyfor 1 hour then extracted with ethyl acetate (300 mL). The separatedorganic extract was washed with water (200 mL) and saturated brine (200mL), dried over magnesium sulfate and concentrated under reducedpressure to afford a yellow syrup. Purification by flash chromatographyusing a solvent gradient of 1 to 2% ethyl acetate in hexane gave 5.84 g(93%) of 2′-(allyloxy)-2,6-dichloro-1,1′-biphenyl as a colorless oil. MS(EI) m/z 278 (M^(+.)).

Step 4: A solution of 2′-(allyloxy)-2,6-dichloro-1,1′-biphenyl (5.7 g,0.0204 mol) in anhydrous 1-methyl-2-pyrrolidinone (50 mL) was heated to180° C. for 42 hours then at 190° C. for 5 days. The cooled reactionmixture was poured into water (300 mL), the mixture stirred vigorouslyfor 15 minutes then the resulting oily suspension extracted with ethylacetate (400 mL). The organic extract was washed with water (300 mL) andsaturated brine (300 mL), dried over magnesium sulfate and concentratedunder reduced pressure to afford a brown oil. Purification by flashchromatography using a solvent gradient of 2 to 4% ethyl acetate inhexane gave 4.71 g (83%) of 3-allyl-2′,6′-dichloro-1,1′-biphenyl-2-ol asa colorless oil. MS (ES) m/z 278.9 ([M+H]⁺).

Step 5: A mixture of 3-allyl-2′,6′-dichloro-1,1′-biphenyl-2-ol (2.922 g,10.47 mmol) and bis(acetonitrile)dichloropalladium (II) (136 mg, 0.523mmol) in anhydrous dichloromethane was heated to reflux under nitrogenfor 1 hour. The cooled reaction mixture was then concentrated to a smallvolume under reduced pressure and directly pre-adsorbed onto silica gel.Purification by flash chromatography using a solvent gradient of 2 to7.5% ethyl acetate in hexane gave 2.81 g (96%) of2′,6′-dichloro-3-[(1E)-prop-1-enyl]-1,1′-biphenyl-2-ol as a colorlesssyrup. HRMS: calcd for C₁₅H₁₂Cl₂O, 278.02652; found (EI, M+^(.)),278.0262.

Step 6: To a solution of2′,6′-dichloro-3-[(1E)-prop-1-enyl]-1,1′-biphenyl-2-ol (1.35 g, 4.84mmol), (S)-2-hydroxy-3-buten-1-yl p-tosylate (1.64 g, 6.77 mmol) andtriphenylphosphine (1.78 g, 6.77 mmol) in anhydrous toluene (50 mL) wasadded dropwise diethylazodicarboxylate (1.07 mL, 6.77 mmol) and thereaction mixture stirred at room temperature for 19 hours. The reactionwas quenched by the addition of water (40 mL) and the biphasic mixturestirred vigorously for 5 minutes. The mixture was then partitionedbetween diethyl ether (200 mL) and water (200 mL), the organic phaseseparated, washed with water (200 mL) and saturated brine (100 mL),dried over magnesium sulfate, filtered and concentrated under reducedpressure to afford a yellow syrup. Purification by flash chromatographyusing a solvent gradient of 2 to 10% ethyl acetate in hexane afforded2.06 g (85%) of(2R)-2-({2′,6′-dichloro-3-[(1E)-prop-1-enyl]-1,1′-biphenyl-2-yl}oxy)but-3-enyl4-methylbenzenesulfonate as a colorless syrup. MS (ESI) m/z 520([M+NH₄]⁺).

Step 7: To a solution of(2R)-2-({2′,6′-dichloro-3-[(1)-prop-1-enyl]-1,1′-biphenyl-2-yl}oxy)but-3-enyl4-methylbenzenesulfonate (2.02 g, 4.01 mmol) in anhydrous dichloroethane(50 mL) at room temperature under nitrogen was addedbenzylidene-bis(tricyclohexylphosphine)dichlororuthenium (0.33 g, 0.401mmol) and the reaction mixture stirred at room temperature for 20 hoursand then heated to 50° C. for 45 hours. The cooled reaction mixture wasconcentrated to a small volume under reduced pressure and then directlypre-adsorbed onto silica gel. Purification by flash chromatography usinga solvent gradient of 5 to 15% ethyl acetate in hexane afforded 1.52 g(82%) of [(2R)-8-(2,6-dichlorophenyl)-2H-chromen-2-yl]methyl4-methylbenzenesulfonate as a brown foam. MS (ESI) m/z 478 ([M+NH₄]⁺).

Step 8: A solution of[(2R)-8-(2,6-dichlorophenyl)-2H-chromen-2-yl]methyl4-methylbenzenesulfonate (0.846 g, 1.83 mmol) in ethyl acetate (10 mL)was added to a suspension of platinum (IV) oxide (45 mg, 0.198 mmol) inabsolute ethanol (30 mL) and the mixture hydrogenated at 10 psi ofhydrogen for 100 minutes. The reaction mixture was then filtered throughcelite and the filtrate concentrated under reduced pressure to afford abrown syrup. Purification by flash chromatography using a solventgradient of 5 to 20% ethyl acetate in hexane afforded 0.548 g (64%) of[(2R)-8-(2,6-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate as a yellow solid. HRMS: calcd forC₂₃H₂₀Cl₂O₄S+H⁺, 463.05321; found (ESI, [M+H]⁺), 463.0555.

Step 9: To a solution of[(2R)-8-(2,6-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate (239 mg, 0.54 mmol) in anhydrous dimethylsulfoxide (1 mL) was added a solution of methylamine (2.0 M intetrahydrofuran, 2.7 mL, 5.4 mmol) and the mixture heated to 60° C. in asealed vial for 42 hours. The cooled reaction mixture was then pouredinto 1:1 v/v 2.0 M aqueous sodium hydroxide and saturated brine (50 mL)and the mixture extracted with ethyl acetate (50 mL). The separatedorganic phase was washed with 1:1 v/v 2.0 M aqueous sodium hydroxide andsaturated brine (50 mL), and half saturated brine (50 mL), dried overmagnesium sulfate, filtered and concentrated under reduced pressure toafford a yellow syrup. Purification by flash chromatography using asolvent gradient of 0.5 to 5% ammonia saturated methanol solution indichloromethane gave 125 mg (75%) of{[(2R)-8-(2,6-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}methylamineas a white solid. The product was dissolved in 2-propanol (1 mL) anddiethyl ether (2.5 mL) and a solution of hydrogen chloride (1.0 M indiethyl ether, 0.39 mL, 0.39 mmol) was added followed by hexane (3 mL).The resulting white precipitate was filtered to afford 118 mg (64%) of{[(2R)-8-(2,6-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}methylaminehydrochloride as a white crystalline solid. HRMS: calcd forC₁₇H₁₇Cl₂NO+H⁺, 322.07599; found (ESI, [M+H]⁺), 322.0757.

Example 36{[(2R)-8-(2,6-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Step 1: A solution of[(2R)-8-(2,6-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate, prepared in Example 35, step 8 (308 mg, 0.664mmol) and sodium azide (173 mg, 2.66 mmol) in anhydrous dimethylsulfoxide (10 mL) was heated to 75° C. under nitrogen for 22 hours. Thecooled reaction mixture was quenched by the addition of water (20 mL)and the resulting suspension stirred vigorously for 5 minutes. Themixture was then partitioned between ethyl acetate (100 mL) and water(100 mL), the organic phase separated, washed with water (100 mL) andsaturated brine (100 mL), dried over magnesium sulfate, filtered andconcentrated under reduced pressure to afford a cream solid.Purification by flash chromatography using a solvent gradient of 5%ethyl acetate in hexane gave 210 mg (95%) of{[(2R)-8-(2,6-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}azideas a white solid. MS (APPI) m/z 333.1 (M^(+.)).

Step 2: To a solution of{[(2R)-8-(2,6-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}azide(0.21 g, 0.628 mmol) in tetrahydrofuran (10 mL) and water (1 mL) wasadded polymer-bound triphenylphosphine (˜3 mmol/g, 0.628 g, 1.885 mmol)and the reaction mixture stirred at room temperature for 4 days. Thebrown suspension was then filtered through celite, the filter cakewashed with ethyl acetate (50 mL) and the combined filtratesconcentrated under reduced pressure to afford a yellow syrup.Purification by flash chromatography using a solvent gradient of 0.5 to5% ammonia saturated methanol solution in dichloromethane gave 159 mg(82%) of{[(2R)-8-(2,6-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}amineas a colorless syrup. The product was dissolved in 2-propanol (1 mL) anddiethyl ether (2.5 mL) and a solution of hydrogen chloride (1.0 M indiethyl ether, 0.517 mL, 0.517 mmol) was added followed by hexane (2mL). The resulting white precipitate was filtered to afford 155 mg (72%)of{[(2R)-8-(2,6-dichlorophenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride as a white crystalline solid, mp 188-190° C.; [α]_(D)²⁵=−6.74° (c=5.4 mg/0.7 mL MeOH).

HRMS: calcd for C₁₆H₁₅Cl₂NO+H⁺, 308.06034; found (ESI, [M+H]⁺),308.0603.

Example 37{[8-(2-chlorophenyl)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Step 1: To a mixture of 2-bromo-4-fluorophenol (9.75 g, 0.051 mol) andpotassium carbonate (7.76 g, 0.056 mol) in acetone (125 mL) was addedallyl bromide (4.64 mL, 0.054 mol) and the reaction mixture heated toreflux for 3.5 hours. The cooled reaction mixture was then poured intowater and the resulting oily suspension extracted with dichloromethane(2×500 mL). The combined organic extracts were dried over magnesiumsulfate, filtered and concentrated under reduced pressure to afford11.79 g (100%) of 1-(allyloxy)-2-bromo-4-fluorobenzene as a yellow oil.MS (ESI) m/z 229.9 (M^(+.)).

Step 2: A mixture of 1-(allyloxy)-2-bromo-4-fluorobenzene (3 g, 0.013mol) and ethylene glycol (17 mL) was heated at 220° C. in a sealed vialunder microwave irradiation for 20 minutes. The cooled reaction mixturewas then poured into 2 M aqueous sodium hydroxide solution (150 mL) andthe resulting milky suspension washed with diethyl ether (150 mL). Theaqueous phase was then acidified to pH 1 by the addition of concentratedhydrochloric acid and the resulting oily suspension extracted withdiethyl ether (150 mL). The organic extract was washed with water (2×100mL) and saturated brine (100 mL), dried over magnesium sulfate, filteredand concentrated under reduced pressure to afford a yellow oil.Purification by flash chromatography using a solvent gradient of 0 to 1%ethyl acetate in hexane gave 2.07 g (69%) of2-allyl-6-bromo-4-fluorophenol as a colorless oil. MS (ESI) m/z 229.0([M−H]⁻).

Step 3: To a solution of 2-allyl-6-bromo-4-fluorophenol (7.14 g, 0.0309mol) in anhydrous dichloromethane (100 mL) at room temperature undernitrogen was added bis(acetonitrile)dichloropalladium (II) (0.4 g, 1.54mmol) and the reaction mixture heated to reflux for 1 hour. Additionalbis(acetonitrile)dichloropalladium (II) (0.1 g, 0.39 mmol) was added andheating to reflux continued for 1 additional hour. The cooled reactionmixture was then concentrated under reduced pressure to afford a brownsemi-solid. Purification by flash chromatography using a solventgradient of 0 to 2% ethyl acetate in hexane gave 6.44 g (90%) of2-bromo-4-fluoro-6-[(1E)-prop-1-enyl]phenol as a white solid. MS (ESI)m/z 229 ([M−H]⁻).

Step 4: To a solution of 2-bromo-4-fluoro-6-[(1)-prop-1-enyl]phenol(6.37 g, 0.0276 mol), toluene-4-sulfonic acid 2-hydroxy-but-3-enyl ester(8.8 g, 0.0363 mol) and triphenylphosphine (10.12 g, 0.0386 mol) inanhydrous toluene (200 mL) at 0° C. under nitrogen was added a solutionof diethyl azodicarboxylate (6.72 g, 0.0386 mol) in anhydrous toluene(100 mL) over 10 minutes then the reaction mixture stirred at roomtemperature for 19 hours. The reaction was quenched by the addition ofwater (400 mL), stirred vigorously for 5 minutes and the resulting oilysuspension extracted with diethyl ether (300 mL). The organic phase wasseparated, washed with water (2×500 mL), and saturated brine (400 mL),dried over magnesium sulfate, filtered and concentrated under reducedpressure to afford a yellow oil. Purification by flash chromatographyusing a solvent gradient of 2 to 10% ethyl acetate in hexane gave 12.11g (96%) of 2-{2-bromo-4-fluoro-6-[(1E)-prop-1-enyl]phenoxy}but-3-enyl4-methylbenzenesulfonate as a colorless oil. HRMS: calcd forC₂₀H₂₀BrFO₄S+NH₄ ⁺, 472.05879; found (ESI, [M+NH₄]⁺), 472.0581.

Step 5: To a solution of2-{2-bromo-4-fluoro-6-[(1)-prop-1-enyl]phenoxy}but-3-enyl4-methylbenzenesulfonate (10.95 g, 0.024 mol) in dry dichloromethane(300 mL) at room temperature under nitrogen was addedbenzylidene-bis(tricyclohexylphosphine)dichlororuthenium (1.97 g, 2.4mmol) and the reaction mixture stirred at room temperature for 5 days.The reaction mixture was then concentrated under reduced pressure to asmall volume and directly pre-adsorbed onto silica gel. Purification byflash chromatography using a solvent gradient of 5 to 30% ethyl acetatein hexane gave 9.5 g (96%) of (8-bromo-6-fluoro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate as a grey solid.

HRMS: calcd for C₁₇H₁₄BrFO₄S+NH₄ ⁺, 430.01184; found (ESI, [M+NH₄]⁺),430.0116.

Step 6: A solution of (8-bromo-6-fluoro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate (300 mg, 0.73 mmol) in absolute ethanol wasadded to 5% sulfided platinum on carbon (50 mg) and the mixturehydrogenated at 55 psi of hydrogen for 1 hour. The mixture was thenfiltered through celite and the filtrate concentrated under reducedpressure to afford a white semi-solid. Purification by flashchromatography using a solvent gradient of 5 to 25% ethyl acetate inhexane gave 148 mg (49%) of(8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate as a white solid.

HRMS: calcd for C₁₇H₁₆BrFO₄S+H⁺, 415.00095; found (ESI, [M+H]⁺),415.0004.

Step 7: To a solution of(8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate (0.33 g, 0.795 mmol) and 2-chlorophenylboronicacid (249 mg, 1.589 mmol) in dioxane (9 mL) was added a solution ofpotassium carbonate (329 mg, 2.38 mmol) in water (3 mL) and the mixturepurged with nitrogen for 20 minutes.Trans-dichlorobis(tri-o-tolylphosphine)palladium (II) (31.2 mg, 0.0397mmol) was added and the reaction mixture heated to reflux for 18 hours.The cooled reaction mixture was then partitioned between ethyl acetate(100 mL) and 2.0 M aqueous sodium hydroxide (100 mL). The organic layerwas separated, washed with water (100 mL) and saturated brine (100 mL),dried over magnesium sulfate, filtered and concentrated under reducedpressure to afford a yellow syrup. Purification by flash chromatographyusing a solvent gradient of 5 to 20% ethyl acetate in hexane gave 253 mg(71%) of toluene-4-sulfonic acid8-(2-chloro-phenyl)-6-fluoro-chroman-2-ylmethyl ester as a colorlesssyrup. MS (ESI) m/z 464 ([M+NH₄]⁺).

Step 8: A solution of toluene-4-sulfonic acid8-(2-chloro-phenyl)-6-fluoro-chroman-2-ylmethyl ester (253 mg, 0.566mmol) and sodium azide (147 mg, 2.264 mmol) in anhydrous dimethylsulfoxide (8 mL) was heated to 70° C. under nitrogen for 20 hours. Thecooled reaction mixture was quenched by the addition of water (30 mL)and the resulting suspension stirred vigorously for 10 minutes. Themixture was then partitioned between ethyl acetate (100 mL) and water(100 mL), the organic phase separated, washed with water (100 mL) andsaturated brine (100 mL), dried over magnesium sulfate, filtered andconcentrated under reduced pressure to afford 170 mg (95%) of2-azidomethyl-8-(2-chloro-phenyl)-6-fluoro-chroman a colorless syrup.

Step 9: To a solution of2-azidomethyl-8-(2-chloro-phenyl)-6-fluoro-chroman (170 mg, 0.535 mmol)in tetrahydrofuran (5 mL) and water (0.5 mL) was added polymer-boundtriphenylphosphine (˜3 mmol/g, 0.535 g, 1.605 mmol) and the reactionmixture stirred at room temperature for 24 hours. The brown suspensionwas then filtered through celite, the filter cake washed with ethylacetate (50 mL) and the combined filtrates concentrated under reducedpressure to afford a yellow syrup. The product was dissolved in2-propanol (1 mL) and diethyl ether (2 mL) and a solution of hydrogenchloride (1.0 M in diethyl ether, 0.51 mL, 0.51 mmol) added followedhexane (4 mL). The resulting white precipitate was filtered to afford118 mg (67%) of{[8-(2-chlorophenyl)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride as a white solid. HRMS: calcd for C₁₆H₁₅ClFNO+H⁺,292.08990; found (ESI, [M+H]⁺), 292.0903.

Example 381-[(2R)-6-fluoro-8-(2-methoxyphenyl)-3,4-dihydro-2H-chromen-2-yl]methanaminehydrochloride

Step 1: To a solution of 2-bromo-4-fluoro-6-(prop-1-enyl)phenol,prepared in Example 37, step 4 (4.5 g, 0.019 mol) and(S)-toluene-4-sulfonic acid 2-hydroxy-but-3-enyl ester (7.07 g, 0.028mol) and triphenylphosphine (11.22 g, 0.043 mol) in anhydrous THF (200mL) at room temperature was added diethyl azodicarboxylate (7.7 mL,0.047 mol) then the reaction mixture stirred at room temperature for 19hours. The reaction was quenched by the addition of water (100 mL),stirred vigorously for 5 minutes and the resulting oily suspensionextracted with methylene chloride (300 mL). The organic phase wasseparated, washed with water (2×100 mL), and saturated brine (100 mL),dried over anhydrous sodium sulfate, filtered and concentrated underreduced pressure to afford a yellow oil. Purification by flashchromatography using a solvent gradient of 0 to 20% ethyl acetate inhexane gave 7.26 g (82%) of(R)-2-[2-bromo-4-fluoro-6-(prop-1-enyl)phenoxy]but-3-enyl4-methylbenzenesulfonate as a colorless oil. MS (ES) m/z 472.1([M+NH₄]⁺).

Step 2: To a solution of(R)-2-[2-bromo-4-fluoro-6-(prop-1-enyl)phenoxy]but-3-enyl4-methylbenzenesulfonate (7.26 g, 0.016 mol) in dry dichloromethane (300mL) at room temperature under nitrogen was addedbenzylidene-bis(tricyclohexylphosphine)-dichlororuthenium (2.6 g, 3.2mmol) and the reaction mixture stirred at room temperature for 18 hours.The reaction mixture was then concentrated under reduced pressure to asmall volume and directly pre-adsorbed onto silica gel. Purification byflash chromatography using a solvent gradient of 5 to 30% ethyl acetatein hexane gave 6.7 g (100%) of(R)-(8-bromo-6-fluoro-2H-chromen-2-yl)methyl-4-methylbenzenesulfonate asa grey solid. [α]_(D) ²⁵=+206.6° (c 1% solution in MeOH); MS (ES) m/z430.0 ([M+NH₄]⁺).

Step 3: To a solution of(R)-(8-bromo-6-fluoro-2H-chromen-2-yl)methyl-4-methylbenzenesulfonate(0.40 g, 0.97 mmol) and 2-methoxyphenylboronic acid (0.44 g, 2.9 mmol)in dioxane (10 mL) was added potassium carbonate (0.33 g, 2.4 mmol),dichlorobis(tri-o-tolylphosphine)palladium (II) (23 mg, 0.029 mmol) andwater (2 mL). The reaction mixture was heated to reflux for 2 hours. Thecooled reaction mixture was then partitioned between ethyl acetate (100mL) and 2.0 M aqueous sodium hydroxide (100 mL). The organic layer wasseparated, washed with water (100 mL) and saturated brine (100 mL),dried over anhydrous sodium sulfate, filtered and concentrated underreduced pressure. Purification by flash chromatography using a solventgradient of 0 to 20% ethyl acetate in hexane gave 0.46 g (100%) of(R)-6-fluoro-8-(2-methoxyphenyl)-2H-chromen-2-yl)methyl4-methylbenzenesulfonate as a colorless oil. MS (ES) m/z 441.0 ([M+H]⁺).

Step 4: A solution of(R)-6-fluoro-8-(2-methoxyphenyl)-2H-chromen-2-yl)methyl4-methylbenzenesulfonate (0.46 g, 1.04 mmol) in absolute ethanol wasadded to platinum (IV) oxide (50 mg) and the mixture hydrogenated at 45psi of hydrogen for 18 hour. The mixture was then filtered throughcelite and the filtrate concentrated under reduced pressure to afford awhite semi-solid. Purification by flash chromatography using a solventgradient of 5 to 25% ethyl acetate in hexane gave 0.40 g (86%) of(R)-6-fluoro-8-(2-methoxyphenyl)chroman-2-yl)methyl4-methylbenzenesulfonate as a colorless oil. MS (APPI) m/z 443 ([M+H]⁺).

Step 5: A solution of(R)-6-fluoro-8-(2-methoxyphenyl)chroman-2-yl)methyl4-methylbenzenesulfonate (400 mg, 0.90 mmol) and sodium azide (290 mg,4.5 mmol) in anhydrous DMF (20 mL) was heated to 70° C. under nitrogenfor 20 hours. The cooled reaction mixture was quenched by the additionof water (30 mL) and the resulting suspension stirred vigorously for 10minutes. The mixture was then partitioned between ethyl acetate (100 mL)and water (100 mL), the organic phase separated, washed with water (100mL) and saturated brine (100 mL), dried over anhydrous sodium sulfate,filtered and concentrated under reduced pressure. Chromatography with0-20% ethyl acetate in hexanes afforded 0.21 g (74%) of(R)-2-(azidomethyl)-6-fluoro-8-(2-methoxyphenyl)-chroman as a colorlessoil. MS (APPI) m/z 313 ([M+H]⁺).

Step 6: To a solution of(R)-2-(azidomethyl)-6-fluoro-8-(2-methoxyphenyl)-chroman (210 mg, 0.67mmol) in tetrahydrofuran (15 mL) and water (0.5 mL) was addedtriphenylphosphine (0.21 g, 0.80 mmol) and the reaction mixture stirredat room temperature for 24 hours. Chromatography with 0-10% methanol inethyl methylene chloride plus 1% NH₄OH afforded[(R)-6-fluoro-8-(2-methoxyphenyl)-3,4-dihydro-2H-chromen-2-yl]methanamineas a colorless oil. The oil was dissolved in ethyl acetate and made intoits hydrochloride salt (0.95 g, 69%) as a white solid using excessethereal hydrochloric acid, mp 100° C. decomposed; MS (ES) m/z 288.1([M+H]⁺); [α]_(D) ²⁵=−34.64° (c=5.7 mg/0.7 mL MeOH).

Elemental analysis for C₁₇H₁₈FNO₂.HCl.0.3H₂O:

Theory: C, 62.03; H, 6.00; N, 4.25.

Found: C, 62.24; H, 6.47; N, 4.01.

Example 39{[(2R)-8-(2-chlorophenyl)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl}methylaminehydrochloride

Step 1: Racemic (8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate, prepared in Example 37, step 6 was dissolvedin acetonitrile and the resulting solution injected onto a SupercriticalFluid Chromatography instrument. The baseline resolved enantiomers werecollected using the conditions described below.

Column: OJ-H (4.6×250 mm)

Mobile Phase: 20% ethanol/80% CO₂

Column Temperature: 35° C.

Flow Rate: 2 mL/minute

Wavelength: 222 nm

[(2R)-8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate (98.2% enantiomeric excess) was isolated aspeak 1.

MS (ESI) m/z 415 ([M+H]⁺)

[(2S)-8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate (98.6% enantiomeric excess) was isolated aspeak 2.

[α]_(D) ²⁵=+25° (c=0.0107 g/mL, DMSO); MS (ESI) m/z 415 ([M+H]⁺).

Step 2:{[(2R)-8-(2-chlorophenyl)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl}methylaminehydrochloride was prepared according to Example 3, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate with[(2R)-8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate and 2,5-dichlorophenylboronic acid with2-chlorophenylboronic acid in step 2. MS (ESI) m/z 306 ([M+H]⁺).

Example 40{[(2R)-8-(2,5-dichlorophenyl)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl}methylaminehydrochloride

Prepared according to Example 3, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate with[(2R)-8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate in step 2. MS (ESI) m/z 340 ([M+H]⁺).

Example 41{[(2R)-8-(2,4-dichlorophenyl)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl}methylaminehydrochloride

Prepared according to Example 3, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate with[(2R)-8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate and 2,5-dichlorophenylboronic acid with2,4-dichlorophenylboronic acid in step 2. MS (ESI) m/z 340 ([M+H]⁺).

Example 42{[(2R)-6-fluoro-8-phenyl-3,4-dihydro-2H-chromen-2-yl]methyl}methylaminehydrochloride

Prepared according to Example 3, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate with[(2R)-8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate and 2,5-dichlorophenylboronic acid withphenylboronic acid in step 2. MS (ESI) m/z 272 ([M+H]⁺).

Example 43{[(2R)-6-fluoro-8-(2-methylphenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}methylaminehydrochloride

Prepared according to Example 3, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate with[(2R)-8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate and 2,5-dichlorophenylboronic acid with2-methylphenylboronic acid in step 2. MS (ESI) m/z 286 ([M+H]⁺).

Example 44{[(2R)-6-fluoro-8-pyridin-3-yl-3,4-dihydro-2H-chromen-2-yl]methyl}methylaminehydrochloride

Prepared according to Example 3, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate with[(2R)-8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate and 2,5-dichlorophenylboronic acid with3-pyridineboronic acid in step 2. MS (ESI) m/z 273 ([M+H]⁺).

Example 45{[(2R)-8-(2-chlorophenyl)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate with[(2R)-8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate in step 1. MS (ESI) m/z 292 ([M+H]⁺).

Example 46{[(2R)-8-(2,5-dichlorophenyl)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate with[(2R)-8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate and 2-chlorophenylboronic acid with2,5-dichlorophenylboronic acid in step 1. MS (ESI) m/z 326 ([M+H]⁺).

Example 47{[(2R)-8-(2,4-dichlorophenyl)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate with[(2R)-8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate and 2-chlorophenylboronic acid with2,4-dichlorophenylboronic acid in step 1. MS (ESI) m/z 326 ([M+H]⁺).

Example 48{[(2R)-6-fluoro-8-phenyl-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate with[(2R)-8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate and 2-chlorophenylboronic acid withphenylboronic acid in step 1. MS (ESI) m/z 258 ([M+H]⁺).

Example 49{[(2R)-6-fluoro-8-(2-methylphenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate with[(2R)-8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate and 2-chlorophenylboronic acid with2-methylphenylboronic acid in step 1. MS (ESI) m/z 272 ([M+H]⁺).

Example 50{[(2R)-6-fluoro-8-pyridin-3-yl-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate with[(2R)-8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate and 2-chlorophenylboronic acid with3-pyridineboronic acid in step 1. MS (ESI) m/z 259 ([M+H]⁺).

Example 51{[(2S)-8-(2-chlorophenyl)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate with[(2S)-8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate in step 1. MS (ESI) m/z 292 ([M+H]⁺).

Example 52{[(2S)-6-fluoro-8-phenyl-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate with[(2S)-8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate and 2-chlorophenylboronic acid withphenylboronic acid in step 1. MS (ES) m/z 258.1 ([M+H]⁺).

Example 53{[(2S)-6-fluoro-8-(2-methylphenyl)-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate with[(2S)-8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate and 2-chlorophenylboronic acid with2-methylphenylboronic acid in step 1. MS (ES) m/z 272.1 ([M+H]⁺).

Example 54{[(2S)-6-fluoro-8-pyridin-3-yl-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate with[(2S)-8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate and 2-chlorophenylboronic acid with3-pyridineboronic acid in step 1. MS (ESI) m/z 259 ([M+H]⁺).

Example 55{[(2S)-8-(2,5-dichlorophenyl)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate with[(2S)-8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate and 2-chlorophenylboronic acid with2,5-dichlorophenylboronic acid in step 1. MS (ES) m/z 326.0 ([M+H]⁺).

Example 56{[(2S)-8-(2,4-dichlorophenyl)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Prepared according to Example 11, replacing((2R)-8-{[(trifluoromethyl)sulfonyl]oxy}-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzene sulfonate with[(2S)-8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate and 2-chlorophenylboronic acid with2,4-dichlorophenylboronic acid in step 1. MS (ES) m/z 326.1 ([M+H]⁺).

Example 57{[(2R)-8-(2,6-dichlorophenyl)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl}aminehydrochloride

Step 1: To a solution of 2,6-dichlorobromobenzene (3.5 g, 15.7 mmol) andsodium hydroxide (3.14 g, 78.5 mmol) in DME-water (2:1) was added5-fluoro-2-methoxybenzene boronic acid (4.0 g, 23.5 mmol) at 90° C.,followed by tetrakis(triphenylphosphine)palladium (0) (0.9 g, 0.78mmol). The reaction mixture was heated at 90° C. overnight and cooled toroom temperature. The mixture was extracted with methylene chloride andwashed with water. The organic solvent was removed under vacuum.Chromatography with 5% ethyl acetate in hexanes afforded 2.62 g (87%) of2′,6′-dichloro-5-fluoro-2-methoxybiphenyl as a colorless oil. MS (EI)m/z 270 (M⁺).

Step 2: To a solution of 2′,6′-dichloro-5-fluoro-2-methoxybiphenyl(12.44 g, 46 mmol) in methylene chloride (200 mL) was added borontribromide (10.8 mL, 92 mol) at −78° C. The resulting mixture wasstirred at −78° C. to room temperature overnight. The reaction mixturewas poured into the ice-NH₄OH and extracted with methylene chloride. Theorganic layer was washed with water and dried over anhydrous sodiumsulfate and filtered. The solvent was removed under vacuum.Chromatography with 10-40% ethyl acetate in hexanes afforded 11.63 g(98%) of 2′,6′-dichloro-5-fluorobiphenyl-2-ol as a colorless oil. MS(ES) m/z 255.1 ([M−H]⁻).

Step 3: To a solution of 2′,6′-dichloro-5-fluorobiphenyl-2-ol (11.63 g,45 mmol) in DMF (150 mL) was added allyl bromide (5.8 mL, 67.5 mmol) andpotassium carbonate (18.6 g, 135 mmol) at room temperature. Theresulting mixture was stirred at room temperature overnight and pouredinto water. The mixture was extracted with methylene chloride and washedwith water. The solvent was removed under vacuum. Chromatography with0-30% ethyl acetate in hexanes afforded 12.7 g (94%) of2-allyloxy-2′,6′-dichloro-5-fluorobiphenyl as a light yellow oil. MS(EI) m/z 296 (M⁺).

Step 4: A solution of 2-allyloxy-2′,6′-dichloro-5-fluorobiphenyl (11.02g, 37 mmol) in decahydronaphthalene (100 mL) was refluxed for 38 h. Thesolvent was removed under vacuum. Chromatography with 0-20% ethylacetate in hexanes afforded 9.26 g (84%) of3-allyl-2′,6′-dichloro-5-fluorobiphenyl-2-ol as a light yellow oil. MS(ES) m/z 295.0 ([M−H]⁻).

Step 5: A solution of 3-allyl-2′,6′-dichloro-5-fluorobiphenyl-2-ol (6.0g, 20 mmol) and bis(acetonitrile)dichloropalladium (II) (0.53 g, 2.1mmol) in methylene chloride was refluxed for 24 h. The solvent wasremoved under vacuum. Chromatography with 0-30% ethyl acetate in hexanesafforded 3.0 g (50%) of2′,6′-dichloro-5-fluoro-3-(prop-1-enyl)-biphenyl-2-ol as a colorlessoil. MS (ES) m/z 295.0 ([M−H]⁻).

Step 6: To a solution of2′,6′-dichloro-5-fluoro-3-(prop-1-enyl)-biphenyl-2-ol (2.98 g, 10.0mmol), (S)-2-hydroxy-3-buten-1-yl p-tosylate (3.64 g, 15.0 mmol) andtriphenylphosphine (5.3 g, 20.0 mmol) in anhydrous tetrahydrofuran (50mL) was added dropwise diethylazodicarboxylate (4.0 mL, 25.0 mmol) andthe reaction mixture stirred at room temperature for 16 hours. Themixture was extracted with methylene chloride and washed with water. Thesolvent was removed under vacuum. Chromatography with 0-30% ethylacetate in hexanes afforded 3.0 g (57%) of(R)-2-(2′,6′-dichloro-5-fluoro-3-(prop-1-enyl)biphenyl-2-yloxy)but-3-enyl4-methyl benzenesulfonate as a light yellow oil. [α]_(D) ²⁵=−4° (0.9%solution in MeOH); MS (ES) m/z 538.1 (M+NH⁴]⁺).

Step 7: To a solution of(R)-2-(2′,6′-dichloro-5-fluoro-3-(prop-1-enyl)biphenyl-2-yloxy)but-3-enyl4-methyl benzenesulfonate (3.0 g, 5.7 mmol) in anhydrous methylenechloride (50 mL) at room temperature under nitrogen was addedbenzylidene-bis(tricyclohexylphosphine)-dichlororuthenium (0.94 g, 1.14mmol) and the reaction mixture stirred at room temperature overnight.The cooled reaction mixture was concentrated to a small volume underreduced pressure. Chromatography with 0-15% ethyl acetate in hexanesafforded 1.80 g (65%) of[(R)-(8-(2,6-dichlorophenyl)-6-fluoro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate as a brown foam. [α]_(D) ²⁵=+185.2° (c 1%solution in MeOH); MS (ESI) m/z 496.0 ([M+NH₄]⁺).

Step 8: A solution of[(R)-(8-(2,6-dichlorophenyl)-6-fluoro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate (0.6 g, 1.25 mmol) in ethyl acetate/ethanol(10/10 mL) was added platinum(IV) oxide (45 mg, 0.198 mmol) and themixture hydrogenated at 45 psi of hydrogen for 2 hours. The reactionmixture was then filtered through celite and the filtrate concentratedunder reduced pressure. Chromatography with 0-15% ethyl acetate inhexanes afforded 0.48 g (80%) of[(R)-8-(2,6-dichlorophenyl)-6-fluorochroman-2-yl]methyl4-methylbenzenesulfonate as a colorless oil. [α]^(D) ₂₅=+9.51° (c 5.3mg/0.7 mL MeOH); MS (ES) m/z 498.0 ([M+NH₄]⁺).

Step 9: A solution of(R)-8-(2,6-dichlorophenyl)-6-fluorochroman-2-yl]methyl4-methylbenzenesulfonate (460 mg, 0.96 mmol) and sodium azide (0.31 g,4.8 mmol) in anhydrous DMF (20 mL) was heated to 90° C. under nitrogenovernight. The cooled reaction mixture was quenched by the addition ofwater (20 mL). The mixture was then partitioned between ethyl acetate(100 mL) and water (100 mL), the organic phase separated, washed withwater (100 mL) and saturated brine (100 mL), dried over anhydrous sodiumsulfate, filtered and concentrated under reduced pressure to afford acream solid. Chromatography with 0-15% ethyl acetate in hexanes gave 270mg (83%) of (R)-2-(azidomethyl)-8-(2,6-dichlorophenyl)-6-fluorochromanas a light yellow oil. [α]_(D) ²⁵=+19.82° (c 5.3 mg/0.7 mL MeOH); MS(EI) m/z 351 (M⁺).

Step 10: To a solution of(R)-2-(azidomethyl)-8-(2,6-dichlorophenyl)-6-fluorochroman (0.26 g, 0.73mmol) in tetrahydrofuran (10 mL) and water (1 mL) was addedpolymer-bound triphenylphosphine (3 mmol/g, 0.74 g, 2.2 mmol) and thereaction mixture stirred at room temperature for 2 days. The brownsuspension was then filtered through celite, the filter cake washed withethyl acetate (50 mL) and the combined filtrates concentrated undervacuum. The solvent was removed under vacuum. Chromatography with 0-10%methanol in methylene chloride plus 1% NH₄OH afforded{[(R)-8-(2,6-dichlorophenyl)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl}amineas a colorless oil. The colorless oil was dissolved in ethyl acetate andmade into its hydrochloride salt (0.18 g, 67%) as a white crystallinesolid using excess ethereal hydrochloric acid, mp 190-192° C.; MS (ES)m/z 326.0 ([M+H]⁺); [α]_(D) ²⁵=−4.39° (c 1% solution in MeOH).

Elemental Analysis for C₁₆H₁₄Cl₂NFO.HCl:

Theory: C, 52.99; H, 4.17; N, 3.86.

Found: C, 52.99; H, 3.72; N, 3.75

Example 58N-{[(2R)-8-(2,6-dichlorophenyl)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl}ethanaminehydrochloride

Step 1: A solution of(R)-8-(2,6-dichlorophenyl)-6-fluorochroman-2-yl]methyl4-methylbenzenesulfonate, prepared in Example 57, step 8 (100 mg, 0.21mmol) and ethylamine (2.0 M in THF, 1.0 mL, 2.1 mmol) in anhydrous DMSOwas heated at 45° C. for 18 hours. The mixture was then partitionedbetween ethyl acetate (100 mL) and water (100 mL), the organic phaseseparated, washed with water (100 mL) and saturated brine (100 mL),dried over anhydrous sodium sulfate, filtered and concentrated underreduced pressure. Column chromatography on silica gel with 0-10%methanol in methylene chloride plus 1% NH₄OH affordedN-{[(2R)-8-(2,6-dichlorophenyl)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl}ethanamineas a yellow oil. The yellow oil was dissolved in ethyl acetate and madeinto its hydrochloride salt (52 mg, 69%) as a white crystalline solidusing excess ethereal hydrochloric acid, mp>225° C.; MS (EI) m/z 349(M⁺); [α]_(D) ²⁵=−50.0° (c=1% SOLUTION, MeOH); MS (ES) m/z 354.1;

Elemental analysis for C₁₈H₁₈Cl₂FNO.HCl:

Theory: C, 55.33; H, 4.90; N, 3.58.

Found: C, 55.01; H, 4.95; N, 3.50.

Example 59{[(2R)-8-(2,6-dichlorophenyl)-2H-chromen-2-yl]methyl}methylaminehydrochloride

To a solution of [(2R)-8-(2,6-dichlorophenyl)-2H-chromen-2-yl]methyl4-methylbenzenesulfonate, prepared in Example 35, step 7 (0.33 g, 0.715mmol) in anhydrous dimethyl sulfoxide (1.2 mL) was added a solution ofmethylamine (2.0 M in tetrahydrofuran, 3.58 mL, 7.15 mmol) and themixture heated at 60° C. in a sealed vial for 26 hours. The cooledreaction mixture was then poured into 1:1 v/v 2.0 M aqueous sodiumhydroxide solution:saturated brine (50 mL) and the product extractedwith ethyl acetate (50 mL). The separated organic extract was washedwith 1:1 v/v 2.0 M aqueous sodium hydroxide solution:saturated brine (50mL), and half saturated brine (50 mL), dried over magnesium sulfate,filtered and concentrated under reduced pressure to afford a brownsyrup. Purification by flash chromatography using a solvent gradient of0 to 5% ammonia saturated methanol solution in dichloromethane gave 160mg (70%) of{[(2R)-8-(2,6-dichlorophenyl)-2H-chromen-2-yl]methyl}methylamine as ayellow syrup. The product was dissolved 2-propanol (1.5 mL) and diethylether (3 mL) and a solution of hydrogen chloride (1.0 M in diethylether, 0.36 mL, 0.36 mmol) was added followed by hexane (4 mL). Theresulting white precipitate was filtered to afford 121 mg (47%) of{[(2R)-8-(2,6-dichlorophenyl)-2H-chromen-2-yl]methyl}methylaminehydrochloride as a tan solid. HRMS: calcd for C₁₇H₁₅Cl₂NO+H⁺, 320.06034;found (ESI, [M+H]⁺), 320.0619.

Example 60 {[(2R)-8-(2,6-dichlorophenyl)-2H-chromen-2-yl]methyl}aminehydrochloride

Step 1: A solution of[(2R)-8-(2,6-dichlorophenyl)-2H-chromen-2-yl]methyl4-methylbenzenesulfonate prepared in Example 35, step 7 (250 mg, 0.542mmol) and sodium azide (141 mg, 2.17 mmol) in anhydrous dimethylsulfoxide (10 mL) was heated at 70° C. under nitrogen for 20 hours. Thecooled reaction mixture was quenched by the addition of water (20 mL)and the resulting suspension stirred vigorously for 5 minutes. Themixture was then partitioned between ethyl acetate (100 mL) and water(100 mL), the organic phase separated, washed with water (100 mL) andsaturated brine (100 mL), dried over magnesium sulfate, filtered andconcentrated under reduced pressure to afford 120 mg (67%) of(2R)-2-azidomethyl-8-(2,6-dichloro-phenyl)-2H-chromene as a colorlesssyrup that was used without further purification.

Step 2: To a solution of(2R)-2-azidomethyl-8-(2,6-dichloro-phenyl)-2H-chromene (120 mg, 0.361mmol) in tetrahydrofuran (5 mL) and water (0.5 mL) was addedpolymer-bound triphenylphosphine (˜3 mmol/g, 0.361 g, 1.084 mmol) andthe reaction mixture stirred at room temperature for 43 hours. The brownsuspension was then filtered through celite, the filter cake washed withethyl acetate (50 mL) and the combined filtrates concentrated underreduced pressure to afford a yellow syrup. Purification by flashchromatography using a solvent gradient of 0 to 5% ammonia saturatedmethanol solution in dichloromethane gave 100 mg (90%) of{[(2R)-8-(2,6-dichlorophenyl)-2H-chromen-2-yl]methyl}amine as acolorless syrup. The product was dissolved in 2-propanol (1 mL) anddiethyl ether (2 mL), a solution of hydrogen chloride (1.0 M in diethylether, 0.326 mL, 0.326 mmol) was added followed hexane (7 mL). Theresulting white precipitate was filtered to afford 100 mg (80%) of{[(2R)-8-(2,6-dichlorophenyl)-2H-chromen-2-yl]methyl}amine hydrochlorideas an off-white solid. MS (ESI) m/z 306 ([M+H]⁺).

Example 61{[8-(2-chlorophenyl)-6-fluoro-2H-chromen-2-yl]methyl}methylaminehydrochloride

Step 1: A solution of (8-bromo-6-fluoro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate, prepared in Example 37, step 5 (1.0 g, 2.42mmol) and 2-chlorophenylboronic acid (1.14 g, 7.26 mmol) in dioxane (18mL) was added a solution of potassium carbonate (1.0 g, 7.26 mmol) inwater (6 mL) and the mixture purged with nitrogen for 20 minutes.Trans-dichlorobis(tri-o-tolylphosphine)palladium (II) (95 mg, 0.12 mmol)was added and the reaction mixture heated at 100° C. for 2 hours. Thecooled reaction mixture was then partitioned between ethyl acetate (100mL) and 2.0 M aqueous sodium hydroxide (100 mL). The organic layer wasseparated, washed with water (100 mL) and saturated brine (100 mL),dried over magnesium sulfate, filtered and concentrated under reducedpressure to afford a yellow oil. Purification by flash chromatographyusing a solvent gradient of 5 to 20% ethyl acetate in hexane gave 0.57 g(53%) of [8-(2-chlorophenyl)-6-fluoro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate as a white solid. HRMS: calcd forC₂₃H₁₈ClFO₄S+NH₄ ⁺, 462.09366; found (ESI, [M+NH₄]⁺), 462.0916.

Step 2: To a solution of[8-(2-chlorophenyl)-6-fluoro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate (0.33 g, 0.748 mmol) in anhydrous dimethylsulfoxide (1.2 mL) was added a solution of methylamine (2.0 M intetrahydrofuran, 3.74 mL, 7.48 mmol) and the mixture heated to 60° C. ina sealed vial for 2 days. The cooled reaction mixture was then pouredinto 2.0 M aqueous sodium hydroxide solution (40 mL) and the productextracted with ethyl acetate (50 mL). The separated organic extract waswashed with water (50 mL), and saturated brine (50 mL), dried overmagnesium sulfate, filtered and concentrated under reduced pressure toafford a brown syrup. Purification by flash chromatography using asolvent gradient of 0 to 5% ammonia saturated methanol solution indichloromethane gave 101 mg (45%) of{[8-(2-chlorophenyl)-6-fluoro-2H-chromen-2-yl]methyl}methylamine as ayellow syrup. The product was dissolved 2-propanol (1 mL) and diethylether (2 mL), a solution of hydrogen chloride (1.0 M in diethyl ether,0.33 mL, 0.33 mmol) was added followed by hexane (3 mL). The resultingprecipitate was filtered to afford 100 mg (39%) of{[8-(2-chlorophenyl)-6-fluoro-2H-chromen-2-yl]methyl}methylaminehydrochloride as a tan crystalline solid. HRMS: calcd forC₁₇H₁₅ClFNO+H⁺, 304.08990; found (ESI, [M+H]⁺), 304.0891.

Example 62 {[8-(2-chlorophenyl)-6-fluoro-2H-chromen-2-yl]methyl}aminehydrochloride

Step 1: A solution of[8-(2-chlorophenyl)-6-fluoro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate prepared in Example 61, step 1 (204 mg, 0.459mmol) and sodium azide (119 mg, 1.834 mmol) in anhydrous dimethylsulfoxide (8 mL) was heated at 70° C. under nitrogen for 19 hours. Thecooled reaction mixture was quenched by the addition of water (30 mL)and the resulting suspension stirred vigorously for 5 minutes. Themixture was then partitioned between ethyl acetate (100 mL) and water(100 mL), the organic phase separated, washed with water (100 mL) andsaturated brine (100 mL), dried over magnesium sulfate, filtered andconcentrated under reduced pressure to afford 120 mg (67%) of2-azidomethyl-8-(2-chloro-phenyl)-2H-chromene as a yellow syrup that wasused without further purification.

Step 2: To a solution of 2-azidomethyl-8-(2-chloro-phenyl)-2H-chromene(150 mg, 0.459 mmol) in tetrahydrofuran (5 mL) and water (0.5 mL) wasadded polymer-bound triphenylphosphine (˜3 mmol/g, 0.459 g, 1.377 mmol)and the reaction mixture stirred at room temperature for 3 days. Thebrown suspension was then filtered through celite, the filter cakewashed with ethyl acetate (50 mL) and the combined filtratesconcentrated under reduced pressure to afford a yellow syrup. Theproduct was dissolved in 2-propanol (1 mL) and diethyl ether (2 mL), asolution of hydrogen chloride (1.0 M in diethyl ether, 0.46 mL, 0.46mmol) was added followed hexane (3 mL). The resulting precipitate wasfiltered to afford 81 mg (52%) of{[8-(2-chlorophenyl)-6-fluoro-2H-chromen-2-yl]methyl}amine hydrochlorideas a grey solid. HRMS: calcd for C₁₆H₁₃ClFNO+H+, 290.07425; found (ESI,[M+H]⁺), 290.0746.

Example 63{[(2R)-8-(2,5-dichlorophenyl)-6-fluoro-2H-chromen-2-yl]methyl}aminehydrochloride

Step 1: To a solution of[(R)-8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate, prepared in Example 38, step 2 (0.40 g, 0.97mmol) and 2,5-dichlorophenylboronic acid (0.56 g, 2.9 mmol) in dioxane(10 ml) was added a solution of potassium carbonate (0.34 g, 2.4 mmol)in water (2 mL) and the mixture purged with nitrogen for 20 minutes.Dichlorobis(tri-o-tolylphosphine)palladium (II) (20 mg, 0.029 mmol) wasadded and the reaction mixture heated to reflux for 1 hour. The cooledreaction mixture was then partitioned between ethyl acetate (100 mL) and2.0 M aqueous sodium hydroxide (100 mL). The organic layer wasseparated, washed with water (100 mL) and saturated brine (100 mL),dried over anhydrous sodium sulfate, filtered and concentrated underreduced pressure to afford a yellow syrup. Purification by flashchromatography using a solvent gradient of 5 to 20% ethyl acetate inhexane gave 0.41 g (88%) of((R)-8-(2,5-dichlorophenyl)-6-fluoro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate as a colorless oil. MS (ES) m/z 496.0([M+NH₄]⁺).

Step 2: A solution((R)-8-(2,5-dichlorophenyl)-6-fluoro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate (410 mg, 0.85 mmol) and sodium azide (280 mg,4.3 mmol) in anhydrous DMF (20 mL) was heated to 90° C. under nitrogenfor 20 hours. The cooled reaction mixture was quenched by the additionof water (30 mL) and the resulting suspension stirred vigorously for 10minutes. The mixture was then partitioned between ethyl acetate (100 mL)and water (100 mL), the organic phase separated, washed with water (100mL) and saturated brine (100 mL), dried over anhydrous sodium sulfate,filtered and concentrated under reduced pressure. Chromatography with0-30% ethyl acetate in hexanes afforded 240 mg (83%) of(2R)-2-azidomethyl-8-(2,5-dichloro-phenyl)-6-fluoro-chroman as acolorless oil. MS (APPI) m/z 322 ([M-N2+H]⁺).

Step 3: To a solution of(R)-2-azidomethyl-8-(2,5-dichloro-phenyl)-6-fluoro-chroman (240 mg, 0.68mmol) in tetrahydrofuran (10 mL) and water (0.5 mL) was addedtriphenylphosphine (0.27 g, 10.2 mmol) and the reaction mixture stirredat room temperature for 24 hours. The solvent was removed under vacuumto form a colorless oil. Chromatography with 0-5% methanol in methylenechloride plus 1% NH₄OH afforded{[(R)-8-(2,5-dichlorophenyl)-6-fluoro-2H-chromen-2-yl]methyl}amine as acolorless oil. The oil was dissolved in ethyl acetate and made into itshydrochloride salt (121 mg, 45%) using excess ethereal hydrochloric acidto give a white solid, mp 217-219° C.; MS (ES) m/z 324.0 ([M+H]⁺);[α]_(D) ²⁵=+191.22° (c=5.1 mg/0.7 mL MeOH).

Elemental analysis for C₁₆H₁₂Cl₂FNO.HCl:

Theory: C, 53.29; H, 3.63; N, 3.88.

Found: C, 53.14; H, 3.35; N, 3.73.

Example 64{[(2R)-8-(2-chlorophenyl)-6-fluoro-2H-chromen-2-yl]methyl}aminehydrochloride

Step 1: To a solution of(R)-8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate, prepared in Example 38, step 2 (0.40 g, 0.97mmol) and 2-chlorophenylboronic acid (0.45 g, 2.9 mmol) in dioxane (10ml) was added a solution of potassium carbonate (0.34 g, 2.4 mmol) inwater (2 mL) and the mixture purged with nitrogen for 20 minutes.Dichlorobis(tri-o-tolylphosphine)palladium (II) (20 mg, 0.029 mmol) wasadded and the reaction mixture heated to reflux for 1 hour. The cooledreaction mixture was then partitioned between ethyl acetate (100 mL) and2.0 M aqueous sodium hydroxide (100 mL). The organic layer wasseparated, washed with water (100 mL) and saturated brine (100 mL),dried over anhydrous sodium sulfate, filtered and concentrated underreduced pressure to afford a yellow syrup. Purification by flashchromatography using a solvent gradient of 5 to 20% ethyl acetate inhexane gave 0.40 g (93%) of((R)-8-(2-chlorophenyl)-6-fluoro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate as a colorless oil. MS (ES) m/z 462.0([M+NH₄]⁺).

Step 2: A solution((R)-8-(2-chlorophenyl)-6-fluoro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate (400 mg, 0.90 mmol) and sodium azide (0.29 g,4.5 mmol) in anhydrous DMF (20 mL) was heated to 90° C. under nitrogenfor 20 hours. The cooled reaction mixture was quenched by the additionof water (30 mL) and the resulting suspension stirred vigorously for 10minutes. The mixture was then partitioned between ethyl acetate (100 mL)and water (100 mL), the organic phase separated, washed with water (100mL) and saturated brine (100 mL), dried over anhydrous sodium sulfate,filtered and concentrated under reduced pressure. Chromatography with0-30% ethyl acetate in hexanes afforded 240 mg (88%) of(R)-2-azidomethyl-8-(2-chloro-phenyl)-6-fluoro-chroman as a colorlessoil. MS (APPI) m/z 288 ([M-N2+H]⁺).

Step 3: To a solution of(R)-2-azidomethyl-8-(2-chloro-phenyl)-6-fluoro-chroman (210 mg, 0.67mmol) in tetrahydrofuran (10 mL) and water (0.5 mL) was addedtriphenylphosphine (0.26 g, 10 mmol) and the reaction mixture stirred atroom temperature for 24 hours. The solvent was removed under vacuum toform a colorless oil. Chromatography with 0-5% methanol in methylenechloride plus 1% NH₄OH afforded{[(R)-8-(2-chlorophenyl)-6-fluoro-2H-chromen-2-yl]methyl}amine as acolorless oil. The colorless oil was dissolved in ethyl acetate and madeinto its hydrochloride salt (56 mg, 25%) as a beige solid using excessethereal hydrochloric acid, mp 145-147° C.; [α]_(D) ²⁵=+256.01° (c=5.3mg/0.7 mL MeOH).

Elemental analysis for C₁₆H₁₃ClFNO.HCl.0.75H₂O:

Theory: C, 56.57; H, 4.60; N, 4.12. Found: C, 56.87; H, 4.41; N, 3.98.

Example 65{[(2R)-6-fluoro-8-(2-methoxyphenyl)-2H-chromen-2-yl]methyl}aminehydrochloride

Step 1: To a solution of(R)-8-bromo-6-fluoro-3,4-dihydro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate, prepared in Example 38, step 2 (0.30 g, 0.73mmol) and 2-methoxyphenylboronic acid (0.22 g, 1.5 mmol) in dioxane (10ml) was added a solution of potassium carbonate (0.25 g, 1.8 mmol) inwater (2 mL) and the mixture purged with nitrogen for 20 minutes.Dichlorobis(tri-o-tolylphosphine)palladium (II) (17 mg, 0.022 mmol) wasadded and the reaction mixture heated to reflux for 1 hour. The cooledreaction mixture was then partitioned between ethyl acetate (100 mL) and2.0 M aqueous sodium hydroxide (100 mL). The organic layer wasseparated, washed with water (100 mL) and saturated brine (100 mL),dried over anhydrous sodium sulfate, filtered and concentrated underreduced pressure to afford a yellow syrup. Purification by flashchromatography using a solvent gradient of 5 to 20% ethyl acetate inhexane gave 0.30 g (94%) of((R)-8-(2-methoxyphenyl)-6-fluoro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate as a colorless oil. MS (ES) m/z 458.1([M+NH₄]⁺).

Step 2: A solution((R)-8-(2-methoxyphenyl)-6-fluoro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate (300 mg, 0.67 mmol) and sodium azide (0.22 g,3.4 mmol) in anhydrous DMF (20 mL) was heated to 90° C. under nitrogenfor 20 hours. The cooled reaction mixture was quenched by the additionof water (30 mL) and the resulting suspension stirred vigorously for 10minutes. The mixture was then partitioned between ethyl acetate (100 mL)and water (100 mL), the organic phase separated, washed with water (100mL) and saturated brine (100 mL), dried over anhydrous sodium sulfate,filtered and concentrated under reduced pressure. Chromatography with0-30% ethyl acetate in hexanes afforded 190 mg (90%) of(2R)-2-azidomethyl-8-(2-methoxy-phenyl)-6-fluoro-chroman as a colorlessoil. MS (APPI) m/z 284 ([M-N2+H]⁺).

Step 3: To a solution of(R)-2-azidomethyl-8-(2-methoxyphenyl)-6-fluoro-chroman (190 mg, 0.32mmol) in tetrahydrofuran (10 mL) and water (0.5 mL) was addedtriphenylphosphine (0.26 g, 10 mmol) and the reaction mixture stirred atroom temperature for 24 hours. The solvent was removed under vacuum toform a colorless oil. Chromatography with 0-5% methanol in methylenechloride plus 1% NH₄OH afforded{[(R)-8-(2-methoxyphenyl)-6-fluoro-2H-chromen-2-yl]methyl}amine as acolorless oil. The colorless oil was dissolved in ethyl acetate and madeinto its hydrochloride salt (119 mg, 61%) as an off-white crystallinesolid, mp 198-200° C.; [α]_(D) ²⁵=+173.89° (c=5.2 mg/0.7 mL MeOH).

Elemental analysis for C₁₇H₁₆FNO₂.HCl:

Theory: C, 63.46; H, 5.33; N, 4.35.

Found: C, 63.26; H, 5.36; N, 4.22.

Example 66{[(2R)-8-(2,6-dichlorophenyl)-6-fluoro-2H-chromen-2-yl]methyl}aminehydrochloride

Step 1: A solution of(R)-(8-(2,6-dichlorophenyl)-6-fluoro-2H-chromen-2-yl]methyl4-methylbenzenesulfonate prepared in Example 57, step 7 (500 mg, 1.0mmol) and sodium azide (340 mg, 5.2 mmol) in anhydrous DMF (20 mL) washeated at 90° C. under nitrogen for 20 hours. The cooled reactionmixture was quenched by the addition of water (20 mL) and the resultingsuspension stirred vigorously for 5 minutes. The mixture was thenpartitioned between ethyl acetate (100 mL) and water (100 mL), theorganic phase separated, washed with water (100 mL) and saturated brine(100 mL), dried over anhydrous sodium sulfate, filtered and concentratedunder reduced pressure. Column chromatography on silica gel with 10-25%ethyl acetate in hexanes afforded 310 mg (85%) of(R)-2-azidomethyl-8-(2,6-dichloro-phenyl)-6-fluoro-2H-chromene as ayellow oil. [α]_(D) ²⁵=+282.1° (c=2.7 mg/0.7 mL MeOH); MS (EI) m/z 349.(M⁺).

Step 2: To a solution of((R)-2-azidomethyl-8-(2,6-dichloro-phenyl)-6-fluoro-2H-chromene (300 mg,0.85 mmol) in tetrahydrofuran (10 mL) and water (0.5 mL) was addedpolymer-bound triphenylphosphine (3 mmol/g, 0.85 g, 2.6 mmol) and thereaction mixture stirred at room temperature for 43 hours. The brownsuspension was then filtered through celite, the filter cake washed withethyl acetate (50 mL) and the combined filtrates concentrated undervacuum. Chromatography with 0-10% methanol in methylene chloride plus 1%NH₄OH afforded{[(2R)-8-(2,6-dichlorophenyl)-6-fluoro-2H-chromen-2-yl]methyl}amine as acolorless oil. The oil was dissolved in ethyl acetate and made into itshydrochloride salt (83 mg, 27%) as a white crystalline solid usingexcess ethereal hydrochloric acid, mp 153-155° C.; [α]_(D) ²⁵=+220.67°(c 1% solution in MeOH); MS (ES) m/z 324.0 ([M+H]⁺).

Elemental Analysis for C₁₆H₁₂Cl₂NFO.HCl

Theory: C, 53.29; H, 3.63; N, 3.88.

Found: C, 53.13; H, 3.80; N, 3.65.

Example 67{[(2R)-9-(2,6-dichlorophenyl)-2,3,4,5-tetrahydro-1-benzoxepin-2-yl]methyl}aminehydrochloride

Step 1: To a solution of 3-allyl-2′,6′-dichloro-1,1′-biphenyl-2-ol,prepared in Example 35, step 4 (0.5 g, 1.791 mmol),(S)-2-hydroxy-3-buten-1-yl p-tosylate (608 mg, 2.507 mmol) andtriphenylphosphine (0.658 g, 2.507 mmol) in anhydrous toluene (20 mL)was added dropwise diethylazodicarboxylate (0.395 mL, 2.507 mmol) andthe reaction mixture stirred at room temperature under nitrogen for 19hours. The reaction was quenched by the addition of water (10 mL) andthe biphasic mixture stirred vigorously for 1 hour. The mixture was thenpartitioned between diethyl ether (100 mL) and water (100 mL), theorganic phase separated, washed with water (100 mL) and saturated brine(100 mL), dried over magnesium sulfate, filtered and concentrated underreduced pressure to afford a yellow syrup. Purification by flashchromatography using a solvent gradient of 3 to 10% ethyl acetate inhexane afforded 0.784 g (87%) of(2R)-2-[(3-allyl-2′,6′-dichlorobiphenyl-2-yl)oxy]but-3-en-1-yl4-methylbenzene sulfonate as a white solid. MS (ESI) m/z 520 9[M+NH₄]⁺).

Step 2: To a solution of(2R)-2-[(3-allyl-2′,6′-dichlorobiphenyl-2-yl)oxy]but-3-en-1-yl4-methylbenzenesulfonate (702 mg, 1.394 mmol) in anhydrousdichloromethane (35 mL) at room temperature under nitrogen was addedbenzylidene-bis(tricyclohexylphosphine)dichlororuthenium (114 mg, 0.1394mmol) and the reaction mixture stirred at room temperature for 5 hours.The reaction mixture was then concentrated under reduced pressure toafford a brown syrup. The crude product was dissolved in ethyl acetate(7 mL) and the solution added to a suspension of platinum (IV) oxide (32mg, 0.139 mmol) in absolute ethanol (21 mL). The mixture was thenhydrogenated at 12 psi of hydrogen for 1 hour. The reaction mixture wasfiltered through celite and the filtrate concentrated under reducedpressure to afford a brown syrup. Purification by flash chromatographyusing a solvent gradient of 3 to 10% ethyl acetate in hexane afforded0.615 g (92%) of[(2R)-9-(2,6-dichlorophenyl)-2,3,4,5-tetrahydro-1-benzoxepin-2-yl]methyl4-methylbenzenesulfonate as a yellow solid. MS (ESI) m/z 477 ([M+H]⁺).

Step 3: A solution of[(2R)-9-(2,6-dichlorophenyl)-2,3,4,5-tetrahydro-1-benzoxepin-2-yl]methyl4-methylbenzenesulfonate (381 mg, 0.798 mmol) and sodium azide (208 mg,3.192 mmol) in anhydrous dimethyl sulfoxide (10 mL) was heated at 70° C.under nitrogen for 19 hours. The cooled reaction mixture was quenched bythe addition of water (30 mL) and the resulting suspension stirredvigorously for 5 minutes. The mixture was then partitioned between ethylacetate (100 mL) and water (100 mL), the organic phase separated, washedwith water (100 mL) and saturated brine (100 mL), dried over magnesiumsulfate, filtered and concentrated under reduced pressure to afford acolorless syrup. Purification by flash chromatography using 3% ethylacetate in hexane as eluant gave 240 mg (86%) of(2R)-2-azidomethyl-9-(2,6-dichloro-phenyl)-2,3,4,5-tetrahydro-benzo[b]oxepineas a colorless syrup.

Step 4: To a solution of(2R)-2-azidomethyl-9-(2,6-dichloro-phenyl)-2,3,4,5-tetrahydro-benzo[b]oxepine(0.24 g, 0.689 mmol) in tetrahydrofuran (10 mL) and water (1 mL) wasadded polymer-bound triphenylphosphine (3 mmol/g, 0.69 g, 2.068 mmol)and the reaction mixture stirred at room temperature for 20 hours. Thebrown suspension was then filtered through celite, the filter cakewashed with ethyl acetate (50 mL) and the combined filtratesconcentrated under reduced pressure to afford a yellow syrup.Purification by flash chromatography using a solvent gradient of 0 to 5%ammonia saturated methanol solution in dichloromethane gave 179 mg (80%)of{[(2R)-9-(2,6-dichlorophenyl)-2,3,4,5-tetrahydro-1-benzoxepin-2-yl]methyl}amineas a colorless syrup. The product was dissolved in 2-propanol (1 mL) anddiethyl ether (3 mL), a solution of hydrogen chloride (1.0 M in diethylether, 0.55 mL, 0.55 mmol) was added followed by hexane (4 mL). Theresulting white precipitate was filtered to afford 182 mg (73%) of{[(2R)-9-(2,6-dichlorophenyl)-2,3,4,5-tetrahydro-1-benzoxepin-2-yl]methyl}aminehydrochloride as a white solid. MS (ESI) m/z 322 ([M+H]⁺).

Example 68{[(2R)-9-(2,6-dichlorophenyl)-7-fluoro-2,3,4,5-tetrahydro-1-benzoxepin-2-yl]methyl}aminehydrochloride

Step 1: A solution of 3-allyl-2′,6′-dichloro-5-fluorobiphenyl-2-ol (3.26g, 11.0 mmol) and (S)-2-hydroxy-3-buten-1-yl p-tosylate (4.0 g, 16.4mmol) and triphenylphosphine (5.76 g, 21.9 mmol) in anhydroustetrahydrofuran (60 mL) was added dropwise diethylazodicarboxylate (4.3mL, 21.9 mmol) and the reaction mixture stirred at room temperature for16 hours. The mixture was extracted with methylene chloride and washedwith water. The solvent was removed under vacuum. Chromatography with0-30% ethyl acetate in hexanes afforded 4.41 g (77%) of(R)-2-(3-allyl-2′,6′-dichloro-5-fluorobiphenyl-2-yloxy)but-3-enyl4-methyl benzenesulfonate as a yellow oil. [α]_(D) ²⁵=−15.92° (c=5.8mg/0.7 mL MeOH); MS (ES) m/z 538.1 ([M+NH⁴]⁺).

Step 2: To a solution of(R)-2-(3-allyl-2′,6′-dichloro-5-fluorobiphenyl-2-yloxy)but-3-enyl4-methyl benzenesulfonate (1.06 g, 20.0 mmol) in anhydrousdichloroethane (50 mL) at room temperature under nitrogen was addedbenzylidene-bis(tricyclohexylphosphine)-dichlororuthenium (0.33 g, 0.4mmol) and the reaction mixture stirred at room temperature overnight.The cooled reaction mixture was concentrated to a small volume underreduced pressure. Chromatography with 0-15% ethyl acetate in hexanesafforded 0.70 g (70%) of(R)-(9-(2,6-dichlorophenyl)-7-fluoro-2,5-dihydrobenzo[b]oxepin-2-yl)methyl4-methylbenzene-sulfonate as a brown foam. [α]^(D) ₂₅=+59.94° (c=5.4mg/0.7 mL MeOH); MS (ESI) m/z 510.1 ([M+NH₄]⁺).

Step 3: A solution(R)-(9-(2,6-dichlorophenyl)-7-fluoro-2,5-dihydrobenzo[b]oxepin-2-yl)methyl4-methylbenzene-sulfonate (0.7 g, 1.4 mmol) in ethyl acetate/ethanol(10/10 mL) was added platinum (IV) oxide (0.2 g) and the mixturehydrogenated at 45 psi of hydrogen for 14 hours. The reaction mixturewas then filtered through celite and the filtrate concentrated underreduced pressure. Chromatography with 10-30% ethyl acetate in hexanesafforded 0.60 g (85%) of(R)-(9-(2,6-dichlorophenyl)-7-fluoro-2,3,4,5-tetrahydrobenzo[b]oxepin-2-yl)methyl4-methylbenzene-sulfonate as a colorless oil. [α]^(D) ₂₅=+24.81° (c=6.6mg/0.7 mL MeOH); MS (ES) m/z 512.1 ([M+NH₄]⁺).

Step 4: A solution of(R)-(9-(2,6-dichlorophenyl)-7-fluoro-2,3,4,5-tetrahydrobenzo[b]oxepin-2-yl)methyl4-methylbenzene-sulfonate (230 mg, 0.46 mmol) and sodium azide (0.15 g,2.3 mmol) in anhydrous DMF (20 mL) was heated to 90° C. under nitrogenovernight. The cooled reaction mixture was quenched by the addition ofwater (20 mL). The mixture was then partitioned between ethyl acetate(100 mL) and water (100 mL), the organic phase separated, washed withwater (100 mL) and saturated brine (100 mL), dried over anhydrous sodiumsulfate, filtered and concentrated under reduced pressure to afford acream solid. Chromatography with 0-15% ethyl acetate in hexanes gave 270mg (83%) of(R)-2-(azidomethyl)-9-(2,6-dichlorophenyl)-7-fluoro-2,3,4,5-tetrahydrobenzo[b]oxepineas a light yellow oil. MS (EI) m/z 365 (M⁺).

Step 5: To a solution of(R)-2-(azidomethyl)-9-(2,6-dichlorophenyl)-7-fluoro-2,3,4,5-tetrahydrobenzo[b]oxepine(0.17 g, 0.46 mmol) in tetrahydrofuran (10 mL) and water (1 mL) wasadded polymer-bound triphenylphosphine (˜3 mmol/g, 0.46 g, 1.4 mmol) andthe reaction mixture stirred at room temperature for 2 days. The brownsuspension was then filtered through celite, the filter cake washed withethyl acetate (50 mL) and the combined filtrates concentrated undervacuum. The solvent was removed under vacuum. Chromatography with 0-10%methanol in methylene chloride plus 1% NH₄OH afforded{[(R)-8-(2,6-dichlorophenyl)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]methyl}amineas a colorless oil. The colorless oil was dissolved in ethyl acetate andmade into its hydrochloride salt (0.13 g, 71%) as a white foam usingexcess ethereal hydrochloric acid, [α]_(D) ²⁵=+38.22° (c 1% solution inMeOH); MS (ES) m/z 340.0 ([M+H]⁺).

Elemental Anal. for C₁₇H₁₆Cl₂NFO.HCl.H₂O

Theory: C, 51.73; H, 4.85; N, 3.55.

Found: C, 51.93; H, 3.80; N, 3.65

Example 69 ((2R)-7-Chloro-8-o-tolylchroman-2-yl)methanaminehydrochloride

Step 1: To a solution of 2-bromotoluene (13.8 g, 80.6 mmol) and sodiumcarbonate (9.0 g, 84.9 mmol) in DME-water (5:1, 250 mL) was added2-chloro-6-methoxybenzene boronic acid (5.0 g, 26.8 mmol) at 82° C.,followed by tetrakis(triphenylphosphine)-palladium (0) (1.5 g, 1.4mmol). The reaction mixture was heated at 82° C. overnight and cooled toroom temperature. The resulting mixture was extracted with ethylacetate, washed with water and saturated sodium chloride, dried (Na₂SO₄)and concentrated under reduced pressure. Purification by ISCO using asolvent gradient of 0 to 5% ethyl acetate in hexanes provided 3.9 g(62%) of 2-chloro-6-methoxy-2′-methylbiphenyl as a colorless oil.

Step 2: 2-Chloro-6-methoxy-2′-methylbiphenyl (15.0 g, 64.5 mmol) washeated in hydrogen bromide (33% in acetic acid, 60 mL) at 65° C.overnight. The resulting mixture was cooled to room temperature, pouredin water and extracted with ethyl acetate. The organic layer was washedwith water and saturated sodium chloride, dried over anhydrous sodiumsulfate, filtered and concentrated under reduced pressure. The residueoil was further treated with potassium carbonate (10.5 g, 75.6 mmol) inmethanol (100 mL) at room temperature for 2 h. The solvent was removedunder reduced pressure. The residue was extracted with ethyl acetate andthe organic layer was washed with water and saturated sodium chloride,dried over anhydrous sodium sulfate, filtered and concentrated underreduced pressure. Purification by ISCO using a solvent gradient of 10 to40% ethyl acetate in hexanes produced 10.9 g (77%) of6-chloro-2′-methyl-biphenyl-2-ol as a colorless oil.

Step 3: To a solution of 6-chloro-2′-methyl-biphenyl-2-ol (4.75 g, 21.7mmol) in DMF (30 mL) was added potassium carbonate (4.5 g, 32.6 mmol)and allyl bromide (3.0 mL, 32.6 mmol) at room temperature. The resultingmixture was stirred at room temperature for 4 h. The mixture wasextracted with ethyl acetate, washed with water and saturated sodiumchloride, dried over anhydrous sodium sulfate, filtered and concentratedunder reduced pressure. Purification by ISCO using a solvent gradient of0 to 30% ethyl acetate in hexanes provided 5.6 g (100%) of2-allyloxy-6-chloro-2′-methylbiphenyl as a light yellow oil.

Step 4: A solution of 2-allyloxy-6-chloro-2′-methylbiphenyl (4.0 g, 15.4mmol) in mesitylene (100 mL) was refluxed for 24 h. The solvent wasremoved under reduced pressure. Purification by ISCO using a solventgradient of 0 to 20% ethyl acetate in hexanes provided 3.0 g (75%) of3-allyl-6-chloro-2′-methylbiphenyl-2-ol as a light yellow oil.

Step 5: To a solution of 3-allyl-6-chloro-2′-methylbiphenyl-2-ol (2.0 g,7.7 mmol) in methylene chloride (70 mL) was addeddichlorobis(acetonitrile)palladium (II) (0.22 g, 0.84 mmol). Theresulting mixture was refluxed overnight. The solvent was removed underreduced pressure. Purification by ISCO using a solvent gradient of 5 to20% ethyl acetate in hexanes provided 1.0 g (50%) of6-chloro-2′-methyl-3-(prop-1-enyl)biphenyl-2-ol as a colorless oil.

Step 6: To a solution of 6-chloro-2′-methyl-3-(prop-1-enyl)biphenyl-2-ol(1.0 g, 3.86 mmol) in toluene (30 mL) was added triphenylphosphine (1.5g, 5.79 mmol) and diethyl azodicarboxylate (0.9 mL, 5.79 mmol) followedby (S)-2-hydroxy-3-buten-1-yl p-tosylate (1.4 g, 5.79 mmol) at roomtemperature. The resulting mixture was stirred at room temperatureovernight. The solvent was removed under reduced pressure. Purificationby ISCO using a solvent gradient of 0 to 10% ethyl acetate in hexanesprovided 1.4 g (75%) of(2R)-2-(6-chloro-2′-methyl-3-(prop-1-enyl)biphenyl-2-yloxy)but-3-enyl4-methylbenzenesulfonate as a colorless oil.

Step 7: To a solution of(2R)-2-(6-chloro-2′-methyl-3-(prop-1-enyl)biphenyl-2-yloxy)but-3-enyl4-methylbenzenesulfonate (1.4 g, 2.9 mmol) in 1,2-dichloroethane (30 mL)was added benzylidene-bis(tricyclohexylphosphine)dichlororuthenium (0.57g, 0.69 mmol) and the resulting mixture was stirred at room temperatureovernight. The solvent was removed under reduced pressure. Purificationby ISCO using a solvent gradient of 0 to 20% ethyl acetate in hexanesprovided 0.8 g (63%) of ((2R)-7-chloro-8-o-tolyl-2H-chromen-2-yl)methyl4-methylbenzenesulfonate as a thick dark oil.

Step 8: A solution of ((2R)-7-chloro-8-o-tolyl-2H-chromen-2-yl)methyl4-methylbenzenesulfonate (0.8 g, 1.8 mmol) in ethanol (40 mL) and ethylacetate (10 mL) was prepared in a hydrogenation bottle and purged withnitrogen. Platinum (IV) oxide (84% Pt, 0.23 g) was added and thereaction mixture was shaken under a hydrogen atmosphere (40 psi) for 3.5h. The resulting mixture was filtered through a pad of Celite and thesolvent was removed under reduced pressure. Purification by ISCO using asolvent gradient of 0 to 20% ethyl acetate in hexanes provided 0.8 g(100%) of ((2R)-7-chloro-8-o-tolylchroman-2-yl)methyl4-methylbenzenesulfonate as a thick dark oil.

Step 9: To a solution of ((2R)-7-chloro-8-o-tolylchroman-2-yl)methyl4-methylbenzenesulfonate (0.8 g, 1.8 mmol) in DMSO (50 mL) was addedsodium azide (1.2 g, 18.4 mmol) and the resulting mixture was heated at60° C. overnight. The mixture was extracted with ethyl acetate, washedwith water and saturated sodium chloride, dried with anhydrous sodiumsulfate and concentrated under reduced pressure. Purification by ISCOusing a solvent gradient of 0 to 20% ethyl acetate in hexanes provided0.5 g (88%) of (2R)-2-(azidomethyl)-7-chloro-8-o-tolylchroman as acolorless oil.

Step 10: To a solution of (2R)-2-(azidomethyl)-7-chloro-8-o-tolylchroman(0.5 g, 1.6 mmol) in THF (15 mL) and water (0.5 mL) was addedpolymer-bound triphenylphosphine (3 mmol/g, 0.8 g, 2.4 mmol) and theresulting mixture was stirred at room temperature overnight. The mixturewas filtered through a pad of Celite and concentrated under reducedpressure. Purification by ISCO using a solvent gradient of 0 to 10%methanol in methylene chloride provided 0.15 g of the title compound asa colorless oil. The oil was dissolved in ethyl acetate (5 mL) and towhich hydrogen chloride (1.0 M in ethyl ether, 1.5 mL, 1.5 mmol) wasadded, solvent was removed and the solid was washed with ethyl ether(3×5 mL) to provide 0.13 g of((2R)-7-chloro-8-o-tolylchroman-2-yl)methanamine hydrochloride as awhite solid salt, mp 155° C.; MS (APPI) m/z 288 ([M+H]⁺); [α]_(D)²⁵=−55° (c=1% SOLN, MeOH).

Elemental analysis for C₁₇H₁₈ClNO.HCl:

Theory: C, 62.97; H, 5.91; N, 4.32.

Found: C, 61.71; H, 6.09; N, 4.00.

Example 70 ((2R)-7-chloro-8-(2-chlorophenyl)chroman-2-yl)methanaminehydrochloride

Step 1: Treatment of 2-bromochlorobenzene (15.5 g, 80.6 mmol) with2-chloro-6-methoxybenzene boronic acid (5.0 g, 26.8 mmol) in DME-water(5:1, 250 mL) according to the procedure described for Example 69, Step1 provided 5.0 g (74%) of 2,2′-dichloro-6-methoxybiphenyl as a colorlessoil.

Step 2: Treatment of 2,2′-dichloro-6-methoxybiphenyl (5.0 g, 20.9 mmol)with hydrogen bromide (33% in acetic acid, 60 mL) according to theprocedure described for Example 69, Step 2 provided 4.2 g (89%) of2′,6-dichlorobiphenyl-2-ol as a colorless oil.

Step 3: To a solution of 2′,6-dichloro-biphenyl-2-ol (10.0 g, 41.8 mmol)in DMF was added sodium hydride (60% in mineral oil, 2.5 g, 62.7 mmol)and allyl bromide (5.4 mL, 62.7 mmol) at room temperature. The resultingmixture was stirred at room temperature overnight. The mixture wasextracted with ethyl acetate, washed with water and saturated sodiumchloride, dried over anhydrous sodium sulfate, filtered and concentratedunder reduced pressure. Purification by ISCO using a solvent gradient of0 to 30% ethyl acetate in hexanes provided 11.6 g (100%) of2-allyloxy-2′,6-dichlorobiphenyl as a light yellow oil

Step 4: A solution of 2-allyloxy-2′,6-dichlorobiphenyl (11.6 g, 41.8mmol) in mesitylene (100 mL) was refluxed for 24 h. The solvent wasremoved under reduced pressure. Purification by ISCO using a solventgradient of 0 to 20% ethyl acetate in hexanes provided 9.0 g (77%) of3-allyl-2′,6-dichlorobiphenyl-2-ol as a light yellow oil.

Step 5: Treatment of 3-allyl-2′,6-dichloro-biphenyl-2-ol (6.2 g, 22.2mmol) in methylene chloride (200 mL) withdichlorobis(acetonitrile)palladium (II) (0.86 g, 3.3 mmol) according tothe procedure described for Example 69, Step 5 provided 3.0 g (48%) of2′,6-dichloro-3-(prop-1-enyl)biphenyl-2-ol as a light yellow oil.

Step 6: Treatment of 2′,6-dichloro-3-(prop-1-enyl)biphenyl-2-ol (3.0 g,10.7 mmol) in toluene (100 mL) with triphenylphosphine (4.22 g, 16.1mmol), diethyl azodicarboxylate (2.5 mL, 16.1 mmol) and(S)-2-hydroxy-3-buten-1-yl p-tosylate (2.4 g, 10.0 mmol) according tothe procedure described for Example 69, Step 6 provided 3.0 g (60%) of(2R)-2-(2′,6-dichloro-3-(prop-1-enyl)biphenyl-2-yloxy)but-3-enyl4-methylbenzenesulfonate as a pale yellow oil.

Step 7: To a solution of(2R)-2-(2′,6-dichloro-3-(prop-1-enyl)biphenyl-2-yloxy)but-3-enyl4-methylbenzenesulfonate (3.0 g, 5.96 mmol) in 1,2-dichloroethane (60mL) was added benzylidene-bis(tricyclohexylphosphine)dichlororuthenium(1.5 g, 1.82 mmol) and the resulting mixture was stirred at roomtemperature overnight. The solvent was removed under reduced pressure.Purification by ISCO using a solvent gradient of 0 to 20% ethyl acetatein hexanes provided 2.15 g (78%) of((2R)-7-chloro-8-(2-chlorophenyl)-2H-chromen-2-yl)methyl4-methylbenzenesulfonate as an off-white solid. MS (ESI) m/z 460.9([M+H]⁺); m/z 477.9 ([M+NH₄]⁺).

Step 8: Treatment of((2R)-7-chloro-8-(2-chlorophenyl)-2H-chromen-2-yl)methyl4-methylbenzenesulfonate (2.13 g, 4.62 mmol) in ethanol (100 mL) andethyl acetate (15 mL) with platinum (IV) oxide (84% Pt, 0.50 g)according to the procedure described for Example 69, Step 8 provided2.10 g (96%) of ((2R)-7-chloro-8-(2-chlorophenyl)chroman-2-yl)methyl4-methylbenzenesulfonate as a pale yellow solid.

Step 9: Treatment of((2R)-7-chloro-8-(2-chlorophenyl)chroman-2-yl)methyl4-methylbenzenesulfonate (2.10 g, 4.53 mmol) with sodium azide (1.77 g,27.20 mmol) in DMSO (50 mL) according to the procedure described forExample 69, Step 9 provided 1.5 g (99%) of(2R)-2-(azidomethyl)-7-chloro-8-(2-chlorophenyl)chroman as a whitesolid. MS (EI) m/z 333.0 [M]⁺.

Step 10: Treatment of(2R)-2-(azidomethyl)-7-chloro-8-(2-chlorophenyl)chroman (1.5 g, 4.48mmol) with polymer-bound triphenylphosphine (3 mmol/g, 1.94 g, 5.82mmol) according to the procedure described for Example 69, Step 10provided 0.70 g (45%) of((2R)-7-chloro-8-(2-chlorophenyl)chroman-2-yl)methanamine hydrochlorideas a white solid salt, mp 220-222° C.; MS (ESI) m/z 308.1 ([M+H]⁺);[α]_(D) ²⁵=−26.4° (c=1% SOLN, MeOH).

Elemental analysis for C₁₆H₁₅Cl₂NO.HCl:

Theory: C, 55.76; H, 4.68; N, 4.06.

Found: C, 55.88; H, 4.36; N, 3.94.

Example 71 ((2R)-8-(2-chlorophenyl)-7-fluorochroman-2-yl)methanaminehydrochloride

Step 1: Treatment of 2-bromochlorobenzene (9 mL, 77.6 mmol) with2-fluoro-6-methoxybenzene boronic acid (10.0 g, 58.8 mmol) in DME-water(5:1, 250 mL) according to the procedure described for Example 69, Step1 provided 17.0 g of 2′-chloro-2-fluoro-6-methoxybiphenyl as a colorlessoil.

Step 2: Treatment of 2′-chloro-2-fluoro-6-methoxybiphenyl (17.0 g) withhydrogen bromide (33% in acetic acid, 60 mL) according to the proceduredescribed for Example 69, Step 2 provided 7.5 g (57%) of2′-chloro-6-fluorobiphenyl-2-ol as a colorless oil.

Step 3: Treatment of 2′-chloro-6-fluoro-biphenyl-2-ol (5.0 g, 22.5 mmol)with potassium carbonate (4.6 g, 33.7 mmol) and allyl bromide (2.9 mL,33.7 mmol) in DMSO (100 mL) according to the procedure described forExample 69, Step 3 provided 4.5 g (76%) of2-allyloxy-2′-chloro-6-fluorobiphenyl as a pale yellow oil.

Step 4: A solution of 2-allyloxy-2′-chloro-6-fluorobiphenyl (9.0 g, 33.7mmol) in mesitylene (100 mL) was refluxed for 24 h. The solvent wasremoved under reduced pressure. Purification by ISCO using a solventgradient of 0 to 20% ethyl acetate in hexanes provided 7.0 g (81%) of3-allyl-2′-chloro-6-fluorobiphenyl-2-ol as a colorless oil.

Step 5: Treatment of 3-allyl-2′-chloro-6-fluoro-biphenyl-2-ol (3.8 g,14.5 mmol) in methylene chloride (150 mL) withdichlorobis(acetonitrile)palladium (II) (0.56 g, 2.2 mmol) according tothe procedure described for Example 69, Step 5 provided 1.5 g (39%) of2′-chloro-6-fluoro-3-(prop-1-enyl)biphenyl-2-ol as a light yellow oil.

Step 6: Treatment of 2′-chloro-6-fluoro-3-(prop-1-enyl)biphenyl-2-ol(2.0 g, 7.61 mmol) in toluene (60 mL) with triphenylphosphine (3.0 g,11.45 mmol), diethyl azodicarboxylate (1.78 mL, 11.45 mmol) and(S)-2-hydroxy-3-buten-1-yl p-tosylate (3.0 g, 12.38 mmol) according tothe procedure described for Example 69, Step 6 provided 1.5 g (40%) of(2R)-2-(2′-chloro-6-fluoro-3-(prop-1-enyl)biphenyl-2-yloxy)but-3-enyl4-methylbenzenesulfonate as a pale yellow oil.

Step 7: Treatment of(2R)-2-(2′-chloro-6-fluoro-3-(prop-1-enyl)biphenyl-2-yloxy)but-3-enyl4-methylbenzenesulfonate (1.5 g, 3.08 mmol) withbenzylidene-bis(tricyclohexylphosphine)-dichlororuthenium (0.50 g, 0.61mmol) in 1,2-dichloroethane (30 mL) according to the procedure describedfor Example 69, Step 7 provided 0.7 g (51%) of((2R)-8-(2-chlorophenyl)-7-fluoro-2H-chromen-2-yl)methyl4-methylbenzene-sulfonate as a thick dark oil.

Step 8: Treatment of((2R)-8-(2-chlorophenyl)-7-fluoro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate (0.7 g, 1.57 mmol) in ethanol (40 mL) and ethylacetate (10 mL) with platinum (IV) oxide (84% Pt, 0.21 g) according tothe procedure described for Example 69, Step 8 provided 0.7 g (100%) of((2R)-8-(2-chlorophenyl)-7-fluorochroman-2-yl)methyl4-methylbenzenesulfonate as a pale yellow oil.

Step 9: Treatment of((2R)-8-(2-chlorophenyl)-7-fluorochroman-2-yl)methyl4-methylbenzenesulfonate (0.7 g, 1.56 mmol) with sodium azide (0.61 g,9.40 mmol) in DMSO (20 mL) according to the procedure described forExample 69, Step 9 provided 0.33 g (67%) of(2R)-2-(azidomethyl)-8-(2-chlorophenyl)-7-fluorochroman as a pale yellowoil.

Step 10: Treatment of(2R)-2-(azidomethyl)-8-(2-chlorophenyl)-7-fluorochroman (0.33 g, 1.04mmol) with polymer-bound triphenylphosphine (3 mmol/g, 0.5 g, 1.50 mmol)in THF (10 mL) and water (0.5 mL) according to the procedure describedfor Example 69, Step 10 provided 0.23 g (70%) of((2R)-8-(2-chlorophenyl)-7-fluorochroman-2-yl)methanamine hydrochlorideas a white salt, mp 223-225° C.; MS (APPI) m/z 292 ([M+H]⁺; [α]_(D)²⁵=−40.00° (c=1% SOLN, MeOH).

Elemental analysis for C₁₆H₁₅ClFNO.HCl:

Theory: C, 58.55; H, 4.91; N, 4.27.

Found: C, 58.52; H, 4.68; N, 4.11.

Example 72((2R)-8-(4-Chloro-2-methylphenyl)-7-fluorochroman-2-yl)methanaminehydrochloride

Step 1: Treatment of 2-bromo-4-chlorotoluene (20 mL, 0.15 mol) with2-fluoro-6-methoxybenzene boronic acid (10.0 g, 58.8 mmol) in DME-water(5:1, 300 mL) according to the procedure described for Example 69, Step1 provided 21.0 g of 4-chloro-2′-fluoro-6′-methoxy-2-methylbiphenyl as acolorless oil.

Step 2: Treatment of 4-chloro-2′-fluoro-6′-methoxy-2-methylbiphenyl (2.7g, 10.8 mmol) with hydrogen bromide (33% in acetic acid, 50 mL)according to the procedure described for Example 69, Step 2 provided 2.2g (86%) of 4′-chloro-6-fluoro-2′-methylbiphenyl-2-ol as a colorless oil.

Step 3: Treatment of 4′-chloro-6-fluoro-2′-methylbiphenyl-2-ol (2.7 g,11.4 mmol) with potassium carbonate (2.4 g, 17.1 mmol) and allyl bromide(1.5 mL, 17.1 mmol) in DMSO (100 mL) according to the proceduredescribed for Example 69, Step 3 provided 2.1 g (66%) of2′-allyloxy-4-chloro-6′-fluoro-2-methylbiphenyl as a colorless oil.

Step 4: A solution of 2′-allyloxy-4-chloro-6′-fluoro-2-methylbiphenyl(2.1 g, 7.6 mmol) in mesitylene (70 mL) was refluxed for 24 h. Thesolvent was removed under reduced pressure. Purification by ISCO using asolvent gradient of 0 to 20% ethyl acetate in hexanes provided 2.0 g(95%) of 3-allyl-4′-chloro-6-fluoro-2′-methylbiphenyl-2-ol as a paleyellow oil.

Step 5: Treatment of 3-allyl-4′-chloro-6-fluoro-2′-methylbiphenyl-2-ol(2.0 g, 7.22 mmol) in methylene chloride (70 mL) withdichlorobis(acetonitrile)palladium (II) (0.25 g, 1.0 mmol) according tothe procedure described for Example 69, Step 5 provided 1.6 g (80%) of4′-chloro-6-fluoro-2′-methyl-3-(prop-1-enyl)biphenyl-2-ol as a colorlessoil, MS (ESI) m/z 275.00 [M−H]⁻.

Step 6: Treatment of4′-chloro-6-fluoro-2′-methyl-3-(prop-1-enyl)biphenyl-2-ol (1.6 g, 5.78mmol) in toluene (60 mL) with triphenylphosphine (2.27 g, 8.67 mmol),diethyl azodicarboxylate (1.51 g, 8.67 mmol) and(S)-2-hydroxy-3-buten-1-yl p-tosylate (2.10 g, 8.67 mmol) according tothe procedure described for Example 69, Step 6 provided 1.35 g (47%) of(2R)-2-(4′-chloro-6-fluoro-2′-methyl-3-(prop-1-enyl)biphenyl-2-yloxy)but-3-enyl4-methylbenzenesulfonate as a light yellow oil.

Step 7: Treatment of(2R)-2-(4′-chloro-6-fluoro-2′-methyl-3-(prop-1-enyl)biphenyl-2-yloxy)but-3-enyl4-methylbenzenesulfonate (1.35 g, 2.69 mmol) withbenzylidene-bis(tricyclohexylphosphine)dichlororuthenium (0.70 g, 0.85mmol) in methylene chloride (30 mL) according to the procedure describedfor Example 69, Step 7 provided 0.5 g (41%) of((2R)-8-(4-chloro-2-methylphenyl)-7-fluoro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate as a brown oil.

Step 8: Treatment of((2R)-8-(4-chloro-2-methylphenyl)-7-fluoro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate (0.5 g, 1.09 mmol) with platinum (IV) oxide(84% Pt, 0.21 g) in ethanol (25 mL) and ethyl acetate (5 mL) accordingto the procedure described for Example 69, Step 8 provided 0.5 g (100%)of ((2R)-8-(4-chloro-2-methylphenyl)-7-fluorochroman-2-yl)methyl4-methylbenzenesulfonate as a light brown oil.

Step 9: Treatment of((2R)-8-(4-chloro-2-methylphenyl)-7-fluorochroman-2-yl)methyl4-methylbenzenesulfonate (0.5 g, 1.09 mmol) with sodium azide (0.43 g,6.54 mmol) in DMSO (15 mL) according to the procedure described forExample 69, Step 9 provided 0.30 g (83%) of(2R)-2-(azidomethyl)-8-(4-chloro-2-methylphenyl)-7-fluorochroman as acolorless oil.

Step 10: Treatment of(2R)-2-(azidomethyl)-8-(4-chloro-2-methylphenyl)-7-fluorochroman (0.30g, 0.90 mmol) with polymer-bound triphenylphosphine (3 mmol/g, 0.5 g,1.50 mmol) in THF (10 mL) and water (0.5 mL) according to the proceduredescribed for Example 69, Step 10 provided 0.21 g (69%) of((2R)-8-(4-chloro-2-methylphenyl)-7-fluorochroman-2-yl)methanaminehydrochloride as a white solid salt, mp 100-102° C.; MS (ESI) m/z 306.1([M+H]⁺).

Elemental analysis for C₁₇H₁₇ClFNO.HCl.0.3H₂O.0.4C₄H₈O₂:

Theory: C, 58.35; H, 5.74; N, 3.66.

Found: C, 58.44; H, 5.93; N, 3.31.

Example 73 ((2R)-8-(2,4-dichlorophenyl)-7-fluorochroman-2-yl)methanaminehydrochloride

Step 1: Treatment of 2,4-dichlorobromobenzene (13.8 g, 61.2 mmol) with2-fluoro-6-methoxybenzene boronic acid (5.0 g, 29.4 mmol) in DME-water(5:1, 150 mL) according to the procedure described for Example 69, Step1 provided 5.0 g (63%) of 2,4-dichloro-2′-fluoro-6′-methoxybiphenyl as acolorless oil.

Step 2: Treatment of 2,4-dichloro-2′-fluoro-6′-methoxybiphenyl (5.0 g,18.4 mmol) with hydrogen bromide (33% in acetic acid, 100 mL) accordingto the procedure described for Example 69, Step 2 provided 4.2 g (89%)of 2′,4′-dichloro-6-fluorobiphenyl-2-ol as a light brown oil.

Step 3: Treatment of 2′,4′-dichloro-6-fluorobiphenyl-2-ol (1.6 g, 6.2mmol) with potassium carbonate (1.3 g, 9.3 mmol) and allyl bromide (0.79mL, 9.3 mmol) in DMSO (50 mL) according to the procedure described forExample 69, Step 3 provided 1.7 g (92%) of2′-allyloxy-2,4-dichloro-6′-fluorobiphenyl as a pale yellow oil.

Step 4: A solution of 2′-allyloxy-2,4-dichloro-6′-fluorobiphenyl (1.7 g,5.7 mmol) in mesitylene (50 mL) was refluxed for 48 h. The solvent wasremoved under reduced pressure. Purification by ISCO using a solventgradient of 0 to 20% ethyl acetate in hexanes provided 1.1 g (65%) of3-allyl-2′,4′-dichloro-6-fluorobiphenyl-2-ol as a pale yellow oil.

Step 5: Treatment of 3-allyl-2′,4′-dichloro-6-fluorobiphenyl-2-ol (1.1g, 3.70 mmol) with dichlorobis(acetonitrile)palladium (II) (0.15 g, 0.58mmol) in methylene chloride (50 mL) according to the procedure describedfor Example 69, Step 5 provided 0.8 g (73%) of2′,4′-dichloro-6-fluoro-3-(prop-1-enyl)biphenyl-2-ol as a pale yellowoil.

Step 6: Treatment of2′,4′-dichloro-6-fluoro-3-(prop-1-enyl)biphenyl-2-ol (0.8 g, 2.69 mmol)in toluene (25 mL) with triphenylphosphine (1.06 g, 4.03 mmol), diethylazodicarboxylate (0.70 g, 4.03 mmol) and (S)-2-hydroxy-3-buten-1-ylp-tosylate (0.97 g, 4.03 mmol) according to the procedure described forExample 69, Step 6 provided 0.6 g (43%) of(2R)-2-(2′,4′-dichloro-6-fluoro-3-(prop-1-enyl)biphenyl-2-yloxy)but-3-enyl4-methylbenzenesulfonate as a light yellow oil.

Step 7: Treatment of(2R)-2-(2′,4′-dichloro-6-fluoro-3-(prop-1-enyl)biphenyl-2-yloxy)but-3-enyl4-methylbenzenesulfonate (0.6 g, 1.15 mmol) withbenzylidene-bis(tricyclohexylphosphine)dichlororuthenium (0.30 g, 0.36mmol) in 1,2-dichloroethane (30 mL) according to the procedure describedfor Example 69, Step 7 provided 0.35 g (63%) of((2R)-8-(2,4-dichlorophenyl)-7-fluoro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate as a brown oil.

Step 8: Treatment of((2R)-8-(2,4-dichlorophenyl)-7-fluoro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate (0.35 g, 0.73 mmol) with platinum (IV) oxide(84% Pt, 0.14 g) in ethanol (20 mL) and ethyl acetate (5 mL) accordingto the procedure described for Example 69, Step 8 provided 0.35 g (100%)of ((2R)-8-(2,4-dichlorophenyl)-7-fluorochroman-2-yl)methyl4-methylbenzenesulfonate as a light brown oil.

Step 9: Treatment of((2R)-8-(2,4-dichlorophenyl)-7-fluorochroman-2-yl)methyl4-methylbenzenesulfonate (0.35 g, 0.73 mmol) with sodium azide (0.28 g,4.38 mmol) in DMSO (10 mL) according to the procedure described forExample 69, Step 9 provided 0.22 g (86%) of(2R)-2-(azidomethyl)-8-(2,4-dichlorophenyl)-7-fluorochroman as acolorless oil.

Step 10: Treatment of(2R)-2-(azidomethyl)-8-(2,4-dichlorophenyl)-7-fluorochroman (0.22 g,0.62 mmol) with polymer-bound triphenylphosphine (3 mmol/g, 0.35 g, 1.05mmol) in THF (10 mL) and water (0.5 mL) according to the proceduredescribed for Example 69, Step 10 provided 97 mg (43%) of((2R)-8-(2,4-dichlorophenyl)-7-fluorochroman-2-yl)methanaminehydrochloride as a white solid salt, mp 164-166° C.; MS (ESI) m/z 326.0([M+H]⁺); [α]_(D) ²⁵=−26.00° (c=1% SOLN, MeOH).

Elemental analysis for C₁₆H₁₄Cl₂FNO.HCl:

Theory: C, 52.99; H, 4.17; N, 3.86.

Found: C, 53.24; H, 3.91; N, 3.59.

Example 74 ((2R)-8-(Biphenyl-2-yl)-6-fluorochroman-2-yl)methanaminehydrochloride

Step 1: Treatment of 2-bromobiphenyl (6.85 g, 29.4 mmol) with2-fluoro-6-methoxybenzene boronic acid (5.0 g, 29.4 mmol) in DME-water(5:1, 150 mL) according to the procedure described for Example 69, Step1 provided 7.3 g (89%) of 5-fluoro-2-methoxy-2′-phenylbiphenyl as acolorless oil.

Step 2: To a solution of 5-fluoro-2-methoxy-2′-phenylbiphenyl (7.3 g,26.2 mmol) in methylene chloride (100 mL) cooled to −78° C. was addedthrough syringe boron tribromide (1.0 M in dichloromethane, 40.0 mL,40.0 mmol). The reaction mixture was stirred and allowed to warm up toroom temperature overnight. The resulting mixture was diluted withdichloromethane, washed with water and saturated sodium chloride, driedover anhydrous sodium sulfate and concentrated under reduced pressure.Purification by ISCO using a solvent gradient of 0 to 40% ethyl acetatein hexanes provided 6.8 g (98%) of 5-fluoro-2′-phenylbiphenyl-2-ol as alight brown oil.

Step 3: Treatment of 5-fluoro-2′-phenylbiphenyl-2-ol (6.8 g, 25.7 mmol)with potassium carbonate (5.3 g, 38.6 mmol) and allyl bromide (3.3 mL,38.6 mmol) in DMSO (150 mL) according to the procedure described forExample 69, Step 3 provided 6.4 g (82%) of2-allyloxy-5-fluoro-2′-phenylbiphenyl as a white solid. MS (EI) m/z304.1264 ([M]⁺); mp 48-49° C.

Step 4: A solution of 2-allyloxy-5-fluoro-2′-phenylbiphenyl (6.4 g, 21.0mmol) in mesitylene (200 mL) was refluxed for 72 h. The solvent wasremoved under reduced pressure. Purification by ISCO using a solventgradient of 0 to 20% ethyl acetate in hexanes afforded 6.2 g (96%) of3-allyl-5-fluoro-2′-phenylbiphenyl-2-ol as a pale yellow oil.

Step 5: Treatment of 3-allyl-5-fluoro-2′-phenylbiphenyl-2-ol (3.0 g, 9.8mmol) in methylene chloride (100 mL) withdichlorobis(acetonitrile)palladium (II) (0.50 g, 1.93 mmol) according tothe procedure described for Example 69, Step 5 provided 2.78 g (93%) of5-fluoro-2′-phenyl-3-(prop-1-enyl)biphenyl-2-ol as a pale yellow oil.

Step 6: Treatment of 5-fluoro-2′-phenyl-3-(prop-1-enyl)biphenyl-2-ol(2.78 g, 9.13 mmol) in toluene (100 mL) with triphenylphosphine (3.59 g,13.69 mmol), diethyl azodicarboxylate (2.38 g, 13.69 mmol) and(S)-2-hydroxy-3-buten-1-yl p-tosylate (2.87 g, 11.87 mmol) according tothe procedure described for Intermediate X6 provided 1.8 g (37%) of(2R)-2-(5-fluoro-2′-phenyl-3-(prop-1-enyl)biphenyl-2-yloxy)but-3-enyl4-methylbenzenesulfonate as a light yellow solid. MS (ESI) m/z 546.1[M+NH₄]⁺.

Step 7: Treatment of(2R)-2-(5-fluoro-2′-phenyl-3-(prop-1-enyl)biphenyl-2-yloxy)but-3-enyl4-methylbenzenesulfonate (1.8 g, 3.40 mmol) withbenzylidene-bis(tricyclohexylphosphine)-dichlororuthenium (1.0 g, 1.22mmol) in 1,2-dichloroethane (100 mL) according to the proceduredescribed for Example 69, Step 7 provided 1.36 g (82%) of((2R)-8-(biphenyl-2-yl)-6-fluoro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate as a brown solid. MS (ESI) m/z 504.1([M+NH₄]⁻).

Step 8: Treatment of((2R)-8-(biphenyl-2-yl)-6-fluoro-2H-chromen-2-yl)methyl4-methylbenzenesulfonate (1.36 g, 2.79 mmol) with platinum (IV) oxide(84% Pt, 0.35 g) in ethanol (40 mL) and ethyl acetate (10 mL) accordingto the procedure described for Example 69, Step 8 provided 1.30 g (96%)of ((2R)-8-(biphenyl-2-yl)-6-fluorochroman-2-yl)methyl4-methylbenzenesulfonate as an off-white solid. MS (ESI) m/z 489.2([M+H]⁺); m/z 506.2 ([M+NH₄]⁺).

Step 9: Treatment of ((2R)-8-(biphenyl-2-yl)-6-fluorochroman-2-yl)methyl4-methylbenzenesulfonate (1.30 g, 2.66 mmol) with sodium azide (1.04 g,15.96 mmol) in DMSO (30 mL) according to the procedure described forExample 69, Step 9 provided 0.85 g (89%) of(2R)-2-(azidomethyl)-8-(biphenyl-2-yl)-6-fluorochroman as a pale yellowoil.

Step 10: Treatment of(2R)-2-(azidomethyl)-8-(biphenyl-2-yl)-6-fluorochroman (0.85 g, 2.36mmol) with polymer-bound triphenylphosphine (3 mmol/g, 1.02 g, 3.06mmol) in THF (30 mL) and water (2 mL) according to the proceduredescribed for Example Cl-Me provided 0.46 g (52%) of((2R)-8-(biphenyl-2-yl)-6-fluorochroman-2-yl)methanamine hydrochlorideas an off-white solid salt, mp 98° C.; MS (ESI) m/z 334.2 [M+H]⁺;[α]_(D) ²⁵=−27.00° (c=1% SOLN, MeOH).

Elemental analysis for C₂₂H₂₀FNO.HCl.C₄H₁₀O

Theory: C, 70.53; H, 6.81; N, 3.26.

Found: C, 70.57; H, 6.97; N, 3.22.

Biological Assays A. Assessment of Effectiveness of Compounds as5HT_(2C) Agonists and Partial Agonists

The ability of the compounds of this invention to act as 5HT_(2C)agonists and partial agonists was established using several standardpharmacological test procedures; the procedures used and resultsobtained are provided below. In the test procedures, 5-HT stands for5-hydroxytryptamine, mCPP stands for meta-chlorophenylpiperazine, andDOI stands for 1-(2,5-dimethoxy-4-iodophenyl)isopropylamine.

To evaluate the affinity of various compounds of formula I for activityat the 5-HT_(2C) receptor, a CHO (Chinese Hamster Ovary) cell linetransfected with the cDNA expressing the human 5-hydroxytryptamine-2C(h5-HT_(2C)) receptor was maintained in DMEM (Dulbecco's Modified EagleMedia) supplied with fetal calf serum, glutamine, and the markers:guaninephosphoribosyl transferase (GTP) and hypoxanthinethymidine (HT).The cells were allowed to grow to confluence in large culture disheswith intermediate changes of media and splitting. Upon reachingconfluence, the cells were harvested by scraping. The harvested cellswere suspended in half volume of fresh physiological phosphate bufferedsaline (PBS) solution and centrifuged at low speed (900×g). Thisoperation was repeated once. The collected cells were then homogenizedwith a polytron at setting #7 for 15 sec in ten volumes of 50 mMTris.HCl, pH 7.4 and 0.5 mM EDTA. The homogenate was centrifuged at900×g for 15 min to remove nuclear particles and other cell debris. Thepellet was discarded and the supernatant fluid recentrifuged at 40,000×gfor 30 min. The resulting pellet was resuspended in a small volume ofTris.HCl buffer and the tissue protein content was determined inaliquots of 10-25 μL volumes. Bovine Serum Albumin (BSA) was used as thestandard in the protein determination by the method of Lowry et al., (J.Biol. Chem., 193:265 (1951). The volume of the suspended cell membraneswas adjusted with 50 mM Tris.HCl buffer containing: 0.1% ascorbic acid,10 mM pargyline and 4 mM CaCl₂ to give a tissue protein concentration of1-2 mg per ml of suspension. The preparation membrane suspension (manytimes concentrated) was aliquoted in 1 ml volumes and stored at −70 Cuntil used in subsequent binding experiments.

Binding measurements were performed in a 96 well microtiter plateformat, in a total volume of 200 μL. To each well was added: 60 μL ofincubation buffer made in 50 mM Tris.HCl buffer, pH 7.4 and containing 4mM CaCl₂; 20 μL of [¹²⁵I] DOI (S.A., 2200 Ci/mmol, NEN Life Science).

The dissociation constant, K_(D) of [¹²⁵I] DOI at the human serotonin5-HT_(2C) receptor was 0.4 nM by saturation binding with increasingconcentrations of [¹²⁵I] DOI. The reaction was initiated by the finaladdition of 100 μL of tissue suspension containing 50 μg of receptorprotein. Nonspecific binding is measured in the presence of 1 μMunlabeled DOI added in 20.0 μL volume. Test compounds were added in 20.0μL. The mixture was incubated at room temperature for 60 min. Theincubation was stopped by rapid filtration. The bound ligand-receptorcomplex was filtered off on a 96 well unifilter with a Packard®Filtermate 196 Harvester. The bound complex caught on the filter diskwas dried in a vacuum oven heated to 60° C. and the radioactivitymeasured by liquid scintillation with 40 μL Microscint-20 scintillant ina Packard TopCount® equipped with six (6) photomultiplier detectors.

Specific binding is defined as the total radioactivity bound less theamount bound in the presence of 1 μM unlabeled DOI. Binding in thepresence of varying concentrations of test drugs is expressed as percentof specific binding in the absence of drug. These results are thenplotted as log % bound vs log concentration of test drug. Non linearregression analysis of data points yields both the IC₅₀ and the K_(i)values of test compounds with 95% confidence limits. Alternatively, alinear regression line of decline of data points is plotted, from whichthe IC₅₀ value can be read off the curve and the K_(i) value determinedby solving the following equation:

$K_{i} = \frac{{IC}_{50}}{1 + {L/K_{D}}}$

where L is the concentration of the radioactive ligand used and theK_(D) is the dissociation constant of the ligand for the receptor, bothexpressed in nM.

The following K_(i)'s (95% confidence interval) are provided for variousreference compounds in Table 2, below:

TABLE 2 K_(i) Data for Reference Compounds Compound K_(i) Ritanserin 2.0(1.3-3.1) nM Ketanserin 94.8 (70.7-127.0) nM Mianserin 2.7 (1.9-3.8) nMClozapine 23.2 (16.0-34.0) nM Methiothepin 4.6 (4.0-6.0) nM Methysergide6.3 (4.6-8.6) nM Loxapine 33.0 (24.0-47.0) nM mCPP 6.5 (4.8-9.0) nM DOI6.2 (4.9-8.0) nM

The ability of the compounds of formula I to produce an agonist responseat brain 5-HT_(2C) was assessed by determining their effect on calciummobilization using the following procedure: CHO cells stably expressingthe human 5-HT_(2C) receptor were cultured in Dulbecco's modifiedEagle's medium (DMEM) supplemented with 10% fetal bovine serum andnon-essential amino acids. Cells were plated at a density of 40Kcells/well in 96-well clear-bottom black-wall plates 24 hours prior tothe evaluation of 5-HT_(2C) receptor-stimulated calcium mobilization.For calcium studies, cells were loaded with the calcium indicator dyeFluo-3-AM in Hank's buffered saline (HBS) for 60 minutes at 37° C. Cellswere washed with HBS at room temperature and transferred to thefluorometric imaging plate reader (FLIPR, Molecular Devices, Sunnyvale,Calif.) for acquisition of calcium images. Excitation at 488 nm wasachieved with an Argon ion laser and a 510-560 nm emission filter wasused. Fluorescence images and relative intensities were captured at 1second intervals and cells were stimulated by addition of agonist after10 baseline measurements using the internal fluidics module of theFLIPR. An increase in fluorescence counts corresponds to an increase inintracellular calcium.

For the evaluation of agonist pharmacology the calcium changes inresponse to different concentrations of agonist were determined using amaximum minus minimum calculation of the raw fluorescence count data.Calcium changes were then expressed as a percentage of the responseobserved with a maximally effective concentration of 5-HT. EC₅₀ valueswere estimated by non-linear regression analysis of thelog-concentration % maximum 5-HT response curves using the 4-parameterlogistic function. In certain embodiments, compounds of the presentinvention provide an EC₅₀ of ≦about 1000 nM. In other embodiments,compounds of the present invention provide an EC₅₀ of ≦about 100 nM, inyet other embodiments ≦about 20 nM, in still other embodiments ≦about 5nM, and certain embodiments ≦about 2 nM.

The following EC₅₀'s are provided for various reference compounds inTable 3, below

TABLE 3 EC₅₀ Data for Reference Compounds: Compound EC₅₀ 5-HT 0.5 nM DOI0.5 nM mCPP 5.4 nM

Table 4 below shows the results of the activity of selected compounds ofthis invention in the assays described above. The compound numberscorrespond to the compound numbers in Table 1, supra. Compounds havingan activity designated as “A” provided a K_(i) value of less than orequal to 10 nM; compounds having an activity designated as “B” provideda K_(i) value between 10 nM and 50 nM; and compounds having an activitydesignated as “C” provided a K_(i) value greater than 50 nM. Compoundshaving an activity designated as “D” provided an EC₅₀ value of less thanor equal to 50 nM; compounds having an activity designated as “E”provided a an EC₅₀ value between 50 nM and 200 nM; and compounds havingan activity designated as “F” provided a an EC₅₀ value greater than 200nM. An activity designated as “-”, for any compound listed in Table 4,below, means that the data was not provided for that compound.

TABLE 4 5-HT_(2C) Activity of Selected Compounds Compound 5-HT_(2C)Binding 5-HT_(2C) Function Number K_(i) avg (nM) EC₅₀ (nM) EMax (%) 1 BD 80 2 A D 80 3 A D 90 4 C D 80 5 A E 90 6 A D 90 7 A D 90 8 A D 100 9 AD 100 10 A D 100 11 A D 100 12 B E 90 13 A D 100 14 B F 80 15 A D 90 16A D 100 17 A D 80 18 C D 90 19 A E 80 20 A D 90 21 C E 80 22 C — — 23 C— — 24 B E 100 25 B F 90 26 C — — 27 B E 80 28 B E 100 29 B F 80 30 C —— 31 C — — 32 B E 90 33 B F 80 34 C — — 35 A D 90 36 A D 80 37 A D 10038 A D 80 39 A D 100 40 A D 90 41 B E 90 42 A E 90 43 A E 90 44 B F 8045 A D 90 46 B F 90 47 C E 90 48 A E 90 49 A D 90 50 B D 90 51 B D 80 52C — — 53 B E 70 54 C — — 55 A E 70 56 B E 80 57 A D 80 58 A D 60 59 A D90 60 A D 100 61 A D 90 62 B D 100 63 A D 90 64 A D 90 65 A D 80 66 A D90 67 B E 80 68 B E 80 69 A — — 70 — — — 71 A — — 72 A — — 73 — — — 74 —— —

The compounds of this invention thus have affinity for and agonist orpartial agonist activity at brain serotonin 5-HT_(2C) receptors. Theyare therefore of interest for the treatment of the central nervoussystem conditions described previously herein.

B. Assessment of Effectiveness of Compounds in Obesity Models ObesityModel A

To evaluate acute in vivo efficacy of various compounds, 7 weeks-oldmale C57BL/6J mice are obtained from The Jackson Laboratory (Bar Harbor,Me.) and 6 weeks-old lean Zucker fa/? rats are purchased from CharlesRiver Laboratories (Wilmington, Mass.). Mice and rats are single housedin a temperature-controlled (25° C.) facility with a 12-h light/darkcycle. Animals are allowed normal chow diet (Rodent chow #5001,PharmaServ, Framingham, Mass.) and water ad libitum. After one weekacclimation, animals are randomized to vehicle (saline) or treatmentgroups. Animals are fasted overnight (16 hrs) and orally dosed withvehicle or compounds. Thirty minutes after compound administration,animals are given a weighed amount of food, and food intake was recorded30 minutes, 1 h, 2 h, 4 h, 7 h and 24 h after refeeding.

Obesity Model B

To assess in vivo efficacy of various 5-HT_(2C) compounds on weightloss, 5 weeks-old male C57BL/6J-DIO mice were fed a high-fathigh-sucrose diet (58 kcal % fat, 16.4 kcal % protein, 25.5 kcal %carbohydrate) for 11 weeks. 6 weeks-old male Zucker fa/fa rats purchasedfrom Charles River Laboratories were also used. Mice and rats weresingle housed in a temperature-controlled (25° C.) facility with a 12-hlight/dark cycle. Animals were allowed food and water ad libitum. Afterone week acclimation, animals were randomized to vehicle (saline) ortreatment groups. Animals were orally dosed once daily for 14 days. Bodyweight, food consumption, and/or body composition (NMR) were recorded.Epidydimal adipose tissue was collected at the end of the study. Resultswith respect to C57BL/6J-DIO mice are summarized in Table 5, below.Results with respect to Zucker rats are summarized in Table 6, below.

TABLE 5 % Reduction food intake (vs vehicle) Compound # Dose (mpk) 0.5hour 2 hours 4 hours I-36 30 86 ± 11 72 ± 7 65 ± 8 I-36 50 83 ± 6  77 ±6 67 ± 9

TABLE 6 % Reduction food intake (vs vehicle) Compound # Dose (mpk) 0.5hour 2 hours 4 hours I-36 30  0 ± 16 0 ± 8 0 ± 9  I-36 50 58 ± 9 11 ± 170 ± 13

C. Assessment of Effectiveness in Treatment of Pain

Compounds of formula I may be evaluated in accordance with the presentinvention to establish the extent of their effectiveness to treat pain,and may optionally be compared with other pain treatments.

A variety of methods have been established in the art to evaluate theeffectiveness of compounds for relieving pain. See e.g., Bennett et al,Pain 33: 87-107, 1988; Chaplan et al, J. Neurosci. Methods 53:55-63,1994; and Mosconi et al, Pain 64:37-57, 1996. Below is a specificdescription of one strategy that may be employed.

Procedure: Individually housed Spraque-Dawley rats are given free accessto rat chow and water. A 12-h light/12-h dark cycle is put in effect(lights on from 6:00 am to 6:00 pm). Animal maintenance and research areconducted in accordance with the guidelines provided by the NationalInstitutes of Health Committee on Laboratory Animal Resources. Thesesubjects are used in the tests as set forth below.

Test Method 1: Prostaglandin E₂-Induced Thermal Hypersensitivity.

The terminal 10 cm of the tail is placed into a thermos bottlecontaining water warmed to 38, 42, 46, 50, 54, or 58° C. The latency inseconds for the animal to remove the tail from the water is used as ameasure of nociception. If the animal does not remove the tail within 20sec, the experimenter removes the tail from the water and a maximumlatency of 20 sec is recorded.

Following the assessment of baseline thermal sensitivity, thermalhypersensitivity is produced by a 50 μL injection of 0.1 mgprostaglandin E₂ (PGE₂) into the terminal 1 cm of the tail.Temperature-effect curves are generated before (baseline) and after (15,30, 60, 90 and 120 min) the PGE₂ injection. Previous studies in otherspecies (e.g., monkeys; Brandt et al., J. Pharmacol. Exper. Ther.296:939, 2001) have demonstrated that PGE₂ produces a dose- andtime-dependent thermal hypersensitivity that peaks 15 min afterinjection and dissipates after 2 hr.

Single compound studies. The ability of drugs to reverse PGE₂-inducedthermal hypersensitivity is assessed using a single dose time-courseprocedure. Under this procedure, a single dose of the compound to betested is administered intraperitoneally (IP), orally (PO) orintranasally (IN) 30 min before the injection of PGE₂. Tactilesensitivity is assessed 30 min after PGE₂ injection.Combination compound studies. Combination studies with two or morepotential pain treatment agents can be conducted. A minimally effectivedose of a first agent, e.g., morphine is administered alone and incombination with ineffective doses of one or more compounds of formula Iin the thermal warm-water tail withdrawal assay. Compounds areadministered IP at the same time 30 min before testing.

Combination studies can also be conducted in the PGE₂-induced thermalhypersensitivity assay. For example, a dose of morphine that completelyreverses thermal hypersensitivity (i.e., return to baseline) can beadministered alone and in combination with doses of one or morecompounds of formula I in the PGE₂-induced thermal warm-water tailwithdrawal assay. Compounds are administered IP at the same time asPGE₂, which is administered 30 min before testing.

Test Method 1 Data Analysis The temperature that produced a half-maximalincrease in the tail-withdrawal latency (i.e., T₁₀) is calculated fromeach temperature-effect curve. The T₁₀ is determined by interpolationfrom a line drawn between the point above and the point below 10 sec onthe temperature-effect curve. For these studies, thermalhypersensitivity is defined as a leftward shift in thetemperature-effect curve and a decrease in the T₁₀ value. Reversal ofthermal hypersensitivity is defined as a return to baseline of thetemperature-effect curve and the T₁₀ value and is calculated accordingto the following equation:

${\% \mspace{14mu} {MPE}} = {\frac{( T_{10}^{{drug} + {{PGE}\; 2}} ) - ( T_{10}^{{PGE}\; 2} )}{( T_{10}^{baseline} ) - ( T_{10}^{{PGE}\; 2} )} \times 100}$

in which T₁₀ ^(drug+PGE2) is the T₁₀ after a drug in combination withPGE₂, T₁₀ ^(PGE2) is the T₁₀ after PGE₂ alone, and T₁₀ ^(baseline) isthe T₁₀ under control conditions. A % MPE value of 100 indicates acomplete return to the baseline thermal sensitivity observed without thePGE₂ injection. A value of greater than 100% indicates that the compoundtested reduced thermal sensitivity more than the baseline thermalsensitivity without the PGE₂ injection.

Test Method 2: Chronic Constriction Injury

Rats are anesthetized with 3.5% halothane in O₂ at 1 L/min andmaintained with 1.5% halothane in O₂ during surgery. A modified chronicsciatic nerve constriction injury (Mosconi & Kruger, 1996; Bennett &Xie, 1988) is produced by a cutaneous incision and a blunt dissectionthrough the biceps femoris to expose the sciatic nerve. A PE 90Polyethylene tubing (Intramedic, Clay Adams; Becton Dickinson Co.) cuff(2 mm length) is placed around the sciatic nerve at the level of themid-thigh. The wound is closed in layers using 4-0 silk suture and woundclips. Testing is conducted 6-10 days after surgery.

Animals are placed in elevated wire cages and allowed 45-60 minutes toacclimate to the testing room. Baseline tactile sensitivity is assessedusing a series of calibrated von Frey monofilaments (Stoelting; WoodDale, Ill.) 0-3 days before surgery. Von Frey monofilaments are appliedto the mid-plantar hind paw in sequential ascending or descending order,as necessary, to hover as closely as possible to the threshold ofresponses. The threshold is indicated by the lowest force that evoked abrisk withdrawal response to the stimuli. Thus, a withdrawal responseleads to the presentation of the next lighter stimulus and the lack of awithdrawal response leads to the presentation of the next strongerstimulus. Rats with baseline thresholds<4 g force are excluded from thestudy. Approximately one week following CCI surgery, tactilesensitivities are reassessed and animals that exhibit motor deficiency(i.e. paw dragging) or failure to exhibit subsequent tactilehypersensitivity (threshold≧10 g) are excluded from further testing.Under cumulative dosing conditions, compounds are administered IP every30 minutes with the cumulative dose increasing in ½ log unit increments.Tactile hypersensitivity is assessed 20-30 minutes following each drugadministration.

Test Method 2 Data Analysis. The 50% threshold values (in gm force)estimated by the Dixon non-parametric test (Chaplan et al, 1994) arecalculated and fifteen-grams of force is used as the maximal force.Dose-effect curves are generated for each experimental condition foreach rat. Individual tactile hypersensitivity threshold values areaveraged to provide a mean (±1 SEM). Reversal of tactilehypersensitivity was defined as a return to baseline tactile sensitivityand was calculated according to the following equation:

${\% \mspace{14mu} {Reversal}} = {\frac{( {50\%^{{drug} + {CCI}}} ) - ( {50\%^{CCI}} )}{( {50\%^{baseline}} ) - ( {50\%^{CCI}} )} \times 100}$

in which 50%^(drug+CCI) is the 50% value after compound in animalsapproximately one week after CCI surgery, 50%^(CCI) is the 50% valueapproximately one week after CCI surgery alone, and 50%^(baseline) isthe 50% value before CCI surgery. Maximal effect of 100% reversalrepresents a return to the mean pre-operative threshold value forsubjects in that experimental condition.

Test Method 3: Scheduled-Controlled Responding.

Rats are trained under a multiple-cycle procedure during experimentalsessions conducted five days each week. Each training cycle consists ofa 10-min pretreatment period followed by a 10-min response period.During the pretreatment period, stimulus lights are not illuminated, andresponding has no scheduled consequences. During the response period,the left or right stimulus lights are illuminated (counterbalanced amongsubjects), the response lever is extended and subjects can respond undera fixed ratio 30 schedule of food presentation. Training sessionsconsist of 3 consecutive cycles. Testing sessions are identical totraining sessions except that a single dose of drug is administered atthe start of the first cycle.

Test Method 3 Data analysis. Operant response rates from individualanimals are averaged for the three cycles during test sessions and areconverted to percent of control response rates using the average ratefrom the previous training day as the control value (i.e., average ofthree cycles). Data are presented as the mean (±1 SEM) response rate asa percent of control. Thus, for example, a test value of 100% wouldindicate the response rate after administration of the compound to betested is the same as the control response rate and there is no adverseeffect of the compound tested.Test Method 4: Assessment of Effectiveness in Tactile Allodynia ModelCompound: Test compounds are dissolved in sterile saline and gabapentinis suspended in 2% Tween 80 in 0.5% methylcellulose and sterile water.All compounds are administered intraperitoneally (i.p.).Subjects: Male Sprague-Dawley rats (125-150 g, Harlan; Indianapolis,Ind.) are individually housed on bedding. For all studies animals aremaintained in climate-controlled rooms on a 12-hour light/dark cycle(lights on at 0630) with food and water available ad libitum.Surgery: All surgical procedures are performed under 4% isoflurane/O₂anesthesia, delivered via nose cone and maintained at 2.5% for theduration of the surgery.L5 Spinal Nerve Ligation (SNL): Surgery is performed as previouslydescribed (Kim and Chung) with the exception that nerve injury isproduced by tight ligation of the left L5 spinal nerve.Assessment of Tactile Allodynia (Tactile Sensitivity): Tactilethresholds are assessed using a series of calibrated von Freymonofilaments (Stoelting; Wood Dale, Ill.). The threshold that produceda 50% likelihood of a withdrawal is determined using the up-down method,as previously described (Chaplan et al., 1994). Animals are placed inelevated wire cages and allowed 45-60 minutes to acclimate to thetesting room. Von Frey monofilaments are applied to the mid-plantar lefthind paw in sequential ascending or descending order, as necessary, tohover as closely as possible to the threshold of responses. The lowestforce that evokes a brisk withdrawal response to the stimuli determinedthe pain threshold. Tactile thresholds are determined on the day priorto surgery and rats with baseline thresholds<10 g force are excludedfrom studies. Three weeks after SNL surgery tactile thresholds arereassessed and animals that fail to exhibit subsequent tactile allodynia(threshold≧5 g) are excluded from further testing. Subjects arepseudo-randomly divided into test groups (n=8-10) so that averagebaseline and post-surgery sensitivities are similar among groups. Ratsare administered a test compound (3, 10 or 17.8, i.p.), gabapentin (100mg/kg, i.p., positive control) or vehicle and tactile thresholds areassessed up to 60, 180 and 300 minutes after dosing.Analysis of Results: Statistical analysis is done using a repeatedmeasures analysis of variance (ANOVA) using a customized SAS-excelapplication (SAS Institute, Cary, N.C.). Significant main effects areanalyzed further by subsequent least significant difference analysis.The criterion for significant differences is p<0.05. Reversal of tactileallodynia is calculated according to the following equation:

${\% \mspace{14mu} {Reversal}} = {\frac{( {50\% \mspace{14mu} {threshold}^{{drug} + {{post}\mspace{14mu} {surgery}}}} ) - ( {50\% \mspace{14mu} {treshold}^{{post}\mspace{14mu} {surgery}}} )}{ {( {50\% \mspace{14mu} {threshold}^{{pre}\mspace{14mu} {surgery}}} ) - {50\% \mspace{14mu} {threshold}^{{post}\mspace{14mu} {surgery}}}} )\mspace{14mu}} \times 100}$

In which 50% threshold^(drug+post surgery) is the 50% threshold in gforce after drug in nerve injured subjects, 50% threshold^(post surgery)is the 50% threshold in g force in nerve injured subjects, and 50%threshold^(pre surgery) is the 50% threshold in g force before nerveinjury. Maximal effect of 100% reversal represents a return to the meanpre-operative threshold value for subjects in that experimentalcondition. See FIG. 1.

Test Method 5: Assessment of Effectiveness in Chronic Inflammatory PainCompounds:

Test compounds are dissolved in sterile saline and administeredintraperitoneally (i.p.). Celecoxib was used as a positive control andis suspended in 2% Tween 80 in 0.5% methylcellulose and administeredorally (p.o.).Subjects: Male Sprague-Dawley rats (125-150 g, Harlan; Indianapolis,Ind.) are housed 3/cage on bedding and. animals are maintained inclimate-controlled rooms on a 12-hour light/dark cycle (lights on at0630) with food and water available ad libitum.Freund's complete adjuvant (FCA) of mechanical hyperalgesia: The hindpaw withdrawal thresholds (PWTs) to a noxious mechanical stimulus aredetermined using an analgesimeter (model 7200; Ugo Basile). Cutoff wasset at 250 g, and the endpoint taken is complete paw withdrawal. PWT isdetermined once for each rat at each time point (n=10/group). BaselinePWT is determined, and the rats were anesthetized with isofluorane (2%in oxygen) and received an intraplantar injection of 50% FCA (50 μl,diluted in saline) to the left hind paw. Twenty-four hours after FCAinjection, pre-drug PWTs were measured, and the rats are administeredvehicle or compound and assessed on PWTs 1, 3, 5, and 24 hours post-drugadministration.Analysis of Results: Statistical analysis is done using a one wayanalysis of variance (ANOVA) using a customized SAS-excel application(SAS Institute, Cary, N.C.). Significant main effects are analyzedfurther by subsequent least significant difference analysis. Thecriterion for significant differences is p<0.05 from vehicle-treated FCArats. Data is presented as percent reversal according to the followingequation: percent reversal=[(post-dose threshold)−pre-dosethreshold))/(baseline threshold-pre-dose threshold)]×100.

D. Assessment of Effectiveness in Treatment of Depression

Effectiveness of compounds of the present invention may be determined bythe tail suspension test. While not a direct model of depression, thetail suspension test is an assay that can evaluate antidepressant-likeeffects of drugs. Clinically effective drugs such as Prozac (fluoxetine)are effective in this assay. Specifically, they decrease the amount oftime the mice spend immobile after being hung upside down by their tailsduring the test. It is impossible to determine if a mouse is indeeddepressed. However, the fact that clinically effective antidepressantsreduce immobility lends predictive validity to the model.

Male Swiss Webster mice (Charles River) weighing 25-35 g are housed ingroups of five per cage in an AALAC-accredited facility that ismaintained on a 12-h light dark cycle (lights on at 0600 h) and havefree access to food and water. Experimental groups consist of 12 mice,randomly assigned to treatment groups. Experiments are performed between9:00 AM and noon in accordance to the Guide for the Care and Use ofLaboratory Animals as adopted and promulgated by the National Institutesof Health (Pub. 85-23, 1985).

Solutions of test compounds are dissolved in distilled water. Compoundsare injected i.p. at a volume of 10 ml/kg body weight. Combinationtreatments are cotreated, 30 minutes prior to the test.

The procedure described herein is substantially similar to thatdescribed by Steru et al. (1985). 30 minutes following treatment, themice are suspended upside down by the tail using adhesive laboratorytape (VWR International), to a flat metal bar connected to a straingauge within a tail suspension chamber (Med Associates). The time spentimmobile during a 6-minute test session is automatically recorded. 8mice are simultaneously tested within separate chambers. Data collectedare expressed as a mean of immobility time and statistical analysis isperformed using a one-way ANOVA with least significant difference (LSD)post-hoc test.

The entire disclosure of each patent, patent application, andpublication cited or described in this document is hereby incorporatedby reference.

While we have presented a number of embodiments of this invention, it isapparent that our basic construction can be altered to provide otherembodiments which utilize the compounds and methods of this invention.Therefore, it will be appreciated that the scope of this invention is tobe defined by the appended claims rather than by the specificembodiments which have been represented by way of example.

1-20. (canceled)
 21. A composition comprising a compound of Formula I

or a pharmaceutically acceptable salt thereof, wherein: m is 1 or 2; nis 0 or 1;

designates a single or double bond; Ar is thienyl, furyl, pyridyl, orphenyl wherein Ar is optionally substituted with one or more R^(x)groups; each R^(x) is independently halogen, -Ph, —CN, —R or —OR; each Ris independently hydrogen, C₁₋₆ aliphatic or halo-substituted C₁₋₆aliphatic; y is 0-3; each R¹ is independently —R, —CN, halogen or —OR;R² is hydrogen, C₁₋₃ alkyl, or —O(C₁₋₃ alkyl); each of R³ and R⁴ isindependently hydrogen, C₁₋₆ aliphatic or fluoro-substituted C₁₋₆aliphatic; and one or more pharmaceutically acceptable carriers,diluents, or excipients, further comprising an additional pharmaceuticalagent selected from an anti-psychotic agent, an antidepressive agent, ananti-obesity agent, an agent useful in the modulation of bladderactivity, an opioid antagonist, an agent for treating ADD or ADHD, acognitive improvement agent, an agent for treating sexual dysfunction,or a pain relieving agent.
 22. A method for treating a conditionselected from at least one of psychotic disorder, an anxiety disorder, abipolar disorder, a depressive disorder, premenstrual syndrome (PMS),premenstrual dysphoric disorder (PMDD), an eating disorder, a bladdercontrol disorder, substance abuse or substance dependence, a cognitiondisorder, ADD or ADHD, an impulsivity disorder, an addictive disorder,male or female sexual dysfunction, pain, a motion or motor disorder,Parkinson's disease epilepsy, migraine, chronic fatigue syndrome,anorexia nervosa, a sleep disorder, mutism, or one or more centralnervous system deficiencies in a patient, comprising administering tothe patient a therapeutically effective amount of a compound of FormulaI

or a pharmaceutically acceptable salt thereof, wherein: m is 1 or 2; nis 0 or 1;

designates a single or double bond; Ar is thienyl, furyl, pyridyl, orphenyl wherein Ar is optionally substituted with one or more R^(x)groups; each R¹ is independently halogen, -Ph, —CN, —R or —OR; each R isindependently hydrogen, C₁₋₆ aliphatic or halo-substituted C₁₋₆aliphatic; y is 0-3; each R¹ is independently —R, —CN, halogen or —OR;R² is hydrogen, C₁₋₃ alkyl, or —O(C₁₋₃ alkyl); each of R³ and R⁴ isindependently hydrogen, C₁₋₆ aliphatic or fluoro-substituted C₁₋₆aliphatic; or a composition comprising a compound of Formula I, and oneor more pharmaceutically acceptable carriers, diluents, or excipients.23. The method of claim 22 wherein the psychotic disorder isschizophrenia, paranoid type schizophrenia, disorganized typeschizophrenia, catatonic type schizophrenia, undifferentiated typeschizophrenia, a schizophreniform disorder, a schizoaffective disorder,a delusional disorder, substance-induced psychotic disorder, a psychoticdisorder not otherwise specified; L-DOPA-induced psychosis; psychosisassociated with Alzheimer's dementia; psychosis associated withParkinson's disease; or psychosis associated with Lewy body disease 24.The method of claim 22, wherein the condition is bipolar disorder and isselected from bipolar I disorder, bipolar II disorder, cyclothymicdisorder; bipolar mania, dementia, depression with psychotic features,or cycling between bipolar depression and bipolar mania.
 25. The methodof claim 22, wherein the depressive disorder is major depressivedisorder, seasonal affective disorder, dysthymic disorder,substance-induced mood disorder, depressive disorder not otherwisespecified, treatment resistant depression, major depressive episode. 26.The method of claim 25, further comprising administering to the patientan antidepressive agent selected from serotonin reuptake inhibitors(SRIs), norepinephrine reuptake inhibitors (NRIs), combinedserotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidaseinhibitors (MAOIs), reversible inhibitors of monoamine oxidase (RIMAs),phosphodiesterase-4 (PDE4) inhibitors, corticotropin releasing factor(CRF) antagonists, alpha.-adrenoreceptor antagonists, triple uptakeinhibitors, melatonin agonists, super neurotransmitter uptake blockers(SNUBs), noradrenergic and specific serotonergic antidepressants(NaSSAs), or substance P/neurokinin receptor antagonists.
 27. The methodof claim 22, wherein the cognitive disorder is a learning disorder. 28.The method of claim 22, wherein the patient is treated for obesity. 29.The method of claim 22, wherein the patient is treated for ADD or ADHD.30. The method of claim 22, wherein the substance abuse substancedependence is of a recreational substance, a pharmacologic agent, atranquilizer, a stimulant, sedative, or illicit drug.
 31. The method ofclaim 22, further comprising administering to the patient an additionalpharmaceutical agent selected from an anti-psychotic agent, anantidepressive agent, an anti-obesity agent, an agent useful in themodulation of bladder activity, an opioid antagonist, an agent fortreating ADD or ADHD, a cognitive improvement agent, an agent fortreating sexual dysfunction, or a pain relieving agent.
 32. A method fortreating schizophrenia in a patient, comprising administering to thepatient a therapeutically effective amount of a compound of Formula I.

or a pharmaceutically acceptable salt thereof, wherein: m is 1 or 2; nis 0 or 1;

designates a single or double bond; Ar is thienyl, furyl, pyridyl, orphenyl wherein Ar is optionally substituted with one or more R^(x)groups; each R^(x) is independently halogen, -Ph, —CN, —R or —OR; each Ris independently hydrogen, C₁₋₆ aliphatic or halo-substituted C₁₋₆aliphatic; y is 0-3; each R¹ is independently —R, —CN, halogen or —OR;R² is hydrogen, C₁₋₃ alkyl, or —O(C₁₋₃ alkyl); each of R³ and R⁴ isindependently hydrogen, C₁₋₆ aliphatic or fluoro-substituted C₁₋₆aliphatic; or a composition comprising a compound of Formula I, and oneor more pharmaceutically acceptable carriers, diluents, or excipients.33. A method for treating obesity in a patient, comprising administeringto the patient a therapeutically effective amount of a compound ofFormula I.

or a pharmaceutically acceptable salt thereof, wherein: m is 1 or 2; nis 0 or 1;

designates a single or double bond; Ar is thienyl, furyl, pyridyl, orphenyl wherein Ar is optionally substituted with one or more R^(x)groups; each R^(x) is independently halogen, -Ph, —CN, —R or —OR; each Ris independently hydrogen, C₁₋₆ aliphatic or halo-substituted C₁₋₆aliphatic; y is 0-3; each R¹ is independently —R, —CN, halogen or —OR;R² is hydrogen, C₁₋₃ alkyl, or —O(C₁₋₃ alkyl); each of R³ and R⁴ isindependently hydrogen, C₁₋₆ aliphatic or fluoro-substituted C₁₋₆aliphatic; or a composition comprising a compound of Formula I, and oneor more pharmaceutically acceptable carriers, diluents, or excipients.34. A method for treating bipolar disorder in a patient, comprisingadministering to the patient a therapeutically effective amount of acompound of Formula I

or a pharmaceutically acceptable salt thereof, wherein: m is 1 or 2; nis 0 or 1;

designates a single or double bond; Ar is thienyl, furyl, pyridyl, orphenyl wherein Ar is optionally substituted with one or more R^(x)groups; each R^(x) is independently halogen, -Ph, —CN, —R or —OR; each Ris independently hydrogen, C₁₋₆ aliphatic or halo-substituted C₁₋₆aliphatic; y is 0-3; each R¹ is independently —R, —CN, halogen or —OR;R² is hydrogen, C₁₋₃ alkyl, or —O(C₁₋₃ alkyl); each of R³ and R⁴ isindependently hydrogen, C₁₋₆ aliphatic or fluoro-substituted C₁₋₆aliphatic; or a composition comprising a compound of Formula I, and oneor more pharmaceutically acceptable carriers, diluents, or excipients.35. A method for treating depression in a patient, comprisingadministering to the patient a therapeutically effective amount of acompound of Formula I

or a pharmaceutically acceptable salt thereof wherein: m is 1 or 2; n is0 or 1;

designates a single or double bond; Ar is thienyl, furyl, pyridyl, orphenyl wherein Ar is optionally substituted with one or more R^(x)groups; each R^(x) is independently halogen, -Ph, —CN, —R or —OR; each Ris independently hydrogen, C₁₋₆ aliphatic or halo-substituted C₁₋₆aliphatic; y is 0-3; each R¹ is independently —R, —CN, halogen or —OR;R¹ is hydrogen, C₁₋₃ alkyl, or —O(C₁₋₃ alkyl); each of R³ and R⁴ isindependently hydrogen, C₁₋₆ aliphatic or fluoro-substituted C₁₋₆aliphatic; or a composition comprising a compound of Formula I, and oneor more pharmaceutically acceptable carriers, diluents, or excipients.